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ABSTRACT 
 
Introduction 
The growth hormone (GH)/Insulin-like growth factor-I (IGF) axis is a key 
mediator of childhood growth. Current diagnostic tests have poor specificity for 
disorders affecting this system, namely the growth hormone stimulation test 
(GHST) and IGF-I measurement. Furthermore, advances in genetics and body 
composition analysis may provide new approaches to diagnosing disorders 
involving this axis. 
 
Aim 
To improve the diagnostic evaluation of children with poor growth and possible 
GH deficiency (GHD) through novel approaches to 1) modifying the GHST and 
diagnostic fasting study; 2) utilising liquid chromatography mass spectrometry 
(LCMS) to measure IGF-I and –II concentrations; 3) exploring rare genetic 
causes of poor growth; and 4) studying the association between early body 
composition and early infant growth. 
 
Methods 
I used various approaches including: additional timed GH measurements during 
the diagnostic GHST and fasting study; IGF-I and –II measurement by LCMS in 
a well-characterised birth cohort; population-based screening for genetic 
polymorphisms; focused whole exome testing for rare clinical phenotypes; and 
body composition analysis measured using air displacement plethysmography. 
 
Results 
Intravenous line placement (IVP) is a stimulus for GH secretion and serial 
additional GH measurement after placement will improve the specificity of the 
GHST. Similarly, serial measurement of GH in the context of a diagnostic 
fasting study will improve the specificity for disease. Nutrition interacts with the 
GH/IGF axis, and I have described reference data for body composition to 
improve measurement of nutritional status in infancy. In normal infants, there is 
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a doubling of body fat in the first two months. Using liquid chromatography 
mass spectrometry, I have described reference data for IGF-I and –II at birth and 
demonstrated a relationship between these measurements and this rapid 
accumulation body fat in early infancy. Using a rare phenotype approach and 
chart review to identify potential genetic causes of short stature, we have also 
identified a novel IGF1R mutation in a child with a phenotype consistent with 
IGF-I resistance. 
 
Conclusions 
Diagnosing disorders of the GH/IGF-I axis remain a significant clinical 
challenge. I have expanded the clinical approach to evaluating the child with 
short stature through refining the approaches to the GHST, diagnostic fasting 
study and body composition evaluation. I have also described reference data for 
body composition and IGF-I and –II in infancy, and explored potential novel 
genetic causes of disordered growth. Future work will focus on studying other 
clinical tools in evaluating the child with short stature and predicting the clinical 
response to GH treatment.   
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OVERVIEW OF THIS THESIS 
 
AIM OF THESIS 
The aim of this thesis is to refine the diagnostic approaches to normal and 
abnormal growth in childhood, and disorders of the GH / IGF-I axis. 
 
STRUCTURE 
Section 1: The Diagnosis of Growth Hormone Deficiency 
In the first section, I will explore the potential of modifications to the GHST to 
improve specificity for GHD. This will focus separately on children with 
possible GHD undergoing insulin tolerance tests (ITT), and on children with 
unexplained hypoglycemia undergoing diagnostic fasting studies. 
 
Section 2: Mass Spectrometry and Insulin-like Growth Factor-I 
Measurement 
GH mediates systemic and local IGF-I production, and IGF-I concentrations are 
more consistent in serum than GH. Thus, IGF-I levels are often used as a 
screening tool for GHD1, 2. However, IGF-I measurement has limitations, most 
notably interference in measurement from binding proteins. Radioimmunoassays 
have traditionally been used to measure IGF-I concentrations but LCMS 
represents an opportunity to remove this interference from IGF-I measurement. 
In the second section of this thesis, I will review the literature and describe a 
study in which we used LCMS to measure serum IGF-I levels in a pediatric birth 
cohort. 
 
Section 3: Genetic Approaches to Disorders of the GH / IGF-I Axis 
There have been significant advances in the molecular and genetic understanding 
of the GH/IGF-I axis in recent years. In the third section of this thesis, I will 
focus on genetic approaches to improving our understanding of disorders of this 
axis. Given of the rarity of these disease-causing mutations, multi-centre 
collaboration is required to identify and study subjects with specific mutations. I 
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will describe a study in which separate collaborations were formed to 
demonstrate the pathogenicity of one common population variant, and a separate 
study to identify mutations causing a rare clinical phenotype. Although many 
investigators were involved in each of these studies, I will highlight my specific 
contributions to these bodies of work. 
 
Section 4: Nutrition, Growth and the GH / IGF-I Axis 
In the fourth section of this thesis, I will focus on the role of nutrition in 
childhood growth and the interaction between this and the GH / IGF-I axis. In 
addition to reviewing the interaction between nutrition and the GH/IGF-I axis, I 
will investigate the changes in body composition in early infancy and how this 
related to growth. The interplay between these new reference data for body 
composition in infancy with IGF-I and IGF-II measurement will also be 
described in this section. 
 
Conclusion of Thesis 
I will conclude this thesis with a summary of the contributions that this research 
has made to the evaluation of children with possible disorders of the GH / IGF-I 
axis. I will also provide an overview of my own personal development over the 
course of this thesis, and describe a number of active research studies that are 
building on this work. 
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Figure 1.1: This thesis evaluates three different approaches to evaluating childhood growth. This 
includes: Systemic (measurement and nutrition); Hormonal evaluation of the GH/IGF-I axis; and 
Genetic approaches. 
GH=Growth Hormone, IGF-I=Insulin-like Growth Factor-I. 
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SECTION 1 
DIAGNOSING GROWTH HORMONE DEFICIENCY IN 
CHILDHOOD 
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CHAPTER 1.1:  INTRODUCTION 
 
 
Growth in childhood is a dynamic process that is dependent upon genetic, 
psychosocial, nutritional, and medical factors. Disruption of any of these factors 
can affect growth, and deviations from normal growth patterns may consequently 
be the initial presenting sign of a long list of potential diagnoses. Thus, the 
monitoring of childhood growth is a crucial component of routine paediatric care 
and represents a valuable screening tool for detecting disease3-5. 
 
The growth hormone (GH) / insulin-like growth factor (IGF)-I axis is a key 
mediator of childhood growth, and disordered GH secretion or action is 
considered as a possible cause of short stature when systemic disease has been 
ruled out6. Despite human GH replacement therapy being available since 1956 
and synthetic GH being produced since 19787, the diagnostic approach to GH 
deficiency (GHD) is limited by tests that have poor specificity for disease8, 9. For 
this reason, GHD has been described as “the most difficult condition to diagnose, 
but easiest to treat”10. Deviations from the expected growth pattern may be an 
early sign of disease, but can also represent measurement error or normal 
variants of childhood growth6, 11. This will be reviewed in Chapter 1.2. 
 
Variation in the diagnostic approaches to GHD is a direct result of the absence of 
a suitable “gold standard” test. The growth hormone stimulation test (GHST) is 
widely used, but poorly specific for disease. This is also true for the random 
measurement of GH during hypoglycaemia12, despite erroneously being 
described as a “quick and definitive diagnostic tool” in this setting13. In Chapters 
1.3 and 1.4, I will describe studies in which I have developed and tested 
modified protocols to improve the specificity of these tests for diagnosing GHD.  
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CHAPTER 1.2:  NORMAL GROWTH AND GROWTH MONITORING 
 
 
Growth is a sensitive indicator of health in childhood. The multifactorial 
influences on growth include psychological, systemic and nutritional factors6, 14. 
Hence the detection of abnormal growth prompts a more detailed systemic 
evaluation, requiring the physician to consider and rule out a long list of possible 
diagnoses3, 15. 
 
In this chapter, I will first provide an overview of normal childhood growth 
before outlining the clinical approach to children with abnormal growth patterns, 
including the diagnostic evaluation of GHD. 
 
1.2.1 THE NORMAL PATTERN OF CHILDHOOD GROWTH 
The observed pattern of normal childhood growth depends on the frequency of 
measurement. When measured every 6 to 12 months, a smooth and distinct 
growth trajectory is seen. This trajectory shows three different growth phases 
throughout childhood (Figure 1.2.1A). Weekly measurements unmask a seasonal 
variation in growth rate16, 17 (Figure 1.2.1B), whereas daily measurements 
demonstrate growth bursts in a pattern of “saltation and stasis”18, 19 (Figure 
1.2.1C). An understanding of these patterns of observed growth is key to 
interpreting interval growth measurements in a particular child. Measurement 
error20, 21, as well as diurnal variation22, 23 in height, may introduce further 
challenges when small increments in childhood growth are being observed. 
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Figure 1.2.1: The observed patterns of linear growth seen when a child is measured six- to 
twelve-monthly (A), weekly (B) or daily (C). 
Six- to twelve monthly measurements show distinct phases of constant growth throughout 
childhood (A). More frequent measurement unmasks seasonal variation, as demonstrated in 7-10 
year old children measured three-monthly (adapted from Marshall16). Saltation and stasis of 
growth is seen if daily measurements are used, as shown in a male infant (adapted from 
Lampl19)(C) 
 
1.2.1.1 The Growth Chart 
The earliest known longitudinal description of childhood growth was reported by 
George Louis Leclerc, who described Philibert Guneau de Montbeillard’s 
measurements of his son every six months from his birth in 1759 until he was 18 
years of age24 (Figure 1.2.2). The concept of describing an individual’s growth 
pattern relative to the population followed, with percentiles being proposed as a 
method of describing population anthropometric variation by Francis Galton in 
187525. Henry Bowditch was the first to design a chart of height and weight with 
percentiles in 189126, and his method has evolved into the growth charts that we 
use today27. Current growth reference standards utilise these charts to describe 
linear growth in reference populations. When used in paediatric practice, they 
allow for the identification of abnormal growth patterns in a child through 
comparison of an individual’s growth measurements with population norms. 
 
Age (years)
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
H
ei
gh
t
Decaying
Polynomial
Linear Sigmoid
H
ei
gh
t V
el
oc
ity
 (c
m
/y
r)
Month
Age (months)
Jan Feb Mar Apr May Jun Jul Aug Sept Oct Nov Dec
1
0
2
3
4
5
6
7
8
H
ei
gh
t (
cm
)
12 13 14 15 16 17 18 19 20 21 22 23 24
60
62
64
66
68
70
72
74
50th percentile
(males and females aged 7-10 years)
Infant Male
A B
C
  
 
 
28 
 
Figure 1.2.2: The linear growth of de Montbeillard’s son (1759-1777), plotted on the modern 
Center for Disease Control Growth Chart. This was the first longitudinal description of the 
pattern shown in Figure 1.2.1A. 
 
1.2.1.2 Linear Growth Pattern 
When measured every six months to one year, growth follows a predictable 
pattern that can be described mathematically. This includes rapid but 
decelerating growth in infancy and early childhood, which slowly deviates from 
a straight line and has the appearance of a decaying polynomial. Growth is 
relatively constant and linear through middle childhood and this is followed by a 
sigmoid curve through adolescence (Figure 1.2.1)28. There are genetic and sex 
differences in the timing of these phases of growth29, but the general patterns 
remain consistent. 
 
1.2.1.3 Seasonal Growth 
Leclerc also observed that there is seasonal variation17, 30 in the rate of childhood 
growth. There are between three and six growth spurts each year, each lasting 
from 13 to 155 days31. Height velocity peaks in summer/autumn17, 32, with 
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relatively slower growth in winter and spring17, 23. The difference in rate of 
growth between these seasons is as high as 30%17. This can give an appearance 
of fluctuating height velocity when followed closely throughout the year. 
Marshall demonstrated these observed patterns of growth velocity in children 
aged 7 to 9 years, and these data are shown in Figure 1B16. 
 
When considering longitudinal linear growth, the season of measurement can 
influence interpretation of growth pattern. Where a child’s height is measured 
frequently, seasonal slowing of growth may be misattributed to pathology33. As 
will be discussed later, time of day and measurement error can also be of 
significance. This is particularly true when small increments in height are being 
observed. 
 
1.2.1.4 Daily Growth 
Daily height measurements also demonstrate that growth does not follow the 
linear pattern shown in Figure 1A. In fact, it occurs in bursts (saltation), 
interspersed with periods of stasis (Figure 1C). Lampl et al described this in 31 
infants who were measured frequently over the course of 21 months. This group 
showed that infant growth only occurred during 5 to 10% of this time with bursts 
interspersed by periods of no growth lasting between 2 and 63 days19. 
 
1.2.1.5 Sources of Measurement Error 
Accuracy of measurement is a significant challenge in describing and monitoring 
childhood growth. Where minor increments in growth are being detected, small 
errors may provide false concern or reassurance. The most common sources of 
error are related to equipment or human error. 
 
People are taller in the morning than later in the day22, 23, although the magnitude 
of this effect varies between studies. In a study of 53 children, Voss et al 
reported that 0.31 cm in height was lost between 09:00 and 11:00 am, with a 
further 0.2 cm being lost by 1 pm. Other studies have reported a decrease in 
height of up to 1.5 cm from morning to late afternoon34, 35, with reversal of this 
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decrease after an afternoon nap35. It has been suggested that gentle upward 
traction on the child’s mastoid processes would correct for this diurnal variation 
in height23, 36, but this may just increase the measured height nonspecifically by 
approximately 3 mm22. 
 
Children under the age of two years should be measured supine by two 
observers, using a moveable footplate. The infant should be placed on a stable 
surface. Over the age of two years, a wall mounted stadiometer should be used37. 
Growth charts have been developed using this mode of measurement, and there 
is an approximately 0.7 cm difference between a supine and standing 2-year-
old37. If a child under the age of two years is measured using a standing 
stadiometer, their recorded height percentile will be lower as the growth chart 
has been developed based upon supine measurements. After two years of age, 
the change in position of measurement results in a reduction in the expected 
height at each percentile. Juxtaposition of growth charts before and after two 
years of age demonstrates this effect, and is demonstrated in Figure 1.2.338-41. 
 
Additional recommendations regarding technique are made in an effort to 
minimise inter-observer variation. Shoes should be removed and the child should 
stand against a wall with head, shoulders, buttocks and heels touching the wall. 
The child’s head should be in the Frankfort plane, where the upper margin of the 
ear canal and lower margin of the orbits are on the same horizontal plane37, 42. 
Similar recommendations are made for the supine infant, but this can be difficult 
to achieve. To improve reliability, a minimum of two measurements within 4 
mm of each other should be taken, and the average recorded42. 
 
Regular calibration of equipment is recommended to minimise this potential 
source of measurement error. The importance of this is highlighted by a study by 
Voss et al in 1990. This group evaluated 230 different measurement devices in 
active use in hospitals, schools, and primary care centres in the United Kingdom. 
They used the devices to measure a 100 cm rod and showed that measurements 
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ranged from 90 to 105.2 cm, and that microtoises tended to be fixed too low 
(resulting in an overestimation of the child’s height)43. 
 
Despite closely following these recommendations, height measurement is often 
inaccurate. Inappropriate or damaged equipment44, use of length instead of 
height, incorrect technique20 and/or child movement may all contribute to 
unreliable measurements. Training and standardisation of equipment can 
improve accuracy and facilitate improved growth surveillance21.  
 
 
 
Figure 1.2.3: There is a reduction in expected height when the child’s position changes from 
supine to standing. This figure demonstrates this reduction by juxtaposing the CDC supine 0-2 
year and standing 2-20 year growth charts for boys and girls at 2 years (Adapted from CDC38-41). 
 
1.2.2 THE MEDICAL ASSESSMENT OF FALTERING GROWTH 
The differential diagnosis for faltering growth may include systemic illness, 
psychosocial deprivation, endocrine disorders (e.g. thyroid dysfunction, adrenal 
insufficiency) and familial growth patterns (e.g. constitutional delay in growth 
and puberty). Screening laboratory tests are indicated in all patients where an 
aetiology is not identified45. These tests are shown in Table 1.2.1. 
 
Table 1.2.1: Recommended screening tests for children with unexplained short stature45 
Test Patients 
GIRLS
supine standing
24 362221 23 24 362221 23
BOYS
supine standing
Age (months) Age (months)
Change from Supine to Standing
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Full Blood Count All 
Erythrocyte Sedimentation Rate All 
Creatinine All 
Electrolytes All 
Bicarbonate All 
Calcium All 
Phosphate All 
Alkaline Phosphatase All 
Albumin All 
Thyroid stimulating hormone, thyroxine All 
IGF-I All 
IGFBP-3 All 
Celiac disease screen All 
Bone age x-ray All 
Karyotype Boys with genital abnormalities 
All girls 
Skeletal Survey  If body proportions suggest skeletal 
dysplasia, or height significantly 
below family target 
 
Using this approach, up to 5% of children with unexplained short stature are 
identified as having an underlying cause3. However, in one study of 1373 
patients, only 2% of patients with short stature had all of the recommended tests 
performed15, and it has been suggested that this screening approach in the 
absence of symptoms may not be cost effective15. This study estimated the 
laboratory cost at over $100,000 for each new diagnosis identified by these tests 
alone. 
 
1.2.3 GROWTH HORMONE DEFICIENCY 
GH is a key mediator of childhood growth, and deficiency usually presents with 
short stature. An exception to this is in infancy, where GH plays a less prominent 
role in mediating growth. In infants with GHD, microphallus or hypoglycaemia 
are often the presenting clinical features13, 46 (Chapter 1.4). 
 
As will be briefly described here, and recur as a theme throughout this thesis, the 
diagnostic tests for GHD have poor specificity for disease. Many normally 
growing children without GHD will appear to have this condition if these tests 
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are relied upon to make a diagnosis47-49, thus the tests should be considered 
“confirmatory” rather than “diagnostic”. However, there are also conditions 
where patients with neurosecretory dysfunction (NSD) may pass a stimulation 
test but have GHD50, 51 (see 1.2.4.3). 
 
1.2.3.1 The cost of a GHD misdiagnosis 
Between 30 and 50% of children treated with GH do not show a significant 
improvement in growth, indicating that the misdiagnosis of GHD is 
unfortunately common52. This difficulty in making the correct diagnosis is 
further highlighted by the variation in the reported prevalence of GHD from 1 in 
2,000 to 1 in 30,00053-55 children. This emphasises the need to improve the 
diagnostic tests for GHD, as unnecessary treatment with GH has significant costs 
for society, the family and, importantly, the child. 
 
Recombinant GH is expensive and this cost is borne by society, either through 
taxes or health insurance costs. The estimated cost varies according to brand of 
medication used (Table 1.2.2), dosing schedule56, IGF-I response to treatment57 
and weight. In the U.S., the cost is estimated at $15,000 per year for a 30 kg 
child, which can increase to over $50,000 in a pubertal adolescent58, 59. 
Consequently, GH generates almost $2 billion in annual sales revenue60. When 
used in the absence of GHD (i.e. idiopathic short stature), it has been argued that 
the cost of 4 cm additional growth achieved by treatment of one child could 
provide 200,000 vaccinations against measles for children in developing 
countries61. 
 
Table 1.2.2: Price Comparison for growth hormone products in Ireland in 2015 (per milligram)62. 
Note that the total annual cost does not include discarded growth hormone at the end of each vial. 
Formulation Cost per mg Cost of 1 mg daily 
over one year 
Genotropin (Pfizer) 
Go Quick 5.3 mg € 21.75 € 7,938.75 
Go Quick 12 mg € 26.53 € 9,683.45 
Miniquick € 28.65 € 10,457.25 
Norditropin (Novo Nordisk) 
SimpleXx 15 mg € 30.23 € 11,033.95 
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SimpleXx 10 mg € 38.33 € 13,990.45 
SimpleXx 5 mg € 38.48 € 14,045.20 
Saizen (Merck Serono) 
20 mg € 30.51 € 11,136.15 
12 mg € 30.51 € 11,136.15 
8 mg € 30.51 € 11,136.15 
6 mg € 30.51 € 11,136.15 
Zomacton (Ferring) 
10 mg € 21.80 € 7,957 
 
GH is administered by daily subcutaneous injection, which may cause 
discomfort to the child63. Long-term surveillance studies have shown conflicting 
data regarding a potential increased risk of mortality, malignancy64, 65 and 
stroke66-69. Other possible risks of treatment include intracranial hypertension, 
slipped capitulum of the femoral epiphysis70, and exacerbation of scoliosis; 
although the latter two of these are considered to be secondary to increased linear 
growth. Although generally considered to have a good safety record, the 
Pediatric Endocrine Society and European Society for Paediatric Endocrinology 
have recommended continued surveillance of children and adults who have been 
exposed to GH treatment71. Given this background of concern for potential risks 
associated with treatment, avoiding treatment in children for whom there is 
minimal benefit would be preferred. However, the currently available diagnostic 
tools often do not accurately identify these children. 
 
1.2.4 THE DIAGNOSTIC APPROACH TO GROWTH HORMONE DEFICIENCY 
Current consensus guidelines for diagnosing GHD include the interpretation of 
height both absolutely and relative to the heights of the parents and siblings, 
height velocity, bone age, serum IGF-I and serum insulin-like growth factor 
binding protein 3 (IGFBP-3), and GHST72. Each of these tests has poor 
specificity for diagnosing GHD, making it extremely important to accurately 
measure children and to only investigate children with a clinical phenotype 
suggestive of GHD. The diagnostic steps are summarised in Figure 1.1.4. 
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Figure 1.1.4: Current diagnostic approach to the child with suspected GHD 
 
1.2.4.1 IGF-I Measurement 
IGF-I is a 70 amino acid polypeptide73 with structural similarities to insulin73, 74. 
The somatomedin hypothesis linking GH with hepatic IGF-I production and 
subsequent cellular growth was proposed in 195775, but has undergone numerous 
revisions. The current understanding of the complex relationship between GH, 
IGF-I and growth includes: GH-independent IGF-I mediated prenatal growth; 
GH-dependent postnatal growth mediated by interplay between hepatic IGF-I, 
IGFBP-3 and Acid Labile Subunit (ALS); and local autocrine and paracrine GH-
dependent IGF-I production and action76. Despite circulating levels being 
comprised predominantly of hepatic IGF-I, local autocrine and paracrine action 
of IGF-I can maintain normal linear growth in the absence of hepatic IGF-I 
production77. Therefore, despite the established role of IGF-I measurement in the 
screening for GHD, it is possible that circulating IGF-I does not reflect IGF-I 
action at the growth plate. 
 
The potential role of serum IGF-I measurement by radioimmunoassay to identify 
children with GHD was first proposed in 1977 by Furlanetto78. Copeland et al 
subsequently showed that IGF-I concentrations increase following GH 
administration79. Spontaneous GH secretion was then shown to be associated 
with serum IGF-I concentrations80. IGF-I and IGFBP-3 concentrations were then 
identified as a useful screen for GHD in children with short stature2, 81, and 
aemiacylgopyHhtworG rooP / erutatS trohS
Diagnostic Fasting StudyScreening Laboratory Tests IGF-I, IGFBP-3
Measurement
Growth Hormone Stimulation Test
Diagnosis of GH Deficiency
  
 
 
36 
young adults with childhood onset GHD who were being evaluated for persistent 
GHD at completion of linear growth1. The reported sensitivity and specificity of 
low IGF-I concentrations for GHD are shown in Table 1.2.3. The gold standard 
test used for the diagnosis of GHD in most of these studies was the GHST, 
which, as will be described later in this chapter, has limitations. Regardless, the 
sensitivity of IGF-I measurement ranges from 34 to 86% and specificity from 22 
to 97%. 
 
Limitations and potential areas for optimising IGF-I measurement will be 
explored throughout this thesis. Interference by IGFBPs provides a significant 
challenge for assays and the potential for mass spectrometry to advance this field 
will be studied (Section 2). Nutritional status influences growth and IGF-I 
concentrations, and I will study this association with measures of body 
composition in infancy (Section 4). In addition to this, unique cellular aspects of 
IGF-I production and action will be discussed in Section 3. 
 
1.2.4.2 IGFBP-3 Measurement 
IGFBP-3 is a member of the IGF superfamily of proteins, which contains five 
other IGFBPs. It binds IGF-I with higher affinity than the IGF-I receptor, and 
prolongs IGF-I half life as well as modulating free bioactive IGF-I availability82. 
ALS and IGFBP-3 bind approximately 75% of circulating IGF-I in a ternary 
complex, with other IGFBPs contributing in smaller proportions to IGF-I 
binding83, 84. IGFBP-3 is expressed in numerous tissues, and differential local 
expression has been suggested to have an IGF-I independent role in colon85, 
oesophageal86, 87, prostate88, 89, and breast90 cancers. 
 
Similar to IGF-I, IGFBP-3 concentrations reflect GH activity. Concentrations are 
elevated in acromegaly91, and reduced in adults with GH receptor deficiency92. 
IGF-I treatment of adults with GH receptor deficiency does not normalise 
IGFBP-3 concentrations, demonstrating that IGFBP-3 production is dependent 
upon GH rather than IGF-I92. In addition to GH, other factors can increase 
IGFBP-3 concentration and these include parathyroid hormone, 1,25-
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dihydroxyvitamin D93, insulin94, interleukin-195, and tumor necrosis factor 
alpha96. Factors such as androgens97, estrogens98, and glucocorticoids99 can 
decrease IGFBP-3 concentrations. 
 
IGFBP-3 measurement has an established role in the screening of short children 
with suspected GHD8, 9, where low concentrations are suggestive of disease. 
However, the reported sensitivity and specificity of this approach varies from 22 
to 97% and 60 to 100%, respectively100 (Table 1.2.3). 
 
1.2.4.3 Profiles of GH Secretion 
GH is secreted in a pulsatile pattern, with increased amplitude of these pulses 
occurring during puberty. In childhood, these pulses are periodic and occur 
approximately every 200 minutes101. This pulsatile secretion represents a 
diagnostic challenge when trying to determine if a child has GHD. 
 
The practice of performing 24-hour GH profiles has fallen from favour due to the 
labour-intensive nature of the test and limited additional information provided. 
Despite this, it has been suggested that some children with sufficient peak GH 
concentrations may have reduced spontaneous secretion102, termed NSD. This 
may be more common in children following cranial irradiation, and has been 
reported in that context in children who have been treated for acute 
lymphoblastic leukaemia50, 103, 104. It is possible that NSD may be missed if the 
GHST is relied upon to make the diagnosis in GHD105, although some studies 
have also shown no increase in the diagnostic yield by doing this 24-hour GH 
profile106. As previously mentioned, IGF-I concentrations can correlate with 
spontaneous GH secretion80. NSD may be considered in at-risk children with a 
suggestive clinical phenotype and low IGF-I concentrations, despite normal 
stimulated GH concentrations and normal nutritional status (Chapter 4.2). 
 
Table 1.2.3: The sensitivity and specificity of IGF-I and IGFBP-3 measurement for GHD. 
Adapted from100, MPHD=multiple pituitary hormone deficiency 
Author Population GHD Diagnosis IGF-1 IGFBP-3 
   Limit 
(Z) 
Sens 
(%) 
Spec 
(%) 
Limit 
(Z) 
Sens 
(%) 
Spec 
(%) 
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Blum 
1990107 
132 patients with GHD (116 
isolated GHD, 16 MPHD), 
mean age 11.2y (range 0.25-
34.4). 
Clinical diagnosis of 
GHD 
   -1.6 97 95 
Hasegawa 
1994108 
59 children with GHD Peak GH < 5 ng/ml    -1.6 92 69 
Bussieres 
2000109 
43 prepubertal children with 
GHD (28 isolated GHD, 15 
MPHD) 
Peak GH <10 ng/ml -1.6 72 95    
Nunez 
199681 
104 children with GHD (aged 
3-16 years) 
Peak GH < 7 ng/ml -1.7 69 76 -1.7 50 69 
Boquete 
2003110 
34 children with GHD (23 
isolated GHD, 11 MPHD) 
Peak GH <7 ng/ml on 2 
stimulation tests 
-1.7 68 97 -1.8 90 60 
Cianfarani 
2002111 
33 children with GHD (32 
prepubertal) 
Peak GH <10 ng/ml 
Abnormal MRI brain 
Positive growth 
response to GH Rx 
-1.9 73 95 -1.9 30 98 
Mitchell 
1993112 
318 patients with GHD (aged 
0.9 to 25.4 years) 
Peak GH < 5.2 ng/ml 
Height Velocity <-0.8 
Z 
-2 62 47 -0.5 61 68 
Das  
2003113 
134 children with GHD 
(mean age 5.2y, range 0.1-
16.9) 
Clinical diagnosis of 
GHD 
-2 86 100 -2 79 86 
Lissett 
2003114 
244 children with childhood-
onset GHD 
Peak GH < 3 ng/ml -2 86     
Rikken 
1998115 
63 children with GHD Peak GH < 7.5 ng/ml -2 65 78 -2 53 81 
Tillmann 
1997116 
60 children with GHD (17 
isolated GHD) 
Height <-2 Z 
Height Velocity <-2 Z 
Delayed Bone Age >2y 
-2 34 72 -2 22 92 
Weinzimer 
1999117 
72 children with brain tumors 
and GHD 
Height velocity < -2 Z 
Peak GH < 7 ng/ml 
-2 73  -2 50  
 
1.2.4.4 GH Stimulation Testing 
The GHST comprises the administration of a pharmacological stimulus for GH 
secretion and the subsequent serial measurement of GH concentrations. Various 
stimuli for GH secretion are used in the clinical evaluation of GH reserve, of 
which insulin induced hypoglycaemia is often considered to be the gold 
standard118. There are variations in protocols used for the timing of GH 
measurement during the insulin tolerance test (ITT), with most recommending 
measurement of GH concentrations at baseline and 30, 60 and 90 minutes 
following insulin administration. Other protocols recommend additional 
measurements within the first forty minutes following insulin administration119-
121. Other commonly used pharmacological stimuli include clonidine, arginine, 
levodopa, and glucagon122. Similar to the ITT, protocols used for each of these 
stimuli include the serial measurement of GH after administration119-121. 
 
A peak GH concentration below an arbitrary threshold between 5 and 10 ng/ml is 
generally used to determine if a child has GHD, but this approach is problematic. 
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These thresholds were developed using GH measurements by polyclonal assays, 
and measurements using these may not be consistent with modern monoclonal 
assays123. There is even assay variability in GH measurements between 
monoclonal assays, so results may vary between hospitals depending on the 
specific assay used by the laboratory124. Another factor that may influence result 
interpretation is inter-individual variation in GH pharmacokinetics, resulting in 
measured serum GH concentrations not necessarily reflecting secreted GH125. 
 
When considering all of these issues, it is conceivable that these tests do not 
correlate well with response to GH treatment. The sensitivity of a stimulated GH 
peak concentration below 10 ng/ml for detecting prepubertal children who will 
have a height increase by 0.5 SDS within one year of GH treatment is 82%. 
However, specificity for these parameters is 24%126. Even lower peak GH 
concentrations also do not correlate well with growth response to treatment126-128. 
Almost a quarter of normally growing children without clinical features of GHD 
have a peak GH concentration of less than 7 ng/ml during GHST, and almost 
half will have a peak serum GH concentration of less than 10 ng/ml47. Although 
the sensitivity of these tests for GHD is favorable, many normal children without 
GHD will be characterised as having disease based on a low peak GH 
concentration on stimulation testing alone47-49. Thus, GHST result should be 
interpreted in the clinical context and should not be considered in isolation to 
diagnose GHD72. It should also be noted that these tests are not benign and 
mortality has been reported with the inappropriate management of 
hypoglycaemia following insulin or glucagon administration as part of a 
GHST129. 
 
Despite their poor reproducibility130, 131 and the aforementioned challenges in 
interpreting results, the GHST remains central to diagnosing GHD72. Questions 
surrounding most aspects of GHSTs are debated amongst endocrinologists. 
These include when and how they should be performed, priming of peripubertal 
patients with sex steroids132, assays used, and interpretation of GHTS results are 
issues that remain unresolved. Multiple surveys of practice have highlighted 
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variations in each of these areas62, 133-135. In 1995, only a third of 
endocrinologists believed that GH response to stimulation testing correlated with 
response to therapy133, and more recent studies show that this hasn’t changed. 
Only half of clinicians in 2010 reported that they would continue to use GHST if 
insurance providers did not insist on these prior to approving therapy135. 
 
1.2.4.5 Variation in Approach to diagnosing and treating GHD in Ireland 
Given the aforementioned challenges in interpreting the diagnostic evaluation of 
the child with possible GHD, significant variations in clinical practice have been 
described through international questionnaire-based studies122, 133, 136, 137. I have 
performed a similar survey in Ireland, and shown variable approaches to each 
step of the diagnostic and therapeutic approaches to GHD (Appendix A). This 
includes differences in: number of failed GHSTs required to diagnose GHD; GH 
secretagogues used; sex steroid priming; diagnostic approach to GHD in 
neonates; criteria used to select GH brand used; criteria for stopping GH 
treatment; and retesting after completion of treatment62. 
 
1.2.5 SUMMARY 
While monitoring childhood growth is a central component of general paediatric 
health surveillance, the interpretation of growth is complicated by measurement 
error, as well as daily, seasonal and annual growth variation. Medical causes of 
poor linear growth will be identified in 5% of cases by the recommended 
baseline laboratory screening. Evaluating for GHD is recommended in the subset 
of the remaining 95% with a suggestive clinical phenotype. IGF-I and IGFBP-3 
measurement, as well as GHST play important roles in this evaluation but can 
often lead to the misdiagnosis of GHD. In this thesis, I will explore potential 
areas in which this diagnostic approach may be refined.  
 
In the following chapters of this Section, I will describe novel interventions to 
improving the specificity of the GHST for diagnosing GHD in children with 
short stature (Chapter 1.3) and unexplained hypoglycemia (Chapter 1.4). 
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CHAPTER 1.3: IMPROVING THE SPECIFICITY OF THE GROWTH 
HORMONE STIMULATION TEST THROUGH SERIAL GROWTH 
HORMONE MEASUREMENT AFTER IV CATHETER PLACEMENT 
 
Publication 
Hawkes CP, Mavinkurve M, Fallon M, Grimberg A, Cody DC. Serial GH 
measurement after intravenous catheter placement alone can detect levels above 
stimulation test thresholds in children. J Clin Endocrinol Metab. 
2015;100(11):4357-63. (Appendix B) 
 
 
The GHST comprises a pharmacologic stimulus causing GH secretion, and serial 
serum GH being measured. In order to demonstrate GH sufficiency, one of these 
serum GH measurements should be greater than a predefined arbitrary threshold 
concentration. This is described in more detail in 1.2.4. 
 
As early as 1968, Kaplan et al identified “excitement alone” as a stimulus for GH 
secretion that can complicate provocative testing138. In their study of 134 
children, 53 of whom had hypopituitarism, 18 (22%) of the children without 
GHD had a fasting GH concentration of greater than 9 ng/ml prior to receiving 
insulin. The GH concentration prior to insulin administration was higher than the 
peak concentration after insulin induced hypoglycaemia in eight of these. Of 
note, none of the children with hypopituitarism had a stimulated peak GH 
concentration of greater than 2.2 ng/ml in this study. 
 
The hypothesis was that intravenous line placement (IVP) stimulates GH 
secretion and may deplete GH reserve in some children undergoing subsequent 
ITT. Consequently, frequent measurement of GH concentrations after IVP may 
identify GH sufficient children who would be missed if ITT measurements alone 
were used. 
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1.3.1 AIM 
The aim of this study was to determine if measurement of GH at baseline, 15 and 
30 minutes after IVP would identify additional GH sufficient patients, not 
identified by subsequent ITT. The secondary aim was to determine if this was 
also relevant for cortisol response to ITT. 
 
1.3.2 METHODS 
The ITT protocol was modified at Our Lady’s Children’s Hospital Crumlin 
(OLCHC), Dublin, Ireland to include additional serum GH measurements in the 
thirty minutes following IVP but prior to insulin administration. All children 
undergoing ITT at OLCHC between January 2013 and December 2014 were 
included in this study. This study was approved by the Institutional Review 
Board of OLCHC. 
 
1.3.2.1 Baseline Evaluation 
IGF-I was measured by enzyme-labeled chemiluminescent immunometric assay 
(Immulite 2000 XPi, Siemens Healthcare Diagnostics, Berlin, Germany). Z-
scores were reported according to laboratory standards using chronological age 
and gender reference data. GH, cortisol and IGFBP-3 concentrations were also 
measured by enzyme-labeled chemiluminescent immunometric assays (Immulite 
2000 XPi, Siemens Healthcare Diagnostics, Berlin, Germany). Bone age x-rays 
were performed and these were interpreted by paediatric radiologists using the 
standards of Greulich and Pyle139. 
 
1.3.2.2 Insulin Tolerance Test Protocol 
According to protocol in this institution, all prepubertal patients with a recorded 
bone age over 10 years underwent sex steroid priming prior to insulin tolerance 
test. Variations in practice regarding sex steroid priming have been reported, and 
similar criteria to those used in this study for sex steroid priming are used in 
many centres internationally136. Sex steroid priming for males consisted of one 
100 mg dose of intramuscular testosterone ten days prior to the test, and for 
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females consisted of oral ethinylestradiol 10 mcg daily for three days prior to the 
test. 
 
Children fasted for 12 hours prior to undergoing ITT. Ethyl chloride topical 
analgesia spray was used prior to insertion of an intravenous catheter. If 
placement was unsuccessful, this procedure was repeated with the use of 
analgesia spray. One intravenous line was placed 30 minutes prior to insulin 
administration, and this was used for insulin administration as well as GH and 
cortisol sampling.  
 
Serum GH and cortisol concentrations were measured at the time of IVP and 
again 15 and 30 minutes later (t= -30, -15, 0). Intravenous insulin (0.1 u/kg) was 
administered 30 minutes after IVP (t=0) and GH, cortisol and glucose 
concentrations were measured at 15, 25, 35, 60 and 90 minutes following insulin 
administration (Figure 1.3.1). A glucose concentration of less than 45 mg/dL 
after insulin administration was required for test to be included in this study. 
 
 
Figure 1.3.1: The protocol for insulin tolerance testing used in this study, with additional 
measurements prior to insulin administration marked. 
 
1.3.2.3 Retrospective chart review procedure 
Medical records were reviewed and weight, height, pubertal stage, parental 
heights, and comorbidities were recorded. IGF-I and IGFBP-3 concentrations, 
and bone age results were recorded. Puberty was defined as breast Tanner stage 
≥ 2 in females or testicular volume ≥ 4 ml in males. Patient information was 
tabulated anonymously and maintained on a password-protected file on a secure 
server.  
 
Fast for 12 Hours
0-15-30 453015 907560
IV Placement
(with topical analgesia)
Insulin
Administered
GH, Cortisol and Glucose Measured
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1.3.2.4 Statistical analysis 
Patients were categorised according to the indication for ITT. Children 
undergoing initial evaluation of possible GHD were assigned to Group 1. 
Patients treated with GH who had completed linear growth and were undergoing 
ITT to determine if they had persistent GHD were assigned to Group 2. Peak 
stimulated GH concentrations of Groups 1 and 2 were analysed separately, but 
peak stimulated cortisol was analysed in both groups together. This distinction 
was made because many guidelines use different thresholds for stimulated peak 
GH concentrations in these two patient groups9, 118, 140, whereas the threshold for 
peak stimulated cortisol concentrations is similar in both groups. 
 
Height and weight z-scores at the time of stimulation test were generated using 
the World Health Organization standards141, using STATA/SE version 12.0 
(StataCorp, College Station, TX, USA). All data analyses were performed using 
SPSS 22.0 (IBM, NY, USA). Figures were generated using Prism 5.0 (GraphPad 
Software Inc, CA, USA) and Adobe Illustrator 16.0 (Adobe Systems Inc., 
California, USA). 
 
1.3.3 Results 
During the study period, 97 patients underwent 99 ITTs. Two tests were 
repeated, as the initial test did not induce hypoglycaemia below 45 mg/dL and 
were not included in the analysis. Of the 97 patients, 76 were evaluated for a 
possible new diagnosis of GHD (Group 1) and 21 had been treated for paediatric 
GHD, completed linear growth, and were evaluated at transition for adult GHD 
(Group 2). The demographics of the patients who underwent testing are shown in 
Table 1.3.1. In the children in Group 1, mean (SD) baseline IGF-I z-score was -
1.2 (0.9) and bone age was delayed by 1.4 (1.9) years. 
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Table 1.3.1: Demographics of the patients undergoing insulin tolerance testing in this study. 
Continuous variables presented as mean (SD). *Children classified as having hypopituitarism 
have two or more anterior pituitary hormone deficiencies. CNS=Central Nervous System, 
SGA=Small for Gestational Age 
	 Group	 1	 (Initial	
Evaluation)	(n=76)	
Group	 2	 (Transition)	
(n=21)	
Age	(years)	 10.9	(3.7)	 17.1	(1.2)	
Male	(%)	 58	(76.3%)	 16	(76.2%)	
Pubertal	(%)	 24	(31.6%)	 21	(100%)	
Comorbidity	 	 	
			None	 48	(63.2%)	 11	(52.4%)	
			Hypopituitarism*	 4	(5.3%)	 1	(4.8%)	
			CNS	mass	or	malignancy	diagnosis	 4	(5.3%)	 5	(23.8%)	
			SGA	 3	(3.9%)	 0	
			Genetic	Syndrome	or	Dysmorphism	 8	(10.5%)	 0	
			Other	Dx	(not	associated	with	GHD)	 7	(9.2%)	 4	(19%)	
Height	z-score	 -2.46	(0.96)	 -0.73	(0.88)	
Weight	z-score	 -1.75	(1.37)	 -0.08	(1.27)	
Midparental	Height	z-score	 -0.29	(0.78)	 0.22	(0.73)	
Midparental	Height	z-score	minus	Height	z-score	 2.18	(0.85)	 0.22	(0.73)	
 
Serial GH measurement following IVP and prior to insulin administration 
increased the number of children passing the stimulation test from 8/76 (10.5%) 
to 19/76 (25%) if a threshold of 7 ng/ml were used (Table 1.3.2). Many patients 
in Group 1 had peak stimulated GH concentrations above thresholds of 3 ng/ml, 
5 ng/ml and 7 ng/ml fifteen minutes after IVP (Figure 1.3.2), demonstrating that 
this measurement might identify additional children with sufficient GH 
secretion.  
 
Of the 11 children with peak GH concentrations ≥ 7 ng/ml after IVP only, all 
were being investigated for isolated GHD and none had a coexisting risk factor 
for deficiency such as CNS malignancy or hypopituitarism. Three of these 
children had peak GH concentrations at the time of IVP, five peaked fifteen 
minutes later and five were 30 minutes later (Figure 1.3.3). Only one of these 
children had peak GH concentrations ≥ 7 ng/ml at more than one of these time 
points. This group had a mean (SD) age of 11.6 (3.9) years, IGF-I z-score of -1.3 
(1), IGFBP-3 z-score of 0.8 (1.3), midparental height z-score of -0.04 (0.8), 
height z-score of -2.4 (0.9), weight z-score of -2.1 (0.8), bone age delay of 0.6 
(2.1) years, and peak cortisol on ITT of 20.6 (3.5) mcg/dL. These were not 
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significantly different than the age (10.2 (3.8), p=0.4), IGF-I z-score (-1.2 (0.9), 
p=0.6), IGFBP-3 z-score (1 (1), p=0.9), midparental height z-score (-0.3 (0.8), 
p=0.3), height z-score (-2.5 (1), p=0.9), weight z-score (-1.7 (1.4), p=0.6), bone 
age delay (1.6 (1.9) years, p=0.2) or peak cortisol on ITT (18.7 (5.7) mcg/dL, 
p=0.2) of the other children in Group 1.  
 
Table 1.3.2: The number of tests with peak stimulated growth hormone concentrations greater 
than 3 ng/ml, 5 ng/ml and 7 ng/ml following intravenous line placement, insulin administration, 
or both. 
	 Group	1	(Initial	
Evaluation)		
(n=76)	
Group	 2	
(Transition)	
(n=21)	
All	
(n=97)	
Peak	GH	≥	3	ng/ml	 	 	 	
None	 30	 11	 41	
Intravenous	line	Only	 13	 1	 14	
Insulin	induced	hypoglycaemia	Only	 18	 7	 25	
Both	 15	 2	 17	
	 	 	 	
Peak	GH	≥	5	ng/ml	 	 	 	
None	 48	 12	 60	
Intravenous	line	Only	 10	 3	 13	
Insulin	induced	hypoglycaemia	Only	 11	 6	 17	
Both	 7	 0	 7	
	 	 	 	
Peak	GH	≥	7	ng/ml	 	 	 	
None	 57	 13	 70	
Intravenous	line	Only	 11	 2	 13	
Insulin	induced	hypoglycaemia	Only	 5	 6	 11	
Both	 3	 0	 3	
	 	 	 	
Peak	Cortisol	≥	18	mcg/dL	 	 	 	
None	 31	 9	 40	
Intravenous	line	Only	 2	 2	 4	
Insulin	induced	hypoglycaemia	Only	 33	 7	 40	
Both	 10	 3	 13	
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Figure 1.3.2: The number of patients with growth hormone (A, B) or cortisol concentrations 
above the defined thresholds in the 30 minutes following intravenous line placement (Time -30 
to 0) and following insulin administration (Time 15 to 90 minutes, shown with a grey 
background). The intravenous line was placed at time -30 minutes, and insulin was administered 
at time 0 minutes. 
 
 
Figure 1.3.3: The serum growth hormone concentration profiles in children in Group 1 whose 
peak growth hormone concentration was ≥ 7 ng/ml at 0 (A), 15 (B) and 30 (C) minutes from 
intravenous line insertion without a subsequent peak ≥ 7 ng/ml after insulin administration. Each 
symbol and line represents the growth hormone profile in one patient. Note that one patient had 
growth hormone concentrations ≥ 7 ng/ml at each of these time points and is represented in each 
diagram. 
 
Serial measurement of GH concentrations after IVP in Group 2 had a less 
significant effect on the number of patients reaching a predefined threshold GH 
concentration. The number of patients passing the test increased from 9/21 
(42.9%) to 10/21 (47.6%) if a threshold of 3 ng/ml was used, or from 6/21 
(28.6%) to 8/21 (38.1%) if a threshold of 7 ng/ml was used (Figure 1.3.2, Table 
1.3.2). The total number of patients in both Groups 1 and 2 combined with a 
peak stimulated cortisol concentration of ≥18 mcg/dL increased from 57/97 
(58.8%) to 61/97 (62.9%) with serial measurement before insulin administration. 
This represents an increase in specificity of 6.5%. 
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Peak GH concentration after IVP did not correlate closely with peak GH after 
ITT (Group 1 R2 = 0.05, Group 2 R2 = 0.002). In contrast the peak cortisol 
concentration prior to insulin administration was more closely related to the peak 
cortisol concentration during ITT (Group 1 R2 = 0.26, Group 2 R2 = 0.41) 
(Figure 1.3.4). 
 
 
Figure 1.3.4: Peak cortisol (A) or growth hormone (B) in the 30 minutes prior to insulin 
administration plotted against the peak after administration of insulin. 
 
1.3.4 DISCUSSION 
We have demonstrated that many children undergoing evaluation for GHD can 
have a peak GH concentration greater than 7 ng/ml within 30 minutes of IVP, 
even without pharmacologic stimulation. The subsequent insulin induced 
hypoglycaemia during ITT does not always replicate this peak stimulated GH 
concentration. As a result, serial measurement of GH concentration following 
IVP may identify additional children with GH sufficiency who would not have 
been detected by ITT alone. Similar additional serial measurements of cortisol 
do not add significantly to the identification of children with adrenal sufficiency 
using the ITT. 
 
The hospital environment and IVP may represent stressors to the child 
undergoing GHST, and stress may be a stimulus for GH secretion142. Some 
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authors have recommended that patients be admitted the night before a GHST, in 
order to acclimatise to the environment and to optimise the utility of the test143. 
However, this is often impractical due to limited hospital resources. Most centres 
perform these tests in the outpatient setting, often completing two separate tests 
on the same day62, 133. We have shown that frequent GH measurement after IVP 
should be considered in the context of GHSTs being performed as a day 
procedure. 
 
Thirteen children (11/76 in group 1 and 2/21 in group 2) in this study had a peak 
GH concentration greater than 7 ng/ml following IVP without a subsequent 
response of similar magnitude to insulin-induced hypoglycaemia. Although we 
have performed this analysis only in children undergoing ITT, it is likely that 
this phenomenon is seen with IVP prior to the administration of alternative GH 
secretagogues. It is not clear if a stimulated GH surge prior to ITT will reduce 
the likelihood of subsequent response to ITT and there are children in this study 
with peak GH concentrations above the thresholds following both sequential 
stimuli. However, it is possible that a GH peak can have a negative effect on 
subsequent stimuli. In adult volunteers, sequential stimuli of GH secretion can 
result in an attenuated response to the second stimulus, although this is less 
pronounced when insulin induced hypoglycaemia is the second stimulus142. 
Similarly, the GH response to frequent bouts of heavy exercise is attenuated 
when the duration between these is reduced to less than one hour144. Possible 
mechanisms for the reduction in GH response to a second stimulus include 
depletion of immediately releasable pituitary GH by the first stimulus, or an 
effect of GH autoregulation. GH inhibits GHRH production through direct 
negative feedback and indirectly via the production of somatostatin and IGF-I145, 
both of which exert negative feedback on hypothalamic GHRH production and 
pituitary GH exocytosis146. 
 
While a large proportion of children categorised as having GH insufficiency on 
GHST will not respond to GH treatment, there are also children who have 
sufficient GH secretion and respond well to GH treatment. It seems likely that 
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the children who responded to IVP with a GH level greater than 7 ng/ml are truly 
GH sufficient, but this assumption cannot be verified because there is no gold 
standard test for GHD. In this centre, a stimulated GH threshold of greater than 7 
ng/ml was used to determine whether or not GH was prescribed. Thus, we cannot 
determine whether additional GH measurement reduced the sensitivity of the 
provocative test for GH responsive short stature. We also note that 37% of the 
children in this study did not have a peak cortisol concentration greater than 18 
mcg/dL. This may be due to the heterogenous group of patients included, many 
of whom had hypopituitarism or a CNS malignancy. In addition, we note that 
many children without adrenal insufficiency will have a peak stimulated cortisol 
of less than 18 mcg/dL on ITT147. 
 
The additional benefit of serial GH measurement following IVP shown in this 
study may be ameliorated by variations in practice elsewhere. As previously 
mentioned, the specificity of a single GHST for GHD is poor and many centres 
perform two tests to improve this specificity. The use of a second stimulation test 
in the patients described in this study may have detected more of the children 
with peak GH concentrations above the threshold following IVP. At the time of 
this study, there was no consensus regarding sex steroid priming prior to GHST 
in prepubertal children but the practice of using this for children with bone ages 
greater than 10 years is consistent with many centres136 and the recent Pediatric 
Endocrine Society guidelines72. Sex steroid priming in younger prepubertal 
children may increase the specificity of the GHST for GHD148, and it is possible 
that serial GH measurement following IVP would provide less additional benefit 
if sex steroid priming was used in all prepubertal children undergoing GHST. 
Thus, the results of this study should be interpreted in the context of serial 
measurements after IVP with a single stimulation test in a centre where sex 
steroid priming is only used in limited circumstances. Specifically, we report that 
serial GH measurement after IVP detected 13 children (13.4%) with a peak 
stimulated GH concentration of greater than 7 ng/ml, but it is not known if these 
children would have otherwise been detected in combination with a second 
GHST or sex steroid priming. 
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In conclusion, we advise caution when performing GHSTs, as delays in GH 
measurement may increase the number of patients misclassified as having 
insufficient GH secretion. If the GH secretagogue or stimulus is administered 
immediately following IVP, it is important to ensure that there are frequent 
additional measurements in the first 30 minutes following placement and 
administration of the GH provocative test substance. Also, if there is any delay in 
administering the intravenous stimulus following IVP, the frequent sampling of 
GH in the first thirty minutes following IVP should be performed. 
 
1.3.5 CHAPTER CONCLUSION 
The poor specificity of the GHST is well established, and have caused many 
endocrinologists to question whether or not these tests should even be 
performed149-151. Any modification of this test that improves specificity is 
welcome, and will facilitate the diagnostic evaluation of children with suspected 
GHD. This study has been instrumental in the modification of the GHSTs at 
OLCHC and Children’s University Hospital Temple Street. All institutions in 
Dublin now measure serial GH concentrations after placing IV lines in children 
undergoing GHST.  
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CHAPTER 1.4: EVALUATING CHILDREN WITH HYPOGLYCAEMIA FOR 
GROWTH HORMONE DEFICIENCY 
 
Publications 
Hawkes CP, Stanley CA. Pathophysiology of neonatal hypoglycemia. In: Polin 
RA, Fox WW, Abman SH, editors. Fetal and Neonatal Physiology: Expert 
Consult - Online and Print (In Press). 5 ed: Elsevier/Saunders; 2016. p. 1550-60 
(Appendix C). 
 
Hawkes CP, Grimberg A, Dzata VE, De Leon DD. Adding glucagon-stimulated 
GH testing to the diagnostic fast increases the detection of GH-sufficient 
children. Horm Res Paediatr. 2016;85(4):265-72 (Appendix D). 
 
Presentation 
Hawkes CP, Dzata VE, Grimberg A, De Leon DD. Integrating growth hormone 
testing with hypoglycaemia investigation. American Pediatric Society / Society 
for Pediatric Research, May 2014; Vancouver (Appendix E). 
 
 
GH does not play a significant role in regulating prenatal growth, and length at 
birth in infants with congenital GHD is within the normal range. This is not the 
case for IGF-I, where infants with IGF-I resistance or deficiency can present 
with prenatal growth restriction152, 153. Thus, identifying the infant with 
congenital GHD is a challenge. 
 
The two largest studies of infants with GHD have characterised the clinical 
phenotype13, 46. Bell et al included 169 infants with GHD who presented with 
hypoglycaemia in their study, over 90% of whom also had additional pituitary 
deficiencies and abnormal pituitary MRI evaluations13. Herber et al described 29 
children with GHD and demonstrated that hypoglycaemia is more common in 
those presenting before 6 months of age, than after the first 6 months of life46. As 
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the child becomes older, persistent impaired fasting tolerance is seen but 
hypoglycaemia becomes less problematic154. 
 
Given that neonatal hypoglycaemia may be the only presenting sign of children 
with congenital GHD, the diagnostic evaluation of infants with unexplained 
hypoglycaemia should include consideration of this potential underlying 
diagnosis. The diagnostic tests for GHD in infants are even more challenging 
than in older children. IGF-I measurement in this age group is of limited utility 
with current assays (Chapter 2.2)124. GH measurement during hypoglycaemia has 
been suggested, and even erroneously described by Bell as “a quick and 
definitive diagnostic tool”13. The specificity of such an approach has 
subsequently been shown as close to 30%12. 
 
Hypoglycaemia in childhood can have numerous causes, and can even represent 
normal physiology in the first few days of life. In this chapter, I will provide an 
overview of the physiologic mechanisms for maintaining normoglycemia, 
highlighting the broad differential diagnoses for hypoglycaemia, which include 
GHD. I will then describe a study in which I have modified the local diagnostic 
evaluation of children with unexplained hypoglycaemia and suspected GHD to 
improve the specificity for GHD. 
 
1.4.1 OVERVIEW OF GLUCOSE HOMEOSTASIS 
Clinical hypoglycaemia is defined as a plasma glucose concentration low enough 
to cause signs or symptoms of impaired brain function. Recognition may be 
difficult when the patient cannot communicate symptoms (e.g., infants and 
neonates), but identifying hypoglycaemia is critical in the prevention of 
complications. The brain has a very high rate of metabolism and depends on a 
constant supply of glucose. Because the brain has little or no stores of glycogen, 
interruption of glucose delivery can have devastating consequences, including 
seizures and permanent brain injury155-157. 
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As shown in Figure 1.4.1, the first stage of defence against hypoglycaemia is 
suppression of insulin secretion by pancreatic islets as plasma glucose 
concentrations fall below 80 mg/dL158-162. The second stage is secretion of 
counter-regulatory hormones to stimulate glucose release from liver glycogen 
stores when plasma glucose concentrations fall to ~65 mg/dL (glucagon release 
from pancreatic islets and sympathetic discharge as reflected by a rise in plasma 
epinephrine). Plasma cortisol and GH concentrations also rise as glucose falls to 
~60 mg/dL163, 164. While increases in these hormones do not affect glucose levels 
acutely, they are required for long-term glucose homeostasis. The third stage of 
response to hypoglycaemia is the impairment of brain function itself at a glucose 
threshold of ~50 mg/dL. The glucose thresholds shown in Fig 1.4.1 come 
primarily from studies in adults, but they have been shown to also apply to 
children164, 165. In addition, observations of responses to hypoglycaemia in 
infants and children with various hypoglycaemia disorders suggest that glucose 
thresholds are essentially the same across all ages166, 167. 
 
 
Figure 1.4.1: Glucose thresholds for neuroendocrine and neuroglycopenic responses to 
hypoglycaemia. 
This demonstrates the progressive physiological responses to falling plasma glucose 
concentrations, and the thresholds for symptoms of hypoglycaemia (Adapted from Cryer et al158, 
168, 169). The threshold used for ending provocative fasting studies and for performing laboratory 
evaluation of the fasting fuel response to hypoglycaemia is 50 mg/dL, demonstrated by the 
dashed line. 
 
The importance of correctly detecting, diagnosing and treating infants with 
disorders of hypoglycaemia is emphasised by longitudinal follow up studies 
100 mg/dL
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demonstrating adverse complications. Kaser et al170 used data from a statewide 
fourth-grade school exam and found that children who had a single plasma 
glucose level below 40 mg/dL during the neonatal period had a 50% lower odds 
ratio for proficiency for both literacy (0.43, 95% CI 0.28-0.67) and mathematics 
(0.51, 95% CI 0.34-0.78). Those with a single plasma glucose level below 35 
mg/dL had even lower odds ratios for proficiency, (0.49, 95%CI 0.28-0.83) and 
(0.49, 95%CI 0.29-0.82), respectively. Even infants with a single glucose below 
a cutoff as high as 45 mg/dL had a reduced odds ratio for proficiency in literacy 
(0.62, 95% CI 0.45-0.85), although not mathematics (0.78, 95% CI 0.57-1.08). 
Koivisto et al171 followed neurodevelopmental outcomes in 151 newborns with 
blood glucose concentrations below 30 mg/dL. They found that only 38% of 
infants who had a hypoglycaemic seizure had normal development at 4 years, 
compared with 80% of asymptomatic infants with glucose concentrations in this 
range.  
 
Thus, in newborns, the brain is sensitive to hypoglycaemia and early diagnosis of 
the causative aetiology and initiation of the correct treatment of infants with 
disorders of hypoglycaemia is of great importance. Incorrectly diagnosing a child 
with GHD in this context, for example, may result in treatment with GH but risk 
persistent recurrent hypoglycaemia. 
 
1.4.2 IMPROVING THE SPECIFICITY OF THE DIAGNOSTIC FAST FOR GROWTH 
HORMONE DEFICIENCY 
 
GH plays an important role in the regulation of substrate use in the fasting state. 
Prolonged fasting results in an increase in frequency and amplitude of GH 
bursts172 and GH secretion increases as blood glucose falls below 60 mg/dL173, 
174. GH promotes lipolysis175 and reduces utilisation of protein176-178 and 
glucose179. It also induces insulin resistance through direct downstream effects 
on insulin signaling180, 181, as well as indirectly by increasing non-esterefied free 
fatty acid concentrations175. Consequently, hypoglycaemia can be a presenting 
feature of GHD13, 154, 182. 
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The standard approach to determining the aetiology of hypoglycaemia includes 
the measurement of the fuel and hormonal responses in the “critical” lab sample 
drawn during hypoglycaemia183, 184. Where possible, these serum markers are 
measured during opportunistic hypoglycaemia, but a structured diagnostic 
fasting study may be required. Although GH concentrations increase as blood 
glucose concentration falls (Figure 1.4.1), low GH concentrations during 
hypoglycaemia are commonly seen at the time of drawing the critical sample 
even in the absence of GHD12, 185-187. 
 
The evaluation of GHD as a potential cause of hypoglycaemia is complicated by 
the lack of a reliable and specific gold standard test for this condition, as also 
discussed in Chapters 1.2 and 1.3. Glucagon is used clinically to assess the 
inappropriate availability of glucose stores (glycogen) during hypoglycaemia. In 
a child with hypoglycaemia, an inappropriate rise in glucose concentration 
following glucagon administration may be consistent with hyperinsulinism183, 188 
or hypopituitarism (in the newborn period)189. Glucagon is also a GH 
secretagogue, and serial measurement of GH concentration following glucagon 
administration is used as one of the GHSTs of GH sufficiency in children with 
suspected GHD190. When intramuscular glucagon is used to assess GH secretion, 
peak GH concentrations are generally seen between 90 and 120 minutes 
following administration191, 192. Although glucagon is administered at the end of 
many fasting studies to evaluate glycogen stores, the routine serial measurement 
of GH following this glucagon administration is not performed as part of this 
fasting study. 
 
1.4.2.1 AIM 
The aim of this study was to determine if, in the setting of a diagnostic 
evaluation of a child with unexplained hypoglycaemia, serial measurement of 
GH concentrations following glucagon administration would improve the 
positive predictive value of the diagnostic fasting study for GHD. 
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1.4.2.2 METHODS 
This study was performed at The Children’s Hospital of Philadelphia (CHOP). 
All children presenting to this hospital between July 2012 and March 2015 were 
eligible for inclusion. Only children with unexplained hypoglycemia for whom 
there was a clinical concern for GHD as a possible diagnosis had the modified 
diagnostic fasting protocol performed (described below). This study was 
approved by the Institutional Review Board at CHOP. 
 
Protocol 
Given the poor specificity of GH measurement during hypoglycaemia for 
GHD12, a clinical protocol for incorporating serial GH measurement after 
glucagon administration during hypoglycaemia was developed. The only 
additional intervention in this clinical protocol beyond the standard diagnostic 
fasting study was the serial measurement of GH following glucagon 
administration.  
 
At the CHOP, the evaluation of children with unexplained hypoglycaemia 
includes a diagnostic fasting study188, 193, 194. The maximum fasting time used in 
this evaluation is age dependent. Children aged less than 1 month fast for up to 
18 hours, between 1 and 12 months for up to 24 hours, and over 1 year for up to 
36 hours. The monitoring protocol depends on the clinical scenario, but generally 
includes blood glucose monitoring during the fast using a bedside glucometer 
(Nova StatStrip point-of-care glucose monitor, Nova Biomedical Corporation, 
Waltham, MA, USA) every 3 hours until blood glucose is less than 70 mg/dL, 
hourly until less than 60 mg/dL and every 30 minutes until less than 50 mg/dL. 
Betahydroxybutyrate is also measured at the bedside every 3 hours using a 
handheld meter (PrecisionXtra, Abbott Laboratories). The study is ended when a 
confirmatory glucose concentration of less than 50 mg/dL is recorded, if beta-
hydroxybutyrate concentration exceeds 2.5 mmol/L, or if the maximum pre-
determined fasting time is reached. 
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A full diagnostic blood draw is taken at the end of the fast. This includes 
measurement of glucose, free fatty acids, beta hydroxybutyrate, insulin, 
ammonia, lactate, basal metabolic profile, acylcarnitine, c-peptide, carnitine, 
IGFBP-1, cortisol and GH. At the end of the diagnostic fast, glucagon is 
administered intravenously at a dose of 1 mg for all patients, and glucose is 
measured every 10 minutes by bedside glucose meter. Dextrose is administered 
if blood glucose does not rise by at least 20 mg/dL within 20 minutes. However, 
if glucose concentration rises by at least 20 mg/dL, then blood glucose checks 
are continued for a further 20 minutes before the fast is ended. If at any point 
during the glucagon test the child is unwell, dextrose is administered. The 
administration of dextrose at the end of the fast consists of a 2 ml/kg bolus of 
10% dextrose and the child is provided a meal containing 40g of carbohydrates. 
 
In addition to the standard protocol, additional GH concentrations were 
measured in patients in whom there was clinical suspicion of GHD. GH 
concentrations were measured at 30, 60, 90, 120, 150, 180 and 210 minutes 
following glucagon administration (Figure 1). Where there were clinical 
limitations to the blood volume that could be drawn, the 90 and 120 minute 
specimens were prioritised. 
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Figure 1.4.2: Protocol for additional growth hormone measurements after glucagon 
administration, in the context of a diagnostic fasting study 
 
Laboratory Measurement 
GH was measured by a solid-phase, two-site chemiluminescent immunometric 
assay (Immulite 2000, Siemens, Berlin, Germany), plasma glucose by an oxidase 
colorimetric reaction (Vitros 5600, Ortho Clinical Diagnostics, New Jersey, 
USA) and betahydroxybutyrate by a D-3 hydroxybutyrate dehydrogenase 
colorimetric reaction (Vitros 5600, Ortho Clinical Diagnostics, New Jersey, 
USA). IGF-I was measured by radioimmunoassay after acid ethanol extraction 
(Esoterix Laboratories, Texas, USA) and IGFBP-3 was measured by 
radioimmunoassay (Esoterix Laboratories, Texas, USA). Where relevant, assay-
specific z-scores for age and gender were reported. 
 
Statistical Analysis 
The threshold GH concentration considered to represent GH sufficiency varies 
between centres and generally ranges from 5 to 10 ng/ml137, 195. In our centre, we 
use 7 ng/ml as the threshold for GH sufficiency. In this study, we also describe 
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overall data if thresholds of 5 ng/ml or 10 ng/ml were used, as varying GH 
concentrations are considered to demonstrate sufficiency in different centres. 
 
Height and weight z-scores at the time of stimulation test were generated using 
the World Health Organization standards141. Unless otherwise stated, continuous 
variables were presented as median (IQR). All data analyses were performed 
using SPSS 22.0 (IBM, NY, USA). Figures were generated using Prism 5.0 
(GraphPad Software Inc, CA, USA) and Adobe Illustrator 16.0 (Adobe Systems 
Inc., California, USA).  
 
1.4.2.3 RESULTS 
Twenty-nine patients were enrolled in the study. Median (IQR) height z-score 
was -2.3 (-3.3, -1). Of these patients, six had a final diagnosis of GHD and were 
treated with GH. The remaining patients had a diagnosis of hyperinsulinism 
(n=9), ketotic hypoglycaemia (n=13) or mitochondrial disorder (n=1). Out of all 
children included in this study, 4 (14%), 3 (10%) and 1 (3%) had GH 
concentrations above thresholds of 5, 7 and 10 ng/ml respectively at the end of 
the diagnostic fast. The additional GH measurement after glucagon 
administration identified 24 (86%), 19 (66%) and 15 (52%) children with GH 
concentrations exceeding these thresholds, who would have been missed if 
baseline GH concentration alone was used. The demographics of the patients 
included in this study are shown in Table 1.4.1. 
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Table	 1.4.1:	 Demographic data, diagnoses, critical sample measurements and serial growth 
hormone concentrations following glucagon administration are shown. 
Note that n represents the number of datapoints available for GH measurement at each timepoint. 
All data are presented as median (IQR).	
Demographics  
Male, n (%) 16 (55%) 
Age, years 1.8 (0.7, 3.4) 
Height z-score -2.3 (-3.3, -1) 
Weight z-score -1.2 (-2.3, -1) 
Duration of fast, hours 15 (9.8, 20) 
  
Final Diagnosis: 
Hyperinsulinism 
Ketotic Hypoglycaemia 
Mitochondrial Disorder 
Growth Hormone Deficiency 
9 (31%) 
13 (45%) 
1 (4%) 
6 (21%) 
  
Concentrations at end of fast 
Glucose, mg/dL 45 (42, 51.5) 
Cortisol, mcg/dL 16 (10.3, 20.5) 
Betahydroxybutyrate, mmol/L 2.4 (1.5, 2.75) 
  
GH measurements (ng/ml) 
Baseline (n=29) 2.6 (1, 3.5) 
30 minutes (n=16) 2.5 (1.6, 8.2) 
60 minutes (n=18) 4.9 (2.4, 10.7) 
90 minutes (n=27) 5.6 (4.2, 12.9) 
120 minutes (n=27) 4.4 (2.5, 10.2) 
150 minutes (n=21) 5.1 (2.2, 11) 
180 minutes (n=7) 3.2 (1.2, 11.6) 
210 minutes (n=3) 3.6 (2, 4.9) 
  
Number of subjects who exceeded threshold on testing 
GH > 5 ng/ml at Baseline 4 (14%) 
GH > 5 ng/ml after Serial Measurements 25 (86%) 
GH > 7 ng/ml at Baseline 3 (10%) 
GH > 7 ng/ml after Serial Measurements 19 (66%) 
GH > 10 ng/ml at Baseline 1 (3%) 
GH > 10 ng/ml after Serial Measurements 15 (52%) 
 
Of the 29 patients in this series, only three (10%) had GH concentrations above 7 
ng/ml at the end of the fasting study and all three of these children also had GH 
measurements above this threshold again on serial testing. The percentage of 
samples with GH concentrations above 5 ng/ml, 7 ng/ml and 10 ng/ml at each 
timepoint is shown in Figure 1.5.3. 
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Figure 1.5.3: The percentage of children with growth hormone concentrations greater than or 
equal to thresholds of 5, 7 or 10 ng/ml at the time of glucagon administration at the end of the 
diagnostic fasting study (n=29), or 30 (n=16), 60 (n=18), 90 (n=27), 120 (n=27), 150 (n=21), 180 
(n=7) or 210 (n=3) minutes later. 
 
Of the 26 (90%) patients with GH concentrations less than 7 ng/ml during 
hypoglycaemia, 10 (34%) also had peak GH concentrations below this threshold 
on serial measurement after glucagon administration. Of these ten children 
without GH concentrations above 7 ng/ml, nine underwent additional GH 
stimulation testing using arginine and clonidine. Six were diagnosed with GHD 
and treated with GH. Two children were diagnosed with hyperinsulism and one 
with ketotic hypoglycaemia.  
 
Characteristics and diagnostic evaluation of the ten patients with suboptimal 
peak GH concentrations are shown in Table 1.5.2. Additional diagnostic 
information on cases 7 and 8 from this series is provided, as the diagnosis may 
be unclear from the data presented in this table. Although Case 7 had normal 
growth factor concentrations, it should be noted that IGF-I concentrations are 
sensitive to nutrition196 and, during infancy, do not reliably identify infants with 
GHD due to low IGF-I concentrations being normal in infancy124. This infant 
also had low random GH measurements on days 3 (1.11 ng/ml) and 14 (0.334 
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ng/ml) of life, also supporting the diagnosis of GHD197. Case 8 had a diagnosis 
of focal hyperinsulinism based on a known pathogenic ABCC8 mutation and 
previous fasting evaluations consistent with hyperinsulinism. The diagnostic 
evaluation presented in table 1.4.2 was from an evaluation after the focal lesion 
had been removed and the hyperinsulinism had resolved. Although his peak GH 
concentration did not exceed the threshold of 7 ng/ml, his linear growth pattern 
was not consistent with GHD and a decision was made to observe his growth 
rather than initiate treatment. 
 
 
Table	 1.4.2:	Details of the ten children with peak growth hormone concentrations less than 7 
ng/ml after fasting study and glucagon administration. 
*Additional clinical data supporting diagnosis of GHD: Height velocity 3 cm/yr, bone age 
delayed by 2 years (-2.3 SD from mean), improved growth and no further hypoglycaemia 
following GH treatment. 
GH = Growth Hormone, GHD = Growth Hormone Deficiency, HI = Diazoxide Responsive 
Hyperinsulinism, KH = Ketotic Hypoglycaemia, AI = Adrenal Insufficiency, NA = Data not 
available, NP = Test not performed 
Patient 1 2 3 4 5 6 7 8 9 10 
Age, yrs 7.5 1.2 5.3 1.8 1.4 5.1 0.1 2.6 6.1 0.7 
Sex male male female male female female male male female male 
Height, z-score -1.2 -0.81 -2.33 -2.2 -4.1 -0.75 -0.02 -2.47 -3.6 -0.94 
Midparental Height, z-score -0.43 NA -0.68 0.24 -0.87 -0.46 NA NA -0.48 0.25 
MRI Brain and Pituitary normal NP NP normal NP NP abnormal 
corpus 
callosum 
NP ectopic 
neuro 
hypophys
is 
normal 
Fast Duration, hours 24 15 20 17 10 16 4 13 14 10 
Critical Sample           
Glucose (mg/dL) 41 45 49 47 43 51 46 53 45 52 
Betahydroxybutyrate 
(mmol/L) 
2.9 1.2 2.2 2.9 2.5 4 0.1 2.5 0.8 2.3 
Growth Hormone, ng/ml 3.6 1 1.1 2.4 3.5 3.5 0.8 2.4 0.1 3.2 
Cortisol, mcg/dL 20.8 14.4 28.9 9.3 14.3 40.7 14.9 16.3 6 20.6 
           
Peak GH after glucagon 
(ng/mL) 
5.4 5.2 5.5 5.1 4.7 5.7 4.3 4.7 0.3 6.6 
           
Peak GH on repeat GH 
stimulation test (ng/mL) 
7.1 4.6  6.5 3.7 8.2 1.9 6.2 0.4 1.5 
Thyroid function tests normal NP normal normal normal NP normal normal normal normal 
IGF-I z-score -1.4 NP 0.1 -0.9 -3.1 NP 0.7 -1.5 -2.6 -0.7 
IGFBP-3 z-score -1.6 NP -0.74 -0.18 -1.6 NP 0.77 -0.73 NP -2 
           
Diagnosis GHD* HI KH GHD GHD KH GHD Resolved 
focal HI 
GHD, AI GHD 
 
 
A receiver operating characteristics curve showing the effect of adding serial GH 
measurements to the diagnostic fasting test for children with hypoglycemia 
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suspected GHD is shown in Figure 1.5.4.. Adding serial GH measurements 
increased the area under the curve from 0.77 (95% CI 0.57-0.96) to 0.83 (95% 
CI 0.63-1).  
 
 
Figure 1.5.4: Receiver-Operating Characteristics curve demonstrating an increased area under 
the curve when serial GH measurements are used in addition to baseline GH measurement during 
hypoglycemia. 
 
1.4.2.4 DISCUSSION 
We have shown that serial measurement of GH following the administration of 
glucagon in the context of a fasting study can be a useful adjunct in children 
suspected of having GHD. GH measurement during hypoglycaemia has poor 
specificity for GHD and by adding serial GH measurements following glucagon 
administration, the number of children identified with peak GH concentrations 
above the arbitrary threshold of 7 ng/ml increased by 16 (55%). This resulted in 
a more focused evaluation of GH secretion in a smaller number of children than 
would otherwise have been performed.  
 
The poor specificity of GH measurement during hypoglycaemia has previously 
been described. In a study including 84 children evaluated for unexplained 
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hypoglycaemia, only 30% had peak GH concentrations above 7.5 ng/ml12. In our 
study, there was a lower number (10%) of children with peak GH concentration 
above 7 ng/ml during hypoglycaemia. However, additional GH measurements 
were only performed in children for whom there was clinical suspiction that 
GHD was the etiology of their hypoglycaemia, and this selection bias may have 
contributed to the discrepency in results between our baseline results and 
previously reported data. 
 
One limitation to adapting our clinical protocol was the blood volume required 
for additional GH measurements in small infants with unexplained 
hypoglycaemia. Serial glucose measurement during the diagnostic fast, in 
addition to the critical sample can limit the blood volume that can be extracted 
for further testing. Previous studies suggest that the peak GH concentration 
following glucagon administration (glucagon stimulation test for GH reserve) 
generally occur after 90 and 120 minutes190, 192, 198, 199. Where necessary, GH 
samples were prioritised at 90 and 120 minutes in this study, and we have shown 
that these are the most useful measurements in this context to identify GH 
sufficient children (Figure 1.5.3). Although not evaluated in this study, we note 
that cortisol responses to glucagon administration occur later, at 150 and 180 
minutes191, 199. This should be considered if future studies of this test are be 
adapted to evaluate cortisol response to glucagon in this context. 
 
The mechanism of glucagon-induced GH secretion is not clear. Fluctuations in 
blood glucose following glucagon administration may contribute to GH 
secretion, although recent studies suggest that this may not be necessary190, 200. 
Glucagon administration increases noradrenaline secretion201, which may play a 
role in stimulating GH secretion. However, alpha adrenergic blockade does not 
prevent glucagon-induced GH secretion202. Although fasting increases GH 
secretion203, 204, it is not clear if allowing the patient to feed while measuring GH 
concentrations after glucagon administration would affect the ability of the test 
to identify children with GH concentrations above the stimulation threshold. A 
  
 
 
67 
large proportion (17/27) of children in this study had an appropriate stimulated 
GH response to glucagon despite being allowed to feed. 
 
We do not know if the serial GH response noted in this study would have been 
seen if glucagon was not administered. Hypoglycaemia is a strong stimulus for 
GH secretion in the absence of additional pharmacological stimuli, and this is 
utilised in the commonly used insulin tolerance test of GH secretion. However, 
unlike the induced hypoglycaemia in the insulin tolerance test, Hussain at al 
have shown that the GH response to spontaneous hypoglycaemia in children is 
blunted185. This makes the GH concentrations seen in this study more likely to be 
secondary to glucagon administration rather than hypoglycaemia alone. We also 
acknowledge that an intramuscular injection of glucagon may result in higher 
detectable concentrations of GH relative to intravenous glucagon205, possibly as 
a result of an additional painful stimulus increasing GH secretion206. As 
intramuscular or subcutaneous glucagon are more potent stimuli of GH 
secretion205, 207, 208, it is possible that modifying the protocol to utilise these 
routes of administration would further improve the specificity for GHD. 
However, this route of glucagon administration is not routinely used in 
evaluating the glycaemic response to hypoglycaemia in our practice. Thus, we 
are unable to compare different routes of glucagon administration in this study. 
 
It is important to note that many normal children will be characterised as having 
GHD on GHST alone47-49, and these results should be interpreted in the clinical 
context. Depending on the GH stimulus and GH concentration threshold used, 
the proportion of normal children who do not reach the “sufficient” threshold can 
be as high as half47. In this study, only children suspected as having GHD at the 
time of diagnostic fasting study underwent this additional serial GH 
measurement. Given the poor reliability of the GHST, we do not routinely 
perform GHST in children with peak GH concentrations below 7 ng/ml where 
the laboratory tests performed during hypoglycaemia indicate that an alternative 
diagnoses are more likely.  
 
  
 
 
68 
In conclusion, we have shown that additional GH measurements after glucagon 
administration following a diagnostic fast can improve the identification of 
children with stimulated GH concentrations above test thresholds. This test can 
be performed in addition to the diagnostic fasting study, and does not require 
prolongation of the fast. We also recommend that children with insufficient 
responses to glucagon in this setting should further have GHD confirmed by 
standard GHSTs  if there is clinical suspicion of GHD. 
 
1.4.3 CHAPTER CONCLUSION 
Although short stature and impaired linear growth are the most common 
presentations of GHD in children, hypoglycaemia may be the only clinical sign 
in infancy. Correct diagnosis in this population is of critical importance in 
preventing adverse developmental complications of recurrent hypoglycaemia. 
Conversely, incorrectly attributing hypoglycaemia to be caused by GHD in this 
population may put the infant at risk through failure to treat the true underlying 
diagnosis. In this chapter, I have described a protocol with the potential to steer 
the physician away from an incorrect diagnostic path through increasing the 
specificity of the hypoglycaemia evaluation for GHD. This protocol has been 
adopted by The Hyperinsulinism Center at The Children’s Hospital of 
Philadelphia, the largest referral centre for children with hypoglycaemia in North 
America. 
 
Additional approaches to evaluating children for GH sufficiency, relevant to 
neonates who may have hypoglycaemia, will be discussed in subsequent sections 
of this thesis. Specifically, I will discuss IGF-I measurement in infancy in 
chapters 2.2 and 2.4, and will explore the utility of body composition 
measurement in evaluating growth in these children in chapter 4.2. 
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SECTION 2 
INSULIN-LIKE GROWTH FACTOR MEASUREMENT WITH 
MASS SPECTROMETRY 
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CHAPTER 2.1: INTRODUCTION 
 
As discussed in Section 1, the GHST alone has poor sensitivity and specificity 
for diagnosing GHD. Serum IGF-I concentrations are relatively constant in 
serum and mirror spontaneous GH secretion80. Consequently, IGF-I 
measurement has a role in the diagnostic evaluation of GHD8, 9, 72 and in the 
monitoring of treatment efficacy56, 209, 210 in children receiving GH replacement 
therapy. 
 
IGF-I circulates bound to binding proteins and this prolongs its serum half-life. 
Immunoassays are the mainstay of current IGF-I measurement, but these are 
subject to interference from circulating binding proteins. In Chapter 2.2, I will 
review IGF-I measurements in infants and demonstrate wide variability in the 
reported normal concentrations in this age group between assays. 
 
I will then begin to explore mass spectrometry as a possible solution to binding 
protein interference. My interest in using mass spectrometry to overcome assay 
interference started with a clinical study where I showed that, in vitamin D 
intoxication, 25-hydroxyvitamin D interferes with the radioimmunoassay (RIA) 
for 1,25-dihydroxyvitamin D measurement (Appendix G)211. This study will be 
briefly summarised in Chapter 2.3, before I explore the utility of mass 
spectrometry in IGF-I measurement in infancy, and report reference data for this 
in Chapter 2.4. 
 
This section of the thesis focuses on laboratory measurement of IGF-I. Genetic 
causes of abnormal IGF-I concentrations will be explored in Section 3, and the 
interaction between nutrition and the GH / IGF-I axis will be reviewed and 
explored in Section 4.  
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CHAPTER 2.2: CHALLENGES IN THE MEASUREMENT OF INSULIN-
LIKE GROWTH FACTOR-I 
 
Publication 
Hawkes CP, Grimberg A. Measuring growth hormone and insulin-like growth 
factor-I in infants: what is normal? Pediatr Endocrinol Rev. 2013;11(2):126-46 
(Appendix F). 
 
 
Infants with isolated GHD have a normal weight and length at birth. In the 
neonatal period, hypoglycaemia or a small penis may be the only clinical feature 
of disease13, 46 (Chapter 1.4). IGF-I measurement is generally part of the first line 
screen for GHD, but there is wide variation in the reported IGF-I concentrations 
in normal infants124. Similarly, random GH measurement has been suggested as a 
screen for GHD in infancy197. In this chapter, I will systematically review the 
reported reference data for IGF-I and GH measurements in the first two years of 
life with an emphasis on assay variability. 
 
2.2.1 THE GROWTH HORMONE / INSULIN-LIKE GROWTH FACTOR-I AXIS IN 
INFANCY 
GH secretory patterns differ between neonates and older children212. Higher GH 
peaks are seen in the term neonate than the older child. These peaks become less 
pronounced within the first four days of life, and the frequency of secretory 
pulses also halves over the same time period213. Even higher GH levels are seen 
in preterm infants, but the pulsatile pattern of release is similar to that of the term 
infant214. Sleep is not a stimulus for GH secretion until three months of age215, 
216, but feeding and insulin release stimulate GH secretion at this early stage 
before sleep entrainment217. 
 
The role of GH in the fetus is poorly understood. Although GH is detected in the 
fetal pituitary gland as early as ten weeks’ gestation, and the GH content of the 
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pituitary gland increases with gestational age218, GH is not required for normal 
intrauterine growth219. 
 
Unlike GH, IGF-I plays a major role in fetal growth. IGF-I levels increase 2-3 
fold from 33 weeks’ gestation to term,220 and cord blood levels of IGF-I 
positively correlate with weight, length and head circumference at birth221 
(Chapter 2.4). Postnatal IGF-I production is involved in both somatic and brain 
growth, independent of gestational age and caloric intake222. Postnatally, IGF-I 
concentrations and bioavailability correlate with increased growth in low 
birthweight223 and preterm infants224. 
 
Diagnosing GHD in infancy remains a challenge. A combination of clinical 
phenotype, stimulation testing, imaging and baseline IGF-I, IGFBP-3 and GH 
levels can be used72, 212, 225, 226. Normative data for GH and IGF-I concentrations 
are limited in the non-GH deficient child under 18 months of age. This can be a 
challenge when interpreting IGF-I measurements in this age group. 
 
2.2.2 ASSAYS USED IN MEASURING GROWTH HORMONE AND INSULIN-LIKE 
GROWTH FACTOR-I 
2.2.2.1 Growth Hormone Assays 
Two isoforms of GH are present in serum, as a consequence of alternative 
splicing during transcription. These two isoforms differ by the presence of 15 
amino acids in the larger 22-kDa isoform. The absence of these amino acids in 
the 20-kDa isoform makes it more likely to dimerise. This isoform represents 5-
10% of circulating GH and is less biologically active than the 22-kDa isoform227. 
Human serum contains hetero- and homodimers, as well as multimers, of these 
isoforms228. This heterogeneity in circulating GH complicates its measurement, 
as assays may recognise different isoforms and protein structures differently229, 
230.  
 
  
 
 
73 
Bioassays and radioreceptor assays have been developed to determine the 
biological activity of GH in a serum sample, but they are insensitive and time 
consuming and thus, not widely used in clinical practice227. Commercially 
available immunoassays are generally used to measure serum concentrations of 
GH, and the particular assay used may differ between centres231, 232. 
 
The two main types of immunoassays are the competitive immunoassay and the 
sandwich type immunoassay. In competitive assays, labeled GH is added to 
serum and competes with the sample’s unlabeled GH for binding sites on an 
antibody-coated platform. The concentration of bound labeled GH can be used to 
determine the concentration of unlabeled GH in the sample. Sandwich type 
immunoassays use two different antibodies that bind to different epitopes of the 
GH molecule and are detected using radioactive, enzyme linked or 
chemiluminescent labels233 (Chapter 2.3.1). The method of detection determines 
the specific assay type: RIA; Enzyme-linked ImmunoSorbent Assay (ELISA) or 
Chemiluminescent assays (ECL). 
 
Another difference between assays is the type of antibodies used. The antibodies 
can be directed at one epitope (monoclonal) or multiple epitopes (polyclonal) on 
the GH molecule233. This will restrict the comparability of results between 
assays, as polyclonal assays tend to recognise more isoforms and yield higher 
results233. 
 
2.2.2.2 IGF-I Assays 
Free IGF-I represents a small percentage of total IGF-I in the serum, with the 
majority forming a 150-kDa ternary complex with IGFBP-3 and acid labile 
subunit (ALS). Some IGF-I also circulates in binary complexes with the various 
IGFBPs234. In order to utilise immunoassays to measure IGF-I, IGF-I must first 
be separated from the complexes, and this process can result in significant inter- 
and intra-assay variability. The most commonly used technique for separating 
large molecular weight molecules involves ethanol extraction. While this 
dissociates IGF-I from its binding proteins and precipitates large molecules from 
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the sample, IGFBP-1 and IGFBP-4 do not precipitate well and may affect 
results235. Other techniques such as IGF-II saturation can be used to saturate the 
binding sites on the IGFBPs and thereby reduce the unmeasured IGF-I235-237. 
This can be combined with ethanol precipitation to further reduce the 
interference of binding proteins in IGF-I measurement. 
 
Like the GH assays, antibodies used for IGF-I measurement can be polyclonal or 
monoclonal. Where IGF-II saturation has been used, cross reactivity of the 
antibody with IGF-II must be very low or the results will be falsely elevated. 
 
Liquid chromatography mass spectrometry (LCMS) is a new method of 
measuring IGF-I (and –II) that is not affected by binding protein interference238 
(See 2.4.3.5 for details). This method is becoming increasingly available and 
may represent the future of IGF-I measurement238-241. 
 
2.2.3 MEASUREMENTS OF GROWTH HORMONE AND INSULIN-LIKE GROWTH 
FACTOR-I IN CHILDREN AGED 0-18 MONTHS 
2.2.3.1 Literature Review Methodology 
A PubMed search was performed for “growth hormone” OR “IGF-I” in 
November 2012, limited from birth to 18 months. Titles were used to identify 
articles that were likely to include GH or IGF-I measurement in the fetus or 
infant less than 18 months of age. Abstracts were then read to determine if these 
articles included GH or IGF-I measurement of healthy children, and full articles 
were then accessed to determine a) assay used and b) reported values of GH 
and/or IGF-I concentrations. 
 
Initial PubMed search identified 4451 articles. 525 articles were identified as 
relevant from screening titles. GH was measured in 44 of these articles in healthy 
children less than 18 months of age, while IGF-I was measured in 113. Relevant 
articles that reported mean values with standard deviations were included in this 
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review. Unless otherwise stated, values in this manuscript are presented as mean 
± 1 standard deviation. 
 
2.2.3.2 Growth Hormone 
Due to the pulsatile nature of GH secretion, timing is important in the 
interpretation of GH measurements. Except for the first 15 days of life, random 
GH measurement is of limited utility. Most studies in which this has been 
reported have shown a mean GH concentration below most accepted cutoff 
values for GH stimulation tests. This appears to be consistent regardless of assay 
used (Table 2.2.1). 
 
Random GH measurement within the first 15 days of life may, however, be 
clinically useful. There is a GH surge at birth, and the lowest reported mean 
umbilical cord GH measurement in all assays was 9.2 ng/ml242, 243. Cord GH 
concentration is higher in pregnancies complicated by preeclampsia244. Random 
GH rises further on day two245, 246 and remains elevated up to day five, with 
mean values of 53.4 ± 30.8 ng/ml (IRMA)247 or 21.8 ± 11.2 ng/ml (IFMA)224. By 
day 15, the mean falls to 5.5 ± 3.7 ng/ml (IFMA) 224 and by 3 weeks a mean of 
8.7 ± 8.1 ng/ml (RIA)248 was shown. Assay variability makes comparison of 
values difficult, but a temporal trend is observed in all studies. By one224 and 
two248 months of age, low mean random GH values consistent with those seen in 
older children are seen. 
 
Serial measurements of GH have described the secretory pattern of GH in 
infancy. Pulsatile secretion is also present during this early period of raised GH 
levels. When GH was measured every 20 minutes for 6 hours on the first day of 
life (by RIA with a polyclonal antibody), values ranged between 9 and 191 
ng/ml. Five to six bursts of GH release occurred within the six hour study 
period249. Similarly, GH measurement every thirty minutes for 12 hours in 
infants ranging in age from 8 to 40 hours varied from 4.1 to 105 ng/ml using a 
double antibody RIA213. In slightly older infants, aged between one and four 
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days, GH burst frequency was 7.7 over a 6 hour period214. This is similar to the 
frequency seen in infants on day one of life. 
 
With such a wide range of GH concentrations found on serial measurement in 
infancy, it would be clinically useful to identify a time when GH secretion is 
likely to peak. This would allow for optimally timed single sample measurement 
to identify GH sufficiency in infants where there is a clinical concern regarding 
possible GH deficiency. At two days of age, mean circulating GH concentrations 
measured by RIA after five minutes of active sleep, quiet sleep and waking were 
33.4 ± 7, 52.8 ± 11 and 43.5 ± 36 ng/ml, respectively. These high mean values 
were not seen between four and eight days of age, with respective values of 9.1 ± 
1.1, 9.5 ± 1.3 and 8.3 ± 1.2 ng/L noted250, and may represent the higher GH 
levels in the first few days of life. Sleep entrainment of GH secretion does not 
occur until after three months of age.215 When GH concentrations were measured 
by RIA following 30 minutes of sleep and 30 minutes of wakefulness at different 
ages within the first six months of life, mean sleep and waking values were 
similar until three months of age. Mean awake/asleep GH concentrations were 
20.6 ± 10.9 / 17.6 ± 9.1 ng/ml at 1-4 weeks, 17.1 ± 11.6 / 17.4 ± 10.7 ng/ml at 1-
3 months, 6.5 ±  3.4 / 15.1 ± 13.1 ng/ml at 3-6 months and 6.2 ± 3 / 16.6 ± 9.7 
ng/ml at 6-12 months215. 
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Table 2.2.1: Random GH Measurement within the first 18 months of life 
Author Timing Population Number 
 
Assay -2SD Mean 
(ng/ml) 
+2SD 
ELISA 
Leger 
1996251 
Umbilical 
Cord 
Term infants 44 Solid phase two-site 
Immunoradiometric assay 
(Elisa-hGH, CIS bio 
International) 
1 19 37 
Setia 
2007252 
Umbilical 
Cord 
Term infants 50 Solid phase 
immunoradiometric assay 
1 16.2 31.4 
Binder 
2010225 
Day 2-4 Term infants 269 hGH-ELISA 
(Mediagnost, Reutlingen, 
Germany). Polyclonal Ab 
against 22kDa rhGH in 
rabbit. Measured from 
dried bloodspots on filter 
paper 
 16.6  
Radioimmunoassay 
Desgranges 
1987253 
Umbilical 
Cord 
Term infants 18 Radioimmunoassay 
Double-antibody 
incubation 
4.2 17.4 30.6 
Geary 
2003254 
Umbilical 
Cord 
Term infants 1197 Radioimmunoassay – 
(Hybritech Europe, Liege, 
Belgium) 
0 10.5 27.5 
Kitamura 
2003255 
Umbilical 
Cord 
Term infants 54 Radioimmunoassay 
(Daiichi Rasioisotope 
Laboratories, Tokyo, 
Japan) 
 17.8  
Cornblath 
1965246 
Umbilical 
Cord 
Term infants 20 Radioimmunoassay 0 66 210.4 
Laron 
1967244 
Umbilical 
cord 
Term infants 9 Radioimmunossay  34  
Cornblath 
1965246 
Day 1 Term infants 15 Radioimmunoassay 0 52 130.6 
Laron 
1966245 
Day 1 Term males 36 Radioimmunoassay  38.4  
Laron 
1967244 
Day 1 Term infants 9 Radioimmunoassay  69  
Laron 
1966245 
Day 1 Term 
females 
25 Radioimmunoassay  50  
Cornblath 
1965246 
Day 2 Term infants 13 Radioimmunoassay 0 72 184.6 
Laron 
1966245 
Day 2-3 Term males 36 Radioimmunoassay  76.6  
Laron 
1966245 
Day 2-3 Term 
females 
25 Radioimmunoassay  54  
Cornblath 
1965246 
Day 2-6 Term infants 20 Radioimmunoassay 0 32 70.6 
Laron 
1966245 
Day 4-5 Term males 36 Radioimmunoassay  19.3  
Laron 
1966245 
Day 4-5 Term 
females 
25 Radioimmunoassay  26.2  
Cassio 
1998248 
3 weeks Term infants 12 Commercial liso-solid 
phase radioimmunoassay 
(Technogenetics, Milan, 
Italy) 
0 8.7 24.9 
Cornblath 
1965246 
3-4 weeks Term infants 8 Radioimmunoassay 0.8 16 31.2 
Cassio 
1998248 
4 months Term infants 8 Commercial liso-solid 
phase radioimmunoassay 
(Technogenetics, Milan, 
Italy) 
0 2.8 5.8 
Cassio 
1998248 
7 months Term infants 10 Commercial liso-solid 
phase radioimmunoassay 
(Technogenetics, Milan, 
Italy) 
0.2 2 3.8 
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Table 2.2.1 (continued) 
Author Timing Population Number 
 
Assay -2SD Mean 
(ng/ml) 
+2SD 
IRMA 
Chiesa 
2008256 
Umbilical 
Cord 
AGA Term 
neonates 
87 IRMA (CIS Bio 
International, Schering 
S.A.) 
14.6 18.2 21.8 
Cance-
Rouzaud 
1998247 
Within 
first 5 days 
of life 
AGA Term 
infants 
64 Immunoradiometric assay 
Protein binding to a first 
antibody was revealed by 
a second 125I-labelled 
antibody (ELISA kit, CIS-
Bio International, Gif-sur-
Yvette, France) 
0 53.4 115 
Leger 
1996251 
6 months  12 Solid phase two-site 
Immunoradiometric assay 
(Elisa-hGH, CIS bio 
International) 
0 3.4 8.2 
Leger 
1996251 
12 months  37 Solid phase two-site 
Immunoradiometric assay 
(Elisa-hGH, CIS bio 
International) 
0 2.7 7.1 
Immunofluorometric Assay 
Pagani 
2007224 
Day 5, (8-
9am) 
AGA Term 
infants 
26 Immunoflurometric assay. 
Direct sandwich 
technique. 
AutoDELFIA hGH Kit 
(Wallacoy, Turku, 
Finland) 
0 21.8 44.2 
Pagani 
2007224 
Day 15, (8-
9am) 
AGA Term 
infants 
26 Immunoflurometric assay. 
Direct sandwich 
technique. 
AutoDELFIA hGH Kit 
(Wallacoy, Turku, 
Finland) 
0 5.5 12.9 
Pagani 
2007224 
Day 30, (8-
9am) 
AGA Term 
infants 
26 Immunoflurometric assay. 
Direct sandwich 
technique. 
AutoDELFIA hGH Kit 
(Wallacoy, Turku, 
Finland) 
0 1.8 4.2 
Chemiluminescent immunometric assays 
Chanoine 
2003242 and 
2002243 
Umbilical 
Cord 
AGA Term 
neonates 
90 Chemiluminescent 
immunoassay (Beckman 
Coulter, Fullerton, Calif, 
USA) 
0 9.2 35 
Gesteiro 
2009257 
Umbilical 
Cord 
Term infants 115 Cheminuminescent 
immunometric assays 
(Diagnostic Products 
Corporation, Flanders, 
New Jersey) Ref No 
LKGH1 
0 16.7 36.3 
Osmanagao
glu 2005258 
Umbilical 
Cord 
AGA 50 Two-site 
chemiluminescent enzyme 
immunometric assay 
(Immulite 1000 human 
GH kit, DPC, Los 
Angeles, CA, USA) 
7 11.6 16.2 
Osmanagao
glu 2005258 
Umbilical 
Cord 
SGA 60 Two-site 
chemiluminescent enzyme 
immunometric assay 
(Immulite 1000 human 
GH kit, DPC, Los 
Angeles, CA, USA) 
1.8 11.6 21.4 
Osmanagao
glu 2005258 
Umbilical 
Cord 
LGA 50 Two-site 
chemiluminescent enzyme 
immunometric assay 
(Immulite 1000 human 
GH kit, DPC, Los 
Angeles, CA, USA) 
 
3.2 
12.2 21.2 
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2.2.3.3 Insulin-Like Growth Factor-I 
Serum IGF-I levels reflect spontaneous 24-hour GH secretion80 and, unlike GH, 
random levels are relatively stable259. IGF-I measurements are sensitive to 
extraction methods and assays used. Many studies identified in this review did 
not provide details regarding the extraction methods used, and this may account 
for the variation in reported values in studies where the same assay was used to 
measure IGF-I levels in children of similar ages and stature260. Tables 2.2.2, 
2.2.3 and 2.2.4 summarise the IGF-I values reported in studies including healthy 
children aged less than 18 months. 
 
Factors that may affect IGF-I concentrations in cord blood include ethnicity, 
maternal smoking, and some antenatal medication exposure. Chinese infants 
have higher IGF-I concentrations than Caucasian infants261 while Caucasian 
infants may have a higher IGF-I concentration than African American infants262. 
Maternal smoking may be associated with lower IGF-I levels in cord blood, even 
where infant sizes are similar263. Selective serotonin reuptake inhibitor use in 
pregnancy may be associated with lower umbilical cord IGF-I levels264. Many of 
these studies, however, involved small sample sizes and statistical significance 
was not demonstrated. 
 
In studies where infants and children were categorised according to weight, the 
group of larger children consistently had higher IGF-I concentrations regardless 
of assay used. Some studies have shown that girls have higher IGF-I 
concentrations than age-matched boys with a similar weight, at birth, as well as 
at 12 and 24 months of age254, 265-268. While the etiology of this difference in 
IGF-I concentrations between sexes is not clear, it may be related to differences 
in body composition between males and females that are not captured in weight 
measurement. At birth, girls have been shown to have a greater proportion of 
body fat than boys, even when boys are heavier269, 270. 
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Table 2.2.2: Assay Specific IGF-I measurement in umbilical cord blood 
Author Timing Population Number Weight 
(kg) 
Assay Extraction -2SD Mean 
(ng/ml) 
+2SD 
ELISA 
Akram 
2011271 
Umbilical 
cord 
SGA 12 <2.5 ELISA (Mediagnost, 
Germany). 
 5.77 6.35 6.93 
Akram 
2011271 
Umbilical 
cord 
AGA 21 >3.5 ELISA (Mediagnost, 
Germany). 
 8.86 14.08 19.6 
Jayanthiny 
2011272 
Umbilical 
cord 
Term 
Infants 
200  Enzyme linked 
immunosorbent assay 
(Catalogue No. EIA-2947, 
DRG International, Inc., 
USA) 
 5.9 39 72 
Rohrmann 
2009262 
Umbilical 
cord 
African 
American 
Infants 
75 3.2 
(2.5-3.9) 
ELISA (Diagnostic 
Systems Laboratory) 
 0 72.3 156.3 
Rohrmann 
2009262 
Umbilical 
cord 
Caucasian 
Infants 
38 3.5 
(2.7-4.3) 
ELISA (Diagnostic 
Systems Laboratory) 
 0 90.6 208.2 
Radioimmunoassay 
Bankowski 
2000273 
Umbilical 
cord 
Term 
Infants 
12 3.53 
(2.8-4.2) 
Radioimmunoassay Acid 
Chromatography 
 130  
Beltrand 
2008274 
Umbilical 
cord 
Highest 
antenatal 
growth 
tertile 
78 3.18 
(2–4.4) 
Radioimmunoassay  0 85.6 182.8 
Beltrand 
2008274 
Umbilical 
cord 
Middle 
antenatal 
growth 
tertile 
78 2.97 
(1.7–4.3) 
Radioimmunoassay  0 65.7 137.1 
Beltrand 
2008274 
Umbilical 
cord 
Lowest 
antenatal 
growth 
tertile 
79 2.8  
(2–3.6) 
Radioimmunoassay  0 61.6 180.6 
Bennett 
1983275 
Umbilical 
cord 
Term 
Infants 
32  Radioimmunoassay  41 113 185 
Halhali 
2000276 
Umbilical 
cord 
 20 3.2 
(2.5-3.8) 
Radioimmunossay . 
(Nichols Institute 
Diagnostics) 
Acid ethanol 
extraction 
19 123 227 
Klauwer 
1997277 
Umbilical 
cord 
Term 
Infants 
138 3.3 
(2.2-4.4) 
Radioimmunoassay Acid extraction 
Excess IGF-II 
19 61 103 
Leger 
1996251 
Umbilical 
cord 
Term 
Infants 
44 2.9 
(1.5-4.3) 
Radioimmunoassay using 
polyclonal IGF-I 
antiserum 
Acid 
chromatography 
13 85 157 
Simmons 
1995278 
Umbilical 
cord 
 120 3.5 
(2.3-4.5) 
Radioimmunoassay 
(Ciba-Geigy, Basel, 
Switzerland) 
Ethanol 8.7 57.1 105.5 
Vatten 
2002279 
Umbilical 
cord 
 609  Radioimmunoassay 
(Mediagnost, Tuebingen, 
Germany) 
 10 64 118 
Wang 
2005266 
Umbilical 
cord 
Males 62 3.2 
(2.4-4) 
Radioimmunoassay 
(Daiichi Radioisotope 
Laboratory, Tokyo, Japan) 
 14.9 84.3 153.7 
Wang 
2005266 
Umbilical 
cord 
Females 57 3.1 
(2.3-3.9) 
Radioimmunoassay 
(Daiichi Radioisotope 
Laboratory, Tokyo, Japan) 
 20 95.2 170.8 
Wiznitzer280 Umbilical 
cord 
AGA 20 3.3 
(2.3-4.3) 
Radioimmunoassay  16 80 144 
Wiznitzer280 Umbilical 
cord 
LGA 40 4.3 
(3.6-4.8) 
Radioimmunoassay  5 139 273 
IRMA 
Baik 
2006281 
Umbilical 
cord 
Term 
Infants 
30  IRMA (Diagnostic 
Systems Lab) 
 0 54.3 128.5 
Chiesa 
2008256 
Umbilical 
cord 
Term 
Infants 
87 3.19 
(2.6–3.8) 
IRMA (Immunotech)  0 99 203.7 
Christou 
2001282 
Umbilical 
cord 
AGA 96 3.2 
(3.1–3.3) 
IRMA (Diagnostic 
Systems Lab) 
 0 43.4 109.6 
Christou 
2001282 
Umbilical 
cord 
LGA 46 4 
(3.9-4.1) 
IRMA (Diagnostic 
Systems Lab) 
 0 73.8 153.4 
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Table 2.2.2 (continued) 
Author Timing Population Number Weight 
(kg) 
Assay Extraction -2SD Mean 
(ng/ml) 
+2SD 
Cooley 
2004283 
Umbilical 
cord 
Term 
Infants 
1650 3.4 
(2.3-4.5) 
IRMA (Nichols Institute 
Diagnostics) 
Acidification 
and IGF-II 
excess 
22.8 217.5 412.2 
Davidson 
2009264 
Umbilical 
cord 
Antenatal 
SSRI 
exposure 
21 3.2 
(3–3.4) 
IRMA (Diagnostic 
Systems Lab) 
 66.9 96.1 125.3 
Davidson 
2009264 
Umbilical 
cord 
Term 
Infants 
20 3.3 
(3.2–3.5) 
IRMA (Diagnostic 
Systems Lab) 
 93.1 119.9 146.7 
Geary 
2003254 
Umbilical 
cord 
Males 515 3.5 
(3.4-3.6) 
IRMA (Nichols Institute 
Diagnostics) 
Acidification 
and IGF-II 
excess 
64 66.4 68.8 
Geary 
2003254 
Umbilical 
cord 
Females 472 3.5 
(3.4-3.6) 
IRMA (Nichols Institute 
Diagnostics) 
Acidification 
and IGF-II 
excess 
71.9 74.5 77.1 
Ingvarsson 
2007263 
Umbilical 
cord 
Maternal 
cigarettes 
30 3.9 
(2.9-4.9) 
Two site IRMA (ActiveTM 
IGF-I) 
Yes 0 54.4 119.4 
Ingvarsson 
2007263 
Umbilical 
cord 
No 
maternal 
cigarettes 
60 3.4 
(2.4-4.5) 
Two site IRMA (ActiveTM 
IGF-I) 
Yes 0 93.8 202.8 
Lagiou 
2009284 
Umbilical 
cord 
Caucasian 
American 
Infants 
92 3.6 
(2.6-4.5) 
Immunoradiometric assay 
kit 
(Diagnostic Systems 
Laboratories, Webster, 
Texas) 
 22.8 98.4 174 
Lagiou 
2009284 
Umbilical 
cord 
Chinese 
Infants 
110 3.5 
(2.6-4.5) 
Immunoradiometric assay 
kit 
(Diagnostic Systems 
Laboratories, Webster, 
Texas) 
 0 79 177 
Lo 2002285 Umbilical 
cord 
 43 3.2 
(2.4-4) 
IRMA (Diagnostic 
Systems Laboratories, 
Webster, Texas) 
 13.1 66.5 119.9 
Maffeis 
1999286 
Umbilical 
cord 
Males 48  Immunoradiometric assay 
(CIS Bio International, 
Gif-sur-Yvette, France) 
 30 87.4 144.2 
Maffeis 
1999286 
Umbilical 
cord 
Females 50  Immunoradiometric assay 
(CIS Bio International, 
Gif-sur-Yvette, France) 
 0 73.9 148.9 
Martinez-
Cordero 
2006287 
Umbilical 
cord 
SGA 50 2.3 
(2-2.6) 
Immunoradiometric assay 
(Biocode-Hycel, Liege, 
Belgium) 
 15.4 71 126.6 
Martinez-
Cordero 
2006287 
Umbilical 
cord 
AGA 50 3.8 
(3-4.5) 
Immunoradiometric assay 
(Biocode-Hycel, Liege, 
Belgium) 
 0 76.5 154.7 
Pringle 
2005288 
Umbilical 
cord 
 1192 3.5 
(2.5-4.4) 
Immunoradiometric assay 
(Nichols Institute 
Diagnostics, San Juan, 
Capistrano CA) 
Acidification 
Excess IGF-II 
17.7 68.5 119.3 
Chemiluminescent immunometric assays 
Gesteiro 
2011289 
Umbilical 
cord 
Lowest 
quartile for 
cord 
insulin 
33 3.2 
(2.5-3.9) 
Chemiluminescent 
immunometric assays 
(Diagnostic Products 
Corporation) 
 7 46.8 86.7 
Gesteiro 
2011289 
Umbilical 
cord 
Second 
quartile for 
cord 
insulin 
43 3.3 
(2.6-3.9) 
Chemiluminescent 
immunometric assays 
(Diagnostic Products 
Corporation) 
 10 52.6 103.2 
Gesteiro 
2011289 
Umbilical 
cord 
Third  
quartile for 
cord 
insulin 
44 3.4 
(2.7-4) 
Chemiluminescent 
immunometric assays 
(Diagnostic Products 
Corporation) 
 17.5 64.2 111 
Gesteiro 
2011289 
Umbilical 
cord 
Highest 
quartile for 
cord 
insulin 
56 3.4 
(2.7-4) 
Chemiluminescent 
immunometric assays 
(Diagnostic Products 
Corporation) 
 0 63.7 128.3 
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Table 2.2.2 (continued) 
Author Timing Population Number Weight 
(kg) 
Assay Extraction -2SD Mean 
(ng/ml) 
+2SD 
Gesteiro 
2009257 
Umbilical 
cord 
 109 3.3 
(2.7-4) 
Chemiluminescent 
immunometric assays 
(Diagnostic Products 
Corporation) 
 9.4 55.2 101 
Ibanez 
2008267 
Umbilical 
cord 
SGA 
females 
24 2.3 
(1.9-2.7) 
Immunochemiluminescent 
assay (Immulite 2000; 
Diagnostic Products, Los 
Angeles, CA) 
 10 59 108 
Ibanez 
2008267 
Umbilical 
cord 
AGA 
males 
24 3.4 
(3-3.8) 
Immunochemiluminescent 
assay (Immulite 2000; 
Diagnostic Products, Los 
Angeles, CA) 
 5.2 64 122.8 
Ibanez 
2008267 
Umbilical 
cord 
AGA 
females 
24 3.4 
(3-3.8) 
Immunochemiluminescent 
assay (Immulite 2000; 
Diagnostic Products, Los 
Angeles, CA) 
 35 84 133 
Ibanez 
2008267 
Umbilical 
cord 
SGA males 24 2.3 
(1.9-2.7) 
Immunochemiluminescent 
assay (Immulite 2000; 
Diagnostic Products, Los 
Angeles, CA) 
 1.8 41 80.2 
Kyriakakou 
2009290 
Umbilical 
cord 
IUGR 20 2.4 
(1.9-2.9) 
2 site chemiluminescence 
immunoassay (Nichols 
Diagnostic Institute, San 
Juan Capistrano, CA) 
 17.6 42.6 67.6 
Kyriakakou 
2009290 
Umbilical 
cord 
AGA 20 3.2 
(2.6-3.7) 
2 site chemiluminescence 
immunoassay (Nichols 
Diagnostic Institute, San 
Juan Capistrano, CA) 
 19.6 45.5 71.4 
Luo 2012291 Umbilical 
cord 
 229 3.4 
(2.5-4.3) 
Enzyme-labeled 
chemiluminescent assay 
Acid buffer 
dilution 
8.5 60.5 112.5 
Troisi 
2008261 
Umbilical 
cord 
Caucasian 
Infants 
51 3.6 Direct chemiluminescent 
immunoassay. Immulite 
analyzer (Siemens 
Medical Solutions 
Diagnostics, Los Angeles, 
CA) 
 0 76.3 421.7 
Troisi 
2008261 
Umbilical 
cord 
Chinese 
Infants 
22 3.5 Direct chemiluminescent 
immunoassay. Immulite 
analyzer (Siemens 
Medical Solutions 
Diagnostics, Los Angeles, 
CA) 
 0 90.1 360.5 
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Table 2.2.3: Assay Specific IGF-I measurement 0-6 months of age. Blank cells represent 
unreported data. 
Author Timing Population Number Weight 
(kg) 
Assay Extraction -2SD Mean 
(ng/ml) 
+2SD 
ELISA 
Yuksel 
2011265 
3 
months 
Males 29  ELISA (Diagnostic 
Systems Laboratories Inc) 
 0 110.8 279.8 
Yuksel 
2011265 
3 
months 
Females 22  ELISA (Diagnostic 
Systems Laboratories Inc) 
 0 111.3 290.7 
Yuksel 
2011265 
6 
months 
Males 41  ELISA (Diagnostic 
Systems Laboratories Inc) 
 0 89.3 286.7 
Yuksel 
2011265 
6 
months 
Females 33  ELISA (Diagnostic 
Systems Laboratories Inc) 
 0 67.8 216 
Radioimmunoassay 
Gunes 
2007292 
Day 1 Mothers 
who smoke 
28 3.02 
(2.7-3.3) 
Radioimmunoassay 
Biocode 1010 (Liege 
Belgium) 
 107.6 156.6 205.6 
Gunes 
2007292 
Day 1 Mothers 
who don’t 
smoke 
28 3.5 
(2.94-4) 
Radioimmunoassay 
Biocode 1010 (Liege 
Belgium) 
 104 164.4 224.8 
Koklu 
2007293 
Day 1 LGA, 
mothers 
with 
diabetes 
30 4.3 
(3.9-4.7) 
Radioimmunoassay 
(Biocode 1010, Liege, 
Belgium) 
 85 205.2 325.4 
Koklu 
2007293 
Day 1 LGA 30 4.3 
(3.9-4.7) 
Radioimmunoassay 
(Biocode 1010, Liege, 
Belgium) 
 69.1 179.3 289.5 
Koklu 
2007293 
Day 1 AGA 30 3.6 
(3.2-4) 
Radioimmunoassay 
(Biocode 1010, Liege, 
Belgium) 
 47 113.2 179.4 
Koklu 
2007294 
Day 1 IUGR 40 2.4g 
(2.1-2.8) 
Radioimmunoassay 
(Biocode 1010, Liege, 
Belgium) 
 33.6 75.4 117.2 
Koklu 
2007294 
Day 1 AGA 40 3.6 
(3.2-4) 
Radioimmunoassay 
(Biocode 1010, Liege, 
Belgium) 
 24.4 90.8 157.2 
Rajaram 
1995295 
Day 1  51 3.3 
(2.5-4.1) 
Radioimmunoassay 
(Endocrine Sciences, 
Calabasas Hills, CA) 
 49.7 59.1 68.5 
Iniguez 
2006296 
Day 2 SGA   Locally developed 
radioimmunoassay 
With extraction 23.5 41.9 60.3 
Iniguez 
2006296 
Day 2 AGA   Locally developed 
radioimmunoassay 
With extraction 41.6 59.6 77.6 
Leger 
1996251 
Day 3  36  RIA using polyclonal IGF-I 
antiserum 
Acid 
chromatography 
0 66 138 
Cassio 
1986297 
Day 3 SGA, Term 11 
 
 
 
 
2.6 
(1.9-3.3) 
Radioimmunoassay 
(Nichols Institute Company 
reagents) on capillary 
samples via heel prick 
Heel prick 
samples on filter 
paper. Eluted in 
borosilicate 
tubes with 
protamine-free 
buffer. 
Incubated 1hr 
with antiserum, 
and 16-20hr 
with 125I-labelled 
SmC. 
0 18 39 
Cassio 
1986297 
Day 3 AGA, 
Term 
198 3.4 
(2.2-4.6) 
Radioimmunoassay 
(Nichols Institute Company 
reagents) on capillary 
samples via heel prick 
Heel prick 
samples on filter 
paper. Eluted in 
borosilicate 
tubes with 
protamine-free 
buffer. 
Incubated 1hr 
with antiserum, 
and 16-20hr 
with 125I-labelled 
SmC. 
0 18 39 
Table 2.2.3 (continued) 
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Author Timing Population Number Weight 
(kg) 
Assay Extraction -2SD Mean 
(ng/ml) 
+2SD 
Cassio 
1986297 
Day 4 SGA, Term 48 2.6 
(1.9-3.3) 
Radioimmunoassay 
(Nichols Institute Company 
reagents) on capillary 
samples via heel prick 
Heel prick 
samples on filter 
paper. Eluted in 
borosilicate 
tubes with 
protamine-free 
buffer. 
Incubated 1hr 
with antiserum, 
and 16-20hr 
with 125I-labelled 
SmC. 
7.5 19.5 31.5 
Cassio 
1986297 
Day 4 AGA, 
Term 
417 3.4 
(2.2-4.6) 
Radioimmunoassay 
(Nichols Institute Company 
reagents) on capillary 
samples via heel prick 
Heel prick 
samples on filter 
paper. Eluted in 
borosilicate 
tubes with 
protamine-free 
buffer. 
Incubated 1hr 
with antiserum, 
and 16-20hr 
with 125I-labelled 
SmC. 
4 19.5 34.5 
Cassio 
1986297 
Day 5 SGA, Term 23 2.6 
(1.9-3.3) 
Radioimmunoassay 
(Nichols Institute Company 
reagents) on capillary 
samples via heel prick 
Heel prick 
samples on filter 
paper. Eluted in 
borosilicate 
tubes with 
protamine-free 
buffer. 
Incubated 1hr 
with antiserum, 
and 16-20hr 
with 125I-labelled 
SmC. 
0 19.5 43.5 
Cassio 
1986297 
Day 5 AGA, 
Term 
222 3.4 
(2.2-4.6) 
Radioimmunoassay 
(Nichols Institute Company 
reagents) on capillary 
samples via heel prick 
Heel prick 
samples on filter 
paper. Eluted in 
borosilicate 
tubes with 
protamine-free 
buffer. 
Incubated 1hr 
with antiserum, 
and 16-20hr 
with 125I-labelled 
SmC. 
0 24 48 
Cassio 
1986297 
Day 6 AGA, 
Term 
49 3.4 
(2.2-4.6) 
Radioimmunoassay 
(Nichols Institute Company 
reagents) on capillary 
samples via heel prick 
Heel prick 
samples on filter 
paper. Eluted in 
borosilicate 
tubes with 
protamine-free 
buffer. 
Incubated 1hr 
with antiserum, 
and 16-20hr 
with 125I-labelled 
SmC. 
0 28.5 58.5 
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Table 2.2.3 (continued) 
Author Timing Population Number Weight 
(kg) 
Assay Extraction -2SD Mean 
(ng/ml) 
+2SD 
Cassio 
1986297 
Day 7 AGA, 
Term 
32 3.4 
(2.2-4.6) 
Radioimmunoassay 
(Nichols Institute Company 
reagents) on capillary 
samples via heel prick 
Heel prick 
samples on filter 
paper. Eluted in 
borosilicate 
tubes with 
protamine-free 
buffer. 
Incubated 1hr 
with antiserum, 
and 16-20hr 
with 125I-labelled 
SmC. 
4.5 28.5 52.5 
Mitchell 
1989298 
1 week  99  Filter paper eluted in 
phosphate buffer containing 
rabbit anti-human IGF-I 
antibody, heparin and 
radiolabelled IGF-I 
overnight. 
Goat antirabbit 
gamma-globulin 
in 6% 
polyethylene 
glycol. 
0 13.5 31.5 
Cassio 
1986297 
Day 7-
15 
AGA, 
Term 
50 3.4 
(2.2-4.6) 
Radioimmunoassay 
(Nichols Institute Company 
reagents) on capillary 
samples via heel prick 
Heel prick 
samples on filter 
paper. Eluted in 
borosilicate 
tubes with 
protamine-free 
buffer. 
Incubated 1hr 
with antiserum, 
and 16-20hr 
with 125I-labelled 
SmC. 
0 45 105 
Mitchell 
1989298 
2-3 
weeks 
 42  Filter paper eluted in 
phosphate buffer containing 
rabbit anti-human IGF-I 
antibody, heparin and 
radiolabelled IGF-I 
overnight. 
Goat antirabbit 
gamma-globulin 
in 6% 
polyethylene 
glycol. 
3 54 105 
Cassio 
1998248 
3 weeks  12  Radioimmunoassay 
(Nichols Institute 
Diagnostics, San Juan 
Capistrano, CA) 
 0 68.2 175 
Leger 
1996251 
1 month  51  RIA using polyclonal IGF-I 
antiserum 
Acid 
chromatography 
20 90 160 
Cassio 
1998248 
2 
months 
 6  Radioimmunoassay 
(Nichols Institute 
Diagnostics, San Juan 
Capistrano, CA) 
 57.6 116 174.4 
Rajaram 
1995295 
2 
months 
 51 Birthweight 
3.3 
(2.5-4.1) 
Radioimmunoassay 
(Endocrine Sciences, 
Calabasas Hills, CA) 
 49 55.2 61.4 
Chellakooty 
2006299 
3 
months 
AGA, 
Term 
942 Birthweight 
3.6 
Radioimmunoassay Extracted by 
acid/ethanol and 
cryoprecipitated 
before analysis 
to remove 
binding proteins. 
Monoiodinated 
Tyr31 IGF-I 
used as 
radioligand. 
 92  
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Table 2.2.3 (continued) 
Author Timing Population Number Weight 
(kg) 
Assay Extraction -2SD Mean 
(ng/ml) 
+2SD 
Chellakooty 
2006299 
3 
months 
SGA, Term 49 Birthweight 
2.5 
Radioimmunoassay Extracted by 
acid/ethanol and 
cryoprecipitated 
before analysis 
to remove 
binding proteins. 
Monoiodinated 
Tyr31 IGF-I 
used as 
radioligand. 
 88  
Kai 2006300 3 
months 
Male  Birthweight 
3.6 
(2.6-4.6) 
Radioimmunoassay . 
Monoiodinated Tyr IGF-I 
used as radioligand) 
Acid/ethanol 
extraction and 
cryoprecipitation 
39.6 94 148.4 
Kai 2006300 3 
months 
Female  Birthweight 
3.5 
(2.5-4.5) 
Radioimmunoassay . 
Monoiodinated Tyr IGF-I 
used as radioligand) 
Acid/ethanol 
extraction and 
cryoprecipitation 
40.2 93 145.8 
Leger 
1996251 
3 
months 
 16  RIA using polyclonal IGF-I 
antiserum 
Acid 
chromatography 
20 78 136 
Ong 
2009301 
3 
months 
old 
Breastfed 61 boys 
57 girls 
 Radioimmunoassay 
(Mediagnost, Tubingen, 
Germany) 
Extracted from 
filter paper 
using acidifying 
buffer 
 
11.3 
 
 
8.1 
Boys 
43.7 
 
Girls 
37.3 
 
76.1 
 
 
66.5 
Ong 
2009301 
3 
months 
old 
Formula 
fed 
92 boys 
68 girls 
 Radioimmunoassay 
(Mediagnost, Tubingen, 
Germany) 
Extracted from 
filter paper 
using acidifying 
buffer 
 
12.2 
 
 
8.8 
Boys 
55.4 
 
Girls 
51 
 
98.6 
 
 
93.2 
Cassio 
1998248 
4 
months 
 8  Radioimmunoassay 
(Nichols Institute 
Diagnostics, San Juan 
Capistrano, CA) 
 4 77.2 150.4 
Rajaram 
1995295 
4 
months 
 51 Birthweight 
3.3 
(2.5-4.1) 
Radioimmunoassay 
(Endocrine Sciences, 
Calabasas Hills, CA) 
 43.6 49.8 56 
Hasegawa 
1997302 
1-6 
months 
 52  Monoclonal 
radioimmunoassay 
developed by authors 
Acid ethanol 
extraction 
0 90.3 229.5 
Leger 
1996251 
6 
months 
 12  RIA using polyclonal IGF-I 
antiserum 
Acid 
chromatography 
30 102 174 
Rajaram 
1995295 
6 
months 
 51 Birthweight 
3.3 
(2.5-4.1) 
Radioimmunoassay 
(Endocrine Sciences, 
Calabasas Hills, CA) 
 35 41.2 47.4 
Ong 
2009301 
12 
months 
Breastfed 61 boys 
57 girls 
 Radioimmunoassay 
(Mediagnost, Tubingen, 
Germany) 
Extracted from 
filter paper 
using acidifying 
buffer 
 
8 
 
 
3.6 
Boys 
38.8 
 
Girls 
56 
 
69.6 
 
 
108.4 
Ong 
2009301 
12 
months 
Formula 
fed 
92 boys 
68 girls 
 Radioimmunoassay 
(Mediagnost, Tubingen, 
Germany) 
Extracted from 
filter paper 
using acidifying 
buffer 
 
4.8 
 
 
7.3 
Boys 
47.6 
 
Girls 
59.9 
 
90.4 
 
 
112.5 
IRMA 
Baker Melo 
2009303 
Day 1 SGA 28 1.5 
(0.3-2.7) 
IRMA Active IGF-I DSL-
5600 
IGF-I extraction 
via HCl ethanol 
solution. I-125 
marked 
antibody. 
0 2.78 7.52 
Baker Melo 
2009303 
Day 1 AGA 26 2.4 
(1-3.9) 
IRMA Active IGF-I DSL-
5600 
IGF-I extraction 
via HCl ethanol 
solution. I 
-125 marked 
antibody. 
0 3.99 10.07 
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Table 2.2.3 (continued) 
Author Timing Population Number Weight 
(kg) 
Assay Extraction -2SD Mean 
(ng/ml) 
+2SD 
Low 
2001304 
Day 1 Term, 
AGA 
48  Immunoradiometric assay 
(Diagnostic Systems 
Laboratories Inc, Webster, 
TX, USA). 2 site assay. 
 0.8 48.1 95.4 
Satar 
2004305 
Day 1  19  Immunoradiometric assay 
(Immunotech) 
 20.7 121.5 222.3 
Thieriot-
Prevost 
1988306 
Day 3  62  Radioimmunoassay Extraction on a 
Sep-Pak column 
using kits from 
Immuno Nuclear 
Corporation 
(Stillwater, MN) 
0 48 118.9 
Pagani 
2007224 
Day 4 Term, 
AGA 
26  Immunoradiometric assay 
Diagnostic Systems 
Acid ethanol 
extraction 
32.5 51.2 69.9 
Cance-
Rouzaud 
1998247 
Day 0-5 AGA 64 2.7 
(1.3-4) 
IRMA (IGF-IRMA DSL-
9300 kit, Chiron 
Diagnostics, Cergy-
Pontoise, France) 
Ethanol 
extraction 
0 11.7 28.1 
Cance-
Rouzaud 
1998247 
Day 0-5 SGA 26 1.5 
(0.8-2.2) 
IRMA (IGF-IRMA DSL-
9300 kit, Chiron 
Diagnostics, Cergy-
Pontoise, France) 
Ethanol 
extraction 
0 6.6 14.6 
Bozzola 
1998307 
Day 5 Term 
infants 
19  Immunoradiometric assay 
(Diagnostic Systems 
Laboratories, Webster, 
Texas) 
Acid-ethanol 
extraction 
20.3 27 33.7 
Bozzola 
1996308 
Day 5 Term 
infants 
60  Immunoradiometric assay 
(Diagnostic Systems 
Laboratories, Webster, 
Texas) 
Acid-ethanol 
extraction 
0 67.6 148.2 
Ermis 
2004309 
Day 7 
Mothers 
who 
smoke 
 21 3.2 
(2.5-3.8) 
2 site IRMA 
(Diagnostic Systems 
Laboratories, Webster, 
Texas, USA) 
“Sample 
processed 
according to 
manufacturer’s 
instructions” 
63 119 175 
Ermis 
2004309 
Day 7 
non- 
smoker 
mothers 
 23 3.2 
(2.4-4) 
2 site IRMA 
(Diagnostic Systems 
Laboratories, Webster, 
Texas, USA) 
“Sample 
processed 
according to 
manufacturer’s 
instructions” 
56 126 196 
Satar 
2004305 
Day 10  19  Immunoradiometric assay 
(Immunotech) 
 64.3 133.1 201.9 
Bozzola 
1996308 
1 month Term 
infants 
60  Immunoradiometric assay 
(Diagnostic Systems 
Laboratories, Webster, 
Texas) 
Acid-ethanol 
extraction 
0 72.6 190.3 
Pagani 
2007224 
1 month Term, 
AGA 
26  Immunoradiometric assay 
Diagnostic Systems 
Acid ethanol 
extraction 
19.1 73.3 127.5 
Thieriot-
Prevost 
1988306 
1 month  62  Radioimmunoassay Extraction on a 
Sep-Pak column 
using kits from 
Immuno Nuclear 
Corporation 
(Stillwater, MN) 
0 75 216.7 
Bozzola 
1998307 
3 
months 
Term 
infants 
19  Immunoradiometric assay 
(Diagnostic Systems 
Laboratories, Webster, 
Texas) 
Acid-ethanol 
extraction 
7.4 44.9 82.4 
Bozzola 
1996308 
4 
months 
Term 
infants 
60  Immunoradiometric assay 
(Diagnostic Systems 
Laboratories, Webster, 
Texas) 
Acid-ethanol 
extraction 
0 97.9 248.2 
Low 
2001304 
6 
months 
Term, 
AGA 
48  Immunoradiometric assay 
(Diagnostic Systems 
Laboratories Inc, Webster, 
TX, USA). 2 site assay. 
 0 42 92.4 
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Table 2.2.3 (continued) 
Author Timing Population Number Weight 
(kg) 
Assay Extraction -2SD Mean 
(ng/ml) 
+2SD 
Chemiluminescent immunometric assays 
Kyriakakou 
2009290 
Day 1 
and  
Day 4 
IUGR 20 2.4 
(1.9-2.9) 
2 site chemiluminescence 
immunoassay (Nichols 
Diagnostic Institute, San 
Juan Capistrano, Calif) 
  
14.4 
Day 1 
22.5 
 
30.5 
 
13 
Day 4 
22 
 
30.9 
Kyriakakou 
2009290 
Day 1 
and  
Day 4 
AGA 20 3.2 
(2.6-3.7) 
2 site chemiluminescence 
immunoassay (Nichols 
Diagnostic Institute, San 
Juan Capistrano, Calif) 
  
12.8 
Day 1 
21.7 
 
30.8 
 
11.8 
Day 4 
21.7 
 
31.5 
Skalkidou 
2003310, 311 
Day 0-5 jaundice 209 3.3 Nichols Advantage 
Automated Specially 
System (Nichols Institute, 
San Juan Capistrano, CA) 
 3.4 24 44.5 
Skalkidou 
2003310, 311 
Day 0-5 Non 
jaundice 
123 3.3 Nichols Advantage 
Automated Specially 
System (Nichols Institute, 
San Juan Capistrano, CA) 
 2.1 29.1 56.2 
Elmlinger 
2004312 
Day 1-7  45  Two site, solid phase 
chemiluminescent enzyme 
immunometric assays 
(Immulite, Diagnostic 
Products Corp, Los 
Angeles, CA) 
IGF-II used to 
block IGFBP 
binding sites 
 
Assay specific 
diluent used 
3 15 27 
Elmlinger 
2004312 
Day 8-
14 
 40  Two site, solid phase 
chemiluminescent enzyme 
immunometric assays 
(Immulite, Diagnostic 
Products Corp, Los 
Angeles, CA) 
IGF-II used to 
block IGFBP 
binding sites 
 
Assay specific 
diluent used 
7 25 43 
De Zegher 
2012313 
2 weeks AGA 72 3.9 
(3-4.8) 
Immunochemiluminescence 
(IMMULITE 2000, 
Diagnostic Products, Los 
Angeles, CA) 
 0 55 115.6 
De Zegher 
2012313 
2 weeks SGA 102 2.9 
(1.9-3.9) 
Immunochemiluminescence 
(IMMULITE 2000, 
Diagnostic Products, Los 
Angeles, CA) 
 0 46 107.8 
De Zegher 
2012313 
4 
months 
AGA 72 7.2 
(5.5–8.9) 
Immunochemiluminescence 
(IMMULITE 2000, 
Diagnostic Products, Los 
Angeles, CA) 
 7.7 51 94.3 
De Zegher 
2012313 
4 
months 
SGA 102 6.4 
(5.4–7.4) 
Immunochemiluminescence 
(IMMULITE 2000, 
Diagnostic Products, Los 
Angeles, CA) 
 0 69 141.1 
Elmlinger 
2004312 
0.5-6 
months 
 25  Two site, solid phase 
chemiluminescent enzyme 
immunometric assays 
(Immulite, Diagnostic 
Products Corp, Los 
Angeles, CA) 
IGF-II used to 
block IGFBP 
binding sites 
 
Assay specific 
diluent used 
6 156 306 
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Table 2.2.4: Assay Specific IGF-I measurement 6-18 months of age 
Author Timing Population Number Weight Assay Extraction -2SD Mean 
(ng/ml) 
+2SD 
ELISA 
Yuksel 
2011265 
12 
months 
Males 54  ELISA (Diagnostic 
Systems Laboratories 
Inc) 
 0 82.1 211.1 
Yuksel 
2011265 
12 
months 
Females 45  ELISA (Diagnostic 
Systems Laboratories 
Inc) 
 0 125.3 310.9 
Radioimmunoassay 
Leger 
1996251 
6 months  12  RIA using polyclonal 
IGF-I antiserum 
Acid 
chromatography 
30 102 174 
Cassio 
1998248 
7 months  10  Nichols Institute 
Diagnostics, San Juan 
Capistrano, CA 
Acid ethanol 
extraction 
26.9 83.7 140.5 
Barton 
1996314 
12 
months 
 40  Radioimmunoassay. 
DSL-6600 Diagnostic 
Systems Laboratories, 
Texas. 
 0 61 136.9 
Iniguez 
2006296 
12 
months 
SGA 50  Locally developed 
radioimmunoassay 
With extraction 27.4 67 106.6 
Leger 
1996251 
12 
months 
 37  RIA using polyclonal 
IGF-I antiserum 
Acid 
chromatography 
3 73 143 
Mamabolo 
2007315 
12 
months 
 116 9.4kg (6.5-
12.2) 
RIA on the Cobra II 
Gamma Counter. 
(Diagnostic Systems 
Laboratories Inc, 
Webster, TX, USA) 
 0 24.8 82.2 
Ong 
2009301 
12 
months 
Breastfed 61 boys 
57 girls 
 Radioimmunoassay 
(Mediagnost, 
Tubingen, Germany) 
Extracted from 
filter paper using 
acidifying buffer 
 
8 
 
 
3.6 
Boys 
38.8 
 
Girls 
56 
 
69.6 
 
 
108.4 
Ong 
2009301 
12 
months 
Formula 
fed 
92 boys 
68 girls 
 Radioimmunoassay 
(Mediagnost, 
Tubingen, Germany) 
Extracted from 
filter paper using 
acidifying buffer 
 
4.8 
 
 
7.3 
Boys 
47.6 
 
Girls 
59.9 
 
90.4 
 
 
112.5 
Rajaram 
1995295 
12 
months 
 51 Birthweight 
3.3 
(2.5-4.1) 
Radioimmunoassay 
(Endocrine Sciences, 
Calabasas Hills, CA) 
 46.6 56 65.4 
Juul 
1994316 
1-2 years  44  Radioimmunoassay 
(Mediagnost, 
Tubingen, Germany) 
Acid-ethanol 
extraction and 
cryoprecipitation. 
29 80 157 
IRMA 
Low 
2001304 
12 
months 
Term, 
AGA 
48  Immunoradiometric 
assay (Diagnostic 
Systems Laboratories 
Inc, Webster, TX, 
USA). 2 site assay. 
 0 74 151.9 
Low 
2001304 
18 
months 
Term, 
AGA 
48  Immunoradiometric 
assay (Diagnostic 
Systems Laboratories 
Inc, Webster, TX, 
USA). 2 site assay. 
 0 104 233.8 
Hyun 
2012268 
1-2 years Males 35  IRMA (Immunotech, 
Marseilles, France) 
 0 57.9 123 
Hyun 
2012268 
1-2 years Females 25  IRMA 
(Immunotech, 
Marseilles, France) 
 0 92.4 183.8 
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Table 2.2.4 (continued) 
Author Timing Population Number Weight Assay Extraction -2SD Mean 
(ng/ml) 
+2SD 
Chemiluminescent immunometric assays 
Larnkjaer 
2009317 
9 months Formula 
Feeding 
27  Automated 
chemiluminescent 
assay (IMMULITE 
1000, DPC Biermann 
GmbH, Bad Nauheim, 
Germany) 
Pretreatment 
with acid 
20.2 58.4 96.6 
Elmlinger 
2004312 
6-
12months 
 19  Two site, solid phase 
chemiluminescent 
enzyme immunometric 
assays 
(Immulite, Diagnostic 
Products Corp, Los 
Angeles, CA) 
IGF-II used to 
block IGFBP 
binding sites 
 
Assay specific 
diluent used 
38 140 242 
Larnkjaer 
2009317 
12 
months 
Formula 
Feeding 
28  Automated 
chemiluminescent 
assay (IMMULITE 
1000, DPC Biermann 
GmbH, Bad Nauheim, 
Germany) 
Pretreatment 
with acid 
7.8 54 100.2 
Brabant 
2003318 
1-2 years  77  Two site 
chemiluminescent 
immunoassay (Nichols 
Advantage; Nichols 
Institute Diagnostics, 
Calif, USA) 
Acidification 
 
Incubated with 
excess IGF-II 
and acridium-
ester labeled 
antibody 
2 58 114 
Elmlinger 
2004312 
1-2 years  27  Two site, solid phase 
chemiluminescent 
enzyme immunometric 
assays 
(Immulite, Diagnostic 
Products Corp, Los 
Angeles, CA) 
IGF-II used to 
block IGFBP 
binding sites 
 
Assay specific 
diluent used 
36 134 232 
 
 
2.2.4 DISCUSSION 
Assay variability in GH and IGF-I measurement can present a significant 
challenge in the comparison of results between studies and in clinical 
interpretation. This review highlights the wide variability in reported 
measurements between studies related both to differences in the study population 
and in assays used. 
 
The diagnosis of GH deficiency in the paediatric population can be challenging. 
In the absence of a robust test for diagnosing GH deficiency, paediatric 
endocrinologists vary in practice62, 135, 136. Serum IGF-I levels are stable and 
random values can be clinically useful in this evaluation, with a sensitivity of 70-
90% in the detection of isolated GH deficiency319. The GHST is commonly used, 
but peak GH response to stimulation testing is influenced by assay 
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methodology233. Despite this, almost half of physicians who rely on stimulation 
testing do not know what type of GH assay is utilised by their laboratory133. 
 
Clinical, auxological and radiological data can also guide the clinician in 
diagnosing GH deficiency8, but these can be less useful in infants and small 
children. Children with isolated congenital GH deficiency have a normal birth 
weight and length, and often present only later with growth failure219. 
Hypoglycaemia can be problematic in this population, and may be the only 
clinical feature13, 46, 212.  
 
GH and IGF-I measurements currently play a central role in our evaluation of 
children with possible GH deficiency. In this review, we have highlighted that 
there is wide variability in reported means and standard deviations for IGF-I and 
GH concentrations in this age group, and this adds to the difficulty in diagnosing 
GHD in infants.  
 
2.2.5 CHAPTER CONCLUSION 
Assay variability and interference can contribute to difficulty in using IGF-I and 
GH measurements to guide clinical care, and can cause misclassification of 
results as being abnormal in some cases. This review has demonstrated wide 
variability in the reported concentrations of IGF-I in this age group. In the 
following chapters, I will explore a new modality of measuring IGF-I that is less 
likely to be subject to the interference seen with current assays.  
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CHAPTER 2.3: MASS SPECTROMETRY 
 
Publication 
Hawkes CP, Schnellbacher S, Singh RJ, Levine MA. 25-hydroxyvitamin D can 
interfere with a common assay for 1,25-dihydroxyvitamin D in vitamin D 
intoxication. J Clin Endocrinol Metab. 2015;100(8):2883-9 (Appendix G). 
 
In the previous chapter, I have reviewed the reference data for IGF-I 
concentrations in infancy and demonstrated wide variation across studies. IGFBP 
interference may contribute significantly to these differences between assays. In 
this chapter, I will provide an overview of the mechanisms of this interference in 
competitive and non-competitive assays. I will then explore the potential of mass 
spectrometry to overcome interference. This will provide the background for the 
next chapter, where I will describe reference data for IGF-I concentrations in 
infants using mass spectrometry. 
 
2.3.1 THE EFFECT OF INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 
INTERFERENCE ON INSULIN-LIKE GROWTH FACTOR-I MEASUREMENT 
Competitive immunoassays rely upon serum IGF-I competing with a labeled 
antigen for an antibody (Figure 2.3.1A). Measurement of the antibody-labeled 
antigen complex allows for measurement of serum IGF-I using this technique. 
IGFBP binding to IGF-I can interfere with competitive immunoassays in two 
ways. When bound to an IGFBP, IGF-I may not bind to the antibody and give a 
falsely low measurement (Figure 2.3.1B). IGFBPs in serum may also bind to the 
labeled antigen and cause the opposite effect, i.e. result in a falsely high 
measurement of IGF-I (Figure 2.3.1C). 
 
Non-competitive assays require the binding of labeled antibodies to specific 
epitopes on the protein of interest (Figure 2.3.2A). The presence of binding 
proteins bound to IGF-I can prevent epitope recognition, and consequently cause 
the measurement to be erroneously low (Figure 2.3.2B). 
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Separation of IGF-I from its binding proteins is necessary to overcome the 
unreliable measurements caused by IGFBP interference, although it is not 
generally possible to remove all IGFBPs from solution. As discussed in Chapter 
2.2, the most common approach to this is the disassociation of IGF-I from 
IGFBPs through acidification, followed by separation using gel chromatography 
or ethanol precipitation320. Saturation of binding proteins is often performed by 
the addition of excess IGF-II or other IGFBP blocking agents. 
 
It is important to note that performing any separation technique results in the 
measurement of total IGF-I and does not distinguish free from total IGF-I 
concentrations. The clinical utility of free IGF-I measurement is unknown and 
total IGF-I is currently considered to be appropriate for clinical use321, 322. 
 
 
Figure 2.3.1: The principles of competitive immunoassays in IGF-I measurement, and the 
potential effects of IGFBP interference 
 
 
Competitive Immunoassays
Radiolabelled Tracer
Measured Signal
IGF-I (to be measured)
No Binding Protein Interference
Binding Protein Interference with tracer more than analyte
Reduced signal and 
falsely increased concentration 
of IGF-I reported
Binding Protein Interference with analyte more than tracer
Increased signal and 
falsely reduced concentration 
of IGF-I reported
A
B
C
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Figure 2.3.2: The principles of non-competitive immunoassays in IGF-I measurement, and the 
potential effects of IGFBP interference 
 
 
Numerous competitive and non-competitive IGF-I assays are currently available, 
and most are calibrated against the WHO 87/518 IGF-I standard323. Despite this 
calibration, differences are seen when assays are compared with each other260, 324 
and it is thought that these differences are due to variations in sensitivity of each 
assay to interference from binding proteins323. 
 
The following study highlights the potential of mass spectrometry to overcome 
interfering substances and provide more accurate measurements than RIAs. This 
study prompted our move towards studying IGF-I measured by this modality in 
subsequent chapters. 
 
2.3.2 MASS SPECTROMETRY IS LESS SENSITIVE THAN IMMUNOASSAYS TO 
INTERFERENCE 
 
My impetus for exploring the potential of mass spectrometry to overcome 
interference comes from a study I completed in using this modality in children 
with vitamin D intoxication (Appendix G)211. At the Children’s Hospital of 
Philadelphia, we saw two patients with elevated serum levels of 25-
No Binding Protein Interference Tracer
IGF-I (to be measured)
IGF-I detecting antibody
Measured Signal
Non-Competitive Immunoassays
Binding Protein Interference
Reduced signal and 
falsely reduced concentration 
of IGF-I reported
A
B
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hydroxyvitamin D (25(OH)D) and 1,25-dihydroxyvitamin D (1,25(OH)2D) when 
measured by RIA. 
 
To become fully active, vitamin D must undergo two modifications by 
cytochrome P450 (CYP) enzymes. The first step is 25-hydroxylation of parent 
vitamin D2 and D3 by hepatic microsomal CYP2R1, which generates the 
prohormones 25-hydroxyvitamin D3 (25(OH)D3) and 25-hydroxyvitamin D2 
(25(OH)D2), respectively325.  A second hydroxylation occurs in the kidney where 
CYP27B1, a 1α-hydroxylase located in mitochondrion, converts 25(OH)D to the 
fully active form of the vitamin, 1,25-dihydroxyvitamin D (1,25(OH)2D) (Figure 
2.2.3). 1,25(OH)2D is a potent hormone, and binds with high affinity to the 
vitamin D receptor (VDR), which mediates most physiological actions of 
vitamin D via modulation of the transcription of target genes.  
 
 
Figure 2.3.3: Overview of Vitamin D metabolism 
 
The conversion of 25(OH)D to 1,25(OH)2D by CYP27B1 is tightly regulated by 
calcium, parathyroid hormone (PTH) and fibroblast growth factor 23. Hence, as 
serum levels of 25(OH)D increase excessively there is a parallel decrease in 
levels of serum 1,25(OH)2D, a phenomenon that reflects suppression of PTH by 
hypercalcaemia and a corresponding loss of PTH-dependent stimulation of 
CYP27B1 activity326.  
 
Thus, elevated levels of 1,25(OH)2D on RIA measurement seen in our two 
patients did not make sense. We subsequently used a LCMS assay to measure 
Vitamin D3
25(OH)D3
1,25(OH)2D3
Calcitroic Acid
Lactone
24,25(OH)2D3
↑ Intestinal Calcium
Absorption
↑ Renal Tubular
Calcium Reabsorption
↑ Osteoclast Activity
CYP2R1
CYP27B1
CYP24A1
CYP24A1
Inactive
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1,25(OH)2D in these patients and demonstrated that 1,25(OH)2D levels were not 
elevated (Table 2.3.1). 
 
Table 2.3.1: Clinical characteristics and laboratory findings in two adolescents presenting with 
25(OH)D intoxication 
 Reference Range Case 1 Case 2 
Age, Sex  15 years, male 17 years, female 
Background Diagnoses  Well child Ocular Albinism, Autism 
Calcium (mg/dL) 8.8 – 10.1 13.8 11.3 
Phosphorous (mg/dL) 2.9 – 5.4 4.2 4 
Albumin (g/dL) 3.7 – 5.6 4.3 4.1 
Parathyroid Hormone 
(pg/ml) 9 - 52 <3 <5.5 
Creatinine (mg/dL) 0.6 - 1.3 3.1 0.48 
PTHrP (pmol/L) <2 <2 <2 
CYP24A1 gene   Normal Normal 
    
25(OH)D3 (ng/ml) 
LCMS 30 - 80 685 143 
1,25(OH)D3 (pg/ml) 
RIA 15 - 75 >230 >190 
1,25(OH)D3 (pg/ml) 
LCMS 25 – 86 45 68 
  
This experience prompted me to explore the role of LCMS assays in other areas 
where assay interference may compromise the utility of RIA, notably IGF-I and 
–II measurement. 
 
2.3.3 CHAPTER CONCLUSION 
The majority of assays currently used to measure IGF-I concentrations are RIAs. 
Competitive and non-competitive immunoassays are subject to unpredictable 
interference by IGFBPs when used to measure IGF-I concentration. In this 
chapter, I have described my experience of using LCMS to overcome 
interference of 25(OH)D in the measurement of 1,25(OH)2D with RIA. In the 
following chapter, I will explore the potential of a novel LCMS assay in 
measuring IGF-I and –II concentrations. 
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CHAPTER 2.4: CORRELATION OF INSULIN-LIKE GROWTH FACTOR-I 
AND –II CONCENTRATIONS MEASURED BY MASS SPECTROMETRY 
AT BIRTH WITH GROWTH FROM BIRTH TO TWO MONTHS 
 
Publication 
Hawkes CP, Murray DM, Kenny LC, Kiely M, Caulfield MP, Argon Y, Reitz RE, 
McPhaul MJ, Grimberg A. Correlation of insulin-like growth factor-I and –II 
concentrations at birth measured by mass spectrometry and growth from birth to 
two months. Horm Res Paediatr. 2018 Jan. doi 10.1159/000486035 [Epub ahead 
of print] (Appendix H). 
 
Presentation 
Hawkes CP, Murray DM, Kenny LC, Kiely M, Sikora K, Caulfield MP, Argon Y, 
Reitz RE, McPhaul MJ, Grimberg A. Measurement of IGF-I and –II 
concentrations at birth by mass spectrometry in a large birth cohort: correlation 
with anthropometry. Pediatric Endocrine Society, September 2017 (Poster) 
(Appendix I). 
 
In the preceding chapters, I have described wide variability in GH and IGF-I 
concentrations in infancy and summarised the mechanisms for interfering 
substances in affecting these results. At birth, IGF-I concentrations are low and 
serum IGFBP concentrations vary. Consequently, if clinically significant assay 
interference occurs, newborn infant IGF-I measurement would be the age group 
with the most imprecise measurements. 
 
2.4.1 BACKGROUND 
IGF-I and –II play an important role in prenatal growth, as evidenced by 
mutations affecting IGF-I152, 327 and IGF-II328, 329 signaling significantly reducing 
birth size. The magnitude of this effect is up to 60% in mouse models330, 331. 
Importantly, congenital GHD is associated with normal size at birth332, 
demonstrating that prenatal IGF-I and –II regulation is less dependent on GH 
production333 than in the older child.334 
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Numerous factors outside of the GH/IGF axis may influence prenatal IGF-I and 
–II production. Umbilical cord blood samples from female infants have higher 
IGF-I concentrations than from males 335. Maternal factors such as cigarette 
smoking336, obesity337, and preeclampsia279, 338 may also affect IGF 
concentrations, although most studies to date have focused on IGF-I and not 
IGF-II measurements. Furthermore, small studies have demonstrated a 
correlation between cord IGF-I concentration at birth and birth size221, 262, 280, but 
the association for IGF-II is reported to be weak or absent221, 277, 339. 
 
Over 90% of circulating IGF-I and -II is bound to IGFBPs, prolonging their 
serum half-life and regulating their bioavailability. Prior to measurement, IGF-I 
and –II must be separated from these IGFBPs, and extraction methods such as 
acid ethanol precipitation are commonly used 320. This approach recovers only 
75-80% of the IGF-I complexed to IGFBPs236, and may affect the reliability of 
the reported measurements. This interference is likely to be more problematic in 
infants, who have lower IGF concentrations and higher concentrations of some 
of the IGFBPs than older children124. For example, IGFBP-1 concentrations can 
be increased by the stress of labour340, 341, or in pregnancies complicated by pre-
eclampsia279, and it is likely that interference will significantly affect IGF 
measurement accuracy when susceptible assays are used. Differences in IGF-I 
measurements also have been attributed to their reliance on different reference 
populations, resulting in assay-specific reference ranges. A study of six IGF-I 
immunoassays using the same healthy population-based reference samples still 
yielded different assay-specific reference ranges with variations most noticeable 
at higher IGF-I concentrations260. 
 
LCMS assays are now available to measure IGF-I and –II concentrations342, a 
method that is less susceptible to IGFBP interference even in the presence of 
supra-physiological levels of IGFBP-3238. Isotopically labeled IGF-I can be used 
with the LCMS assay to adjust for the IGF-I and –II lost in acid ethanol 
extraction and chromatography, further improving the accuracy of this method.  
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2.4.2 AIM 
The aim of this study was to explore the relationships of age- and gestational 
age-corrected umbilical cord IGF-I and –II concentrations measured at birth by 
LCMS with weight, length, and occipitofrontal head circumference (OFC) at 
birth and two months. As a secondary objective, we aim to describe gestational 
age- and sex-specific reference data for IGF-I and IGF-II concentrations at birth 
using an LCMS assay.  
 
2.4.3 METHODS 
2.4.3.1 The SCOPE Pregnancy Study and Cork BASELINE Study 
The SCOPE pregnancy study343 is a multicentre cohort study that recruits 
primiparous, low risk women at 15±1 weeks’ gestation. The aim of the SCOPE 
study is to develop biomarkers for the prediction of pre-eclampsia, fetal growth 
restriction and pre-term birth in a low risk population. Therefore the specific 
exclusion criteria were: multiple pregnancies, known major fetal anomalies, pre 
pregnancy essential hypertension, diabetes, renal disease, systemic lupus 
erythematous, antiphospholipid syndrome, major uterine anomaly, cervical cone 
biopsy, ≥3 miscarriages and treatment with low dose aspirin, calcium intake 
>1g/24 hours, low molecular weight heparin, fish oil and antioxidants. 
 
The Cork BASELINE (Babies After Scope; Establishing the Longitudinal 
Impact using Neurological and nutritional Endpoints) study is a longitudinal 
birth cohort study established as a follow on to the SCOPE pregnancy study in 
Ireland. Women recruited to the SCOPE Ireland study were approached at 20 
weeks’ gestation and recruited to the BASELINE study. In addition, firstborn 
healthy children born between August 2008 and August 2011 were eligible for 
this study. A detailed description of this cohort has been reported previously344. 
The Clinical Research Ethics Committee of the Cork Teaching Hospitals 
approved this study. 
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2.4.3.2 Subjects 
For this study, all children born between 37 and 42 weeks gestation were 
included. Gestational age was determined by the first day of the last menstrual 
period. If fetal ultrasound was performed before 16 weeks’ gestation and a 
discrepency of greater than 6 days was noted, ultrasonographic gestational age 
was used. Similarly, gestational age was determined by ultrasound if performed 
up to 21 weeks’ gestation and a discrepency of 10 days was noted. Smoking 
status during the first trimester was ascertained by self-report during pregnancy. 
 
2.4.3.3 Anthropometry 
Weight, length, and OFC were measured on the first day of life using 
standardised protocols. A Harpenden neonatometer (Harlow Healthcare, London, 
UK) was used to measure supine length, and naked weight was measured using 
the Seca 384 Baby Scales (Seca, Hamburg, Germany). Sex- and gestational age-
specific z-scores for weight, length, and OFC were generated from the United 
Kingdom reference charts345 using Stata 12.0 (StataCorp, College Station, TX, 
USA)346. Subjects were measured again at two months of age using the same 
standardised protocols. 
 
2.4.3.4 Sample collection and storage 
Umbilical cord blood samples were collected at birth and processed to serum 
within three hours of collection. They were stored at -80oC until analysis. 
 
2.4.3.5 Mass Spectrometry 
IGF-I and –II concentrations were measured by Quest Diagnostics (San Juan 
Capistrano, CA, USA) using LCMS238, 241. Isotopically labeled IGF-I was added 
to the sample as an internal standard for IGF-I and -II. IGF-I and -II were 
released from their binding proteins by an acid ethanol extraction followed by 
automated online extraction and analytical chromatography using an Aria TX-4 
(Thermo-Fisher, San Jose, CA, USA). IGF-I and -II were quantitated using a 
time-of-flight mass spectrometer using narrow mass extraction of full-scan 
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spectra. The internal standard was used to adjust for any procedural losses during 
extraction. 
 
Performance characteristics of this assay have been previously described238, 241. 
For IGF-I using quality control samples the inter-assay coefficient of variation 
and percent recovery were 5% and 104% at 100 ng/ml, 5.2% and 103% at 400 
ng/ml and 3.5% and 103% at 700 ng/ml. For IGF-II, the inter-assay coefficient 
of variation and percent recovery were 6.1% and 102% at 200 ng/ml, 3.2% and 
99% at 500 ng/ml and 5.3% and 99% at 1200 ng/ml. Similar performance was 
seen with serum pools238, 241. 
 
2.4.3.6 Statistical Analysis 
The lower limit of detection of IGF-I using this assay is 16 ng/ml; samples with 
concentrations below this limit were assigned a value of 15 ng/ml. Similarly, the 
lower limit of detection of IGF-II was 32 ng/ml; samples with concentrations 
below 32 ng/ml were assigned a value of 31 ng/ml. 
 
Sex-specific reference curves for IGF-I and -II concentrations were generated 
using LMS Chartmaker Pro (Harlow Printing Ltd., Tyne and Wear, UK). The 
LMS method347, 348 uses a Box-Cox transformation to obtain normality. Three 
distinct curves were generated for skewness, median, and variability. These were 
combined in one graph, with smoothening of changes over time. They were then 
adjusted until fit of the curve was visually optimised as per software 
recommendations. IGF-I and -II concentrations were then converted to age- and 
sex-specific z-scores from this population for subsequent analysis. 
 
Data analyses were performed using SPSS 22.0 (IBM, New York, NY, USA). 
Normally distributed data were described as mean (SD) and compared using 
independent-sample t-tests. Linear regression analysis was used to determine the 
relationship between continuous variables. 
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2.4.4 RESULTS 
 
Eleven hundred term infants (563 male) met the inclusion criteria for this study. 
Characteristics of the population are shown in Table 2.4.1.  
 
Table 2.4.1: Characteristics of the infants and pregnancies included in this cohort. Values of all 
continuous variables are presented as mean (SD). 
 Male Female All 
Number of infants, n 563 537 1100 
Gestational age, weeks  40.1 (1.1) 40.2 (1.1) 40.2 (1.1) 
Weight, kg 3.55 (0.47) 3.48 (0.44) 3.52 (0.45) 
Length, cm 50.7 (2.1) 50.2 (1.9) 50.4 (2) 
Head circumference, cm 35.1 (1.4) 34.6 (1.3) 34.9 (1.4) 
Maternal age, years 30.1 (4.6) 30 (4.2) 30.1 (4.4) 
Maternal BMI at 15 weeks, kg/m2 24.8 (4.1) 24.9 (4.2) 24.9 (4.1) 
Caucasian, n 555 527 1082 
Maternal smoking during first trimester, n 145 132 277 
IGF-I, ng/ml 48.5 (23.2) 56.7 (23.9) 52.5 (23.9) 
IGF-II, ng/ml 420.8 (95) 428 (101.4) 424.3 (98.2) 
 
 
The mean (SD) IGF-I concentration was 52.5 (23.9) ng/ml (males 48.5 [23.3] 
ng/ml, females 56.7 [23.9] ng/ml). The mean (SD) IGF-II concentration was 
424.3 (98.2) ng/ml (males 420.8 [95] ng/ml, females 428 [101.4] ng/ml). There 
was a significant difference between males and females in IGF-I (p < 0.001) but 
not in IGF-II concentrations (p = 0.2).  
 
Linear regression analysis showed a slight reduction in IGF-I concentrations 
with increasing gestational age in both males (regression coefficient [SEM] -
0.005 [0.002], p = 0.01) and females (regression coefficient [SEM] -0.004 
[0.002], p = 0.03). Gestational age was not associated with IGF-II concentrations 
in either males (regression coefficient [SEM] 0 [0], p = 0.4) or females 
(regression coefficient [SEM] 0.001 [0], p = 0.06). IGF-I and –II concentrations 
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in term male and female infants according to gestational age are presented in 
Figure 2.4.1. 
 
 
Figure 2.4.1: Sex-specific centile charts for IGF-I (A and B) and IGF–II (C and D) 
concentrations in term infants in a healthy population-based cohort, according to gestational age 
from 37 to 42 weeks’ gestation. 
 
Correlation with Anthropometry and Early Growth 
Z-Scores for gestational age- and sex-specific IGF-I concentrations at birth 
correlated with weight, length, and OFC z-scores at birth. The strongest 
association was with birth weight (R2=0.19). Length and weight z-scores at age 
two months correlated significantly with IGF-I concentrations at birth, but the 
strength of the association was lower than at birth. Over two months, weight R2 
decreased from 0.19 to 0.02 and length R2 decreased from 0.07 to 0.04. Although 
IGF-II concentrations correlated significantly with weight, length, and OFC at 
birth, this accounted for <1% of the variance seen in each of these parameters 
(Table 2.4.2). 
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Both IGF-I and -II concentrations at birth were associated with length at age two 
months (p < 0.001 and p = 0.04 respectively), while only IGF-I concentration at 
birth was associated with weight at two months (p < 0.001). The rates of change 
in OFC and weight z-scores over the first two months of life were negatively 
associated with IGF-I concentrations at birth. IGF-II concentrations at birth were 
not associated with growth trajectories in weight, length, or OFC over the first 
two months (Figure 2.4.2). 
 
 
Figure 2.4.2: The relationship between IGF-I and –II z-scores at birth with head circumference, 
weight and length z-scores at birth. 
 
 
An increase in weight, OFC, and length z-score of 1 or more over the first two 
months was seen in 198, 250, and 343 infants respectively. Those with an 
increase in weight z-score of 1 or more had significantly lower mean IGF-I z-
scores at birth (-0.6 vs 0.1, p<0.001), but not IGF-II z-scores (-0.06 vs 0.02, p = 
0.4). Similarly, infants with an increase in OFC z-score during the first two 
months tended to have lower IGF-I z-scores (-0.2 vs 0.05, p = 0.003) but not 
IGF-II z-scores (-0.08 vs 0.02, p = 0.2). No difference was seen in IGF-I (p = 
0.9) or IGF-II (p = 0.9) z-scores at birth in infants who had an increase in length 
z-score of 1 or more. Lower mean (SD) birth weight z-scores were seen in 
infants with increases in z-scores of 1 or more in the first two months for weight 
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(-0.5 vs 0.1, p < 0.001), length (-0.08 vs 0.09, p < 0.001) and OFC (-0.3 vs 0.1, p 
< 0.001). 
 
Table 2.4.2: The relationship between sex- and gestational age-corrected IGF-I and IGF-II z-
scores and growth parameters at birth and 2 months, and growth trajectory from birth to 2 
months. 
Length, weight and head circumference are presented as sex-, age- and gestation corrected z-
scores. For this analysis, IGF-I and –II are the dependent variables and anthropometric measures 
are independent variables. 
 IGF-I IGF-II 
 R2 Regression 
coefficient 
(SEM) 
p R2 Regression 
coefficient 
(SEM) 
p 
Z-Scores at Birth       
Length 0.07 0.28 (0.03) <0.001 0.004 0.07 (0.03) 0.03 
Weight 0.19 0.51 (0.03) <0.001 0.005 0.09 (0.04) 0.01 
Head Circumference 0.028 0.17 (0.03) <0.001 0.004 0.07 (0.03) 0.04 
Z-Scores at 2 months       
Length 0.04 0.21 (0.03) <0.001 0.004 0.07 (0.03) 0.04 
Weight 0.022 0.15 (0.03) <0.001 0.002 0.05 (0.03) 0.16 
Head Circumference 0.001 0.04 (0.04) 0.24 0.003 0.06 (0.04) 0.06 
Delta z-score from 
birth to 2 months 
      
Length 0.002 -0.05 (0.04) 0.14 0.001 0.01 (0.04) 0.8 
Weight 0.07 -0.31 (0.04) <0.001 0.001 -0.03 (0.04) 0.4 
Head Circumference 0.02 -0.17 (0.04) <0.001 0.001 -0.02 (0.04) 0.5 
 
Factors influencing IGF concentrations 
Of the 1100 infants included in this study, 40 had birthlength and 57 had birthweight 
below the 10th percentile. In those with birthlength below the 10th percentile, IGF-I z-
scores (-0.7 vs 0.1, p <0.001) and IGF-II z-scores (-0.3 vs 0, p 0.03) at birth were lower 
(Figure 3D). This was also seen in infants with birthweight below the 10th percentile 
(IGF-I z-scores -1.2 vs 0.07, p < 0.001; IGF-II z-scores -0.4 vs 0, p = 0.01) (Figure 
2.4.3). 
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Figure 2.4.3: The effect of smoking (A), preeclampsia (B) and maternal obesity (C) on umbilical 
cord IGF-I and –II age- and-sex specific z-scores. The association of birth length (D), birth 
weight (E) and birth length and head circumference (F) below the 10th centile with cord IGF-I 
and –II concentrations are also shown. 
 
 
Maternal cigarette smoking during the first trimester and pre-eclampsia were 
associated with lower mean (SD) cord IGF-I concentrations (p < 0.001 and p = 
0.04 respectively) but not IGF-II concentrations (p=0.2 and p=0.5 respectively). 
Maternal BMI > 30 kg/m2 (n = 137) at 15 weeks’ gestation was not associated 
with increased umbilical cord IGF-I or –II concentrations (p = 0.4 and 0.5 
respectively) (Table 2.4.3). 
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Table 2.4.3: Comparison of gestation- and sex-corrected mean (SD) z-scores for IGF-I and –II 
concentrations at birth, according to maternal smoking, maternal obesity, pre-eclampsia, and 
length, weight and OFC percentiles. 
 IGF-I z-score IGF-II z-score 
 Yes No p Yes No p 
Smoking during 
first trimester 
-0.2 (1) 
n=277 
0.07 
(0.99) 
n=823 
<0.001 -0.07 (1) 
n=277 
0.01 
(1.04) 
n=823 
0.2 
Maternal BMI > 
30 kg/m2 at 15 
weeks’ gestation 
-0.07 
(1.1) 
n=137 
0.01 
(0.99) 
n=963 
0.4 0.05 
(1.2) 
n=137 
-0.02 (1) 
n=963 
0.5 
Pre-eclampsia -0.31 
(0.85) 
n=34 
0.01 (1) 
n=1066 
0.04 -0.13 
(1.01) 
n=34 
-0.01 
(0.01) 
n=1066 
0.5 
Birthlength <10th 
percentile 
-0.79 
(0.87) 
n=48 
0.04 (1) 
n=1052 
<0.001 -0.33 
(0.99) 
n=48 
0 (1.02) 
n=1052 
0.03 
Birthweight <10th 
percentile 
-1.17 
(0.77) 
n=59 
0.07 
(0.97) 
n=1041 
<0.001 -0.35 
(0.94) 
n=59 
0.01 
(1.03) 
n=1041 
0.01 
OFC <10th 
percentile 
-0.21 
(1.01) 
n=139 
0.03 (1) 
n=961 
0.01 -0.31 
(1.2) 
n=139 
0.03 (1) 
n=961 
0.001 
 
2.4.5 DISCUSSION 
We have described IGF-I and –II concentrations at birth using a LCMS assay238, 
thus generating accurate measurements at an age where concentrations tend to be 
low. Our large cohort of well-characterised term infants allowed us to investigate 
the relationship between these measurements and birth size and early infant 
growth. Consistent with previous studies using other assays, IGF-I and –II 
concentrations at birth were associated with weight, length, and OFC at birth. At 
age two months, weight and length were associated with birth IGF-I 
concentrations whereas only length was associated with birth IGF-II 
concentrations. Low IGF-I concentrations at birth were associated with 
accelerated increases in weight and OFC z-scores over the first two months. 
Maternal smoking and pre-eclampsia were associated with lower cord IGF-I but 
not IGF-II concentrations. 
 
The correlation of an infant’s birth weight and length with IGF-I concentration 
has been shown previously in smaller studies using RIAs221, 277, 278, 336, 349. The 
relationship between birth weight and IGF-II levels are less well defined, with 
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some studies showing no correlation349, 350. Our results support the findings of 
other studies, where a weak association has been shown221, 351. This weak 
association between cord IGF-II and neonatal anthropometry is surprising given 
the significant effect of mutations affecting IGF-II signaling on mouse330 and 
human328, 329 size at birth. Possible explanations for this include a potential 
neutralising effect of circulating IGF-II receptors on the bioavailability of 
circulating IGF-II221. This interference may be of clinical significance but not 
affect IGF-II measurement by LCMS. Alternatively, IGF-II may be more 
important in regulating growth prior to the third trimester352, 353, and IGF-II 
concentrations at birth may be clinically less significant. 
 
Infants with lower IGF-I concentrations at birth had a greater change in weight 
and OFC over the first two months of life. The mechanism of this effect is 
unclear, but this finding may be related to low IGF-I concentrations being a 
marker of nutritional status196. Thus, this may represent “catch-up” growth in 
infants born small for gestational age who initially have lower IGF-I 
concentrations. An inverse relationship is also seen between early growth and 
cord leptin, another marker of nutritional status at birth354. Birth IGF-II 
concentrations do not correlate with early infant growth in any of these 
parameters, further supporting the interpretation that the role of IGF-II in fetal 
growth is less clinically significant by the time of birth. 
 
Maternal smoking has been shown previously to be associated with reduced cord 
IGF-I concentrations in females336. However, we have shown that this effect is 
seen both in male and female infants. The interplay between IGF-I and –II and 
placental function may provide insight into this relationship. Placental 
vasculature is affected by maternal smoking, with reduced length of villous 
capillaries and decreased trophoblast volume355. This may affect nutrient 
availability to the fetus and subsequently reduce growth parameters and IGF-I 
concentrations. IGF-I and –II are both expressed in chorionic and basal plates of 
the placenta356, and thus may play a key role in regulating placentation. 
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The main strengths of this study in evaluating the relationship between IGFs and 
infant size are the large number of healthy term infants included, and the use of 
an LCMS assay. This assay has been shown previously to be free from IGFBP 
interference when measuring IGF-I and IGF-II concentrations238. A limitation of 
this study is that the Cork BASELINE birth cohort was a relatively homogenous 
population of Caucasian Irish healthy term infants. Consequently, it is not known 
if the reference data can be applied directly to other patient populations. This 
may be particularly important when considering the significant effect of smoking 
during the first trimester on cord IGF-I concentrations, as maternal smoking was 
seen in a quarter of included pregnancies. IGF-I concentrations may be 
marginally higher in populations with lower rates of cigarette smoking, such as 
America where 13% of all females smoke357. In addition, our findings are only 
applicable to term infants and it is not known if the associations are also seen in 
preterm infants. Not all infants in this cohort had cord blood available for 
analysis and it is not known if this introduced bias to our study, although this is 
unlikely as our findings are generally consistent with previous smaller studies. A 
small number of subjects had IGF-I and –II concentrations below the detectable 
limits of the assay, and this may also have influenced our results.  
 
In conclusion, this study has provided reference data for IGF-I and IGF-II 
concentrations at birth in term infants, as measured by LCMS. These data will be 
useful clinically where prenatal defects of IGF production are suspected, and 
may support future research in evaluating the prenatal role of these growth 
factors. We recommend using the LCMS assay when measuring IGF-I and -II in 
conditions where IGFBP interference may significantly affect interpretation of 
results, particularly in young infants where IGF concentrations are generally 
low124. Using this assay, we have corroborated many of the previously known 
associations between IGF-I concentrations and size at birth, demonstrated a 
weaker but significant association between IGF-II and size at birth and shown a 
negative association between IGF-I measurements at birth and change in weight 
or OFC over the first two months of life.  
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2.4.6 CHAPTER CONCLUSION 
The measurement of IGF-I and, to a lesser extent, IGF-II can give insight into 
GH production and action and impaired IGF production can affect growth. In 
Section 1, I highlighted challenges in demonstrating sufficient GH production 
through stimulation testing. Here, I have focused on imperfections in IGF-I 
measurement and explored the potential of LCMS to improve accuracy. 
Interestingly, I have not demonstrated significant improvement in correlating 
IGF-I concentrations with prenatal growth than have been previously described 
with RIA. Thus, it is possible that under normal circumstances, IGF-I 
measurement by LCMS does not provide an advantage over RIA. However, 
proceeding to LCMS may be a reasonable next step in evaluating the GH/IGF-I 
axis where RIA measurement is suspected to be incorrect.  
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SECTION 3 
GENETIC APPROACHES TO DISORDERS OF THE GROWTH 
HORMONE / INSULIN-LIKE GROWTH FACTOR-I AXIS 
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CHAPTER 3.1: INTRODUCTION 
 
Sections 1 and 2 of this thesis focused on the clinical aspects of evaluating 
children with short stature. The focus was on optimising measurement of GH 
secretory capacity and serum IGF-I concentrations, with a view to improving the 
diagnostic evaluation of children with suspected GHD. In this section, I will 
focus on another clinical aspect of childhood growth and the GH/IGF-I axis. 
Specifically, I will describe studies aimed to identify and investigate novel 
genetic disorders of GH/IGF-I production and signaling. 
 
Monogenic causes of isolated GHD, multiple pituitary hormone deficiencies and 
disordered GH/IGF-I signaling have been described358, but many genetic 
aetiologies of short stature remain to be discovered. Complicating the search for 
pathogenic mutations and novel of mechanisms of disease is the high prevalence 
of polymorphisms of unknown or limited clinical significance. Utilisation of 
established genomic databases, characterised cohorts with described genetic 
data, and inter-institutional collaborations are often required to establish the 
significance of previously unknown mutations. In addition to population and 
clinical data, laboratory-based functional evaluation of the in vitro relevance of 
new mutations is also critical. 
 
I will begin this section by providing an overview of the GH/IGF-I signaling 
pathway. I will then describe two studies in which we have tried to identify novel 
mechanisms of disease. Note that, given the large-scale nature of genetic studies, 
multi-centre collaborations were involved in both studies. Where relevant, I will 
focus on my specific contribution while giving an overview of the collaborative 
work. 
 
3.1.1 GROWTH HORMONE SIGNALING 
The Growth Hormone Receptor (GHR) is a homodimeric transmembrane protein 
that is classified as a type 1 cytokine receptor. This consists of an extracellular 
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domain (ECD) connected to a helical transmembrane domain and an intracellular 
domain, which contains Box 1 and Box 2 motifs. The extracellular domain 
contains 267 amino-acids and is encoded by exons 2-7 of the GHR gene. The 
transmembrane domain contains 24 amino acids and is encoded by exon 8 and 
the intracellular domain contains 350 amino acids and is also encoded by exon 8. 
 
It was previously thought that GH binding activated the GHR through 
dimerisation of GHR monomers on the cell membrane. However, it has been 
shown that GHR dimers exist on the cell surface in the absence of GH 
binding359. One GHR monomer binds with strong affinity to a site on the GH 
molecule, while the other monomer binds more weakly. This results in relative 
rotation of one of these monomers359, leading to repositioning of the intracellular 
domains and association of the intracellular Box 1 and Box 2 motifs with Janus 
Kinase (JAK) 2360 (Figure 3.1.1). 
 
 
Figure 3.1.1: Growth hormone intracellular signaling 
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GHR. Phosphorylation of at least three of the seven tyrosines on the intracellular 
domain of the GHR (Y516, Y548, Y609) is essential for Signal Transducer and 
Activator of Transcription (STAT) 5b signaling361. In addition to its kinase role 
in initiating the signaling pathway, JAK2 is also important for GHR stability and 
it reduces endosomal and lysosomal degradation of the GHR362. GH 
predominantly acts through phosphorylation of JAK2, but does also cause 
phosphorylation of JAK1363 and JAK3364. The phosphorylated intracellular GHR 
and JAK2 are docking sites for intracellular signaling molecules. 
 
Signal Transducer and Activator of Transcription (STAT) 5b Pathway 
The phosphorylated intracellular tyrosines on the GHR recruit STAT5b, which 
docks via its Src Homology (SH)2 domain. This tyrosyl-phospho-STAT5b 
complex subsequently forms a homodimer and translocates to the nucleus, where 
STAT5b-dependent genes are expressed. These include IGF-I, IGFBP3, and 
ALS. Non-phosphorylated STAT proteins also exist as dimers and can be 
transcriptionally active at different genes to those targeted by phosphorylated 
forms365. 
 
STAT1 and STAT3 
STAT1 and STAT3 pathways are both initiated by GH binding to the GHR, 
independent of the critical tyrosine residues required for STAT5b signaling361, 
366. The specific roles of these pathways in growth are not clear, and they appear 
to play a more important role in immune function367-369. 
 
Ras - Mitogen-Activated Protein Kinase (MAPK) Signaling Pathway 
In addition to phosphorylating itself and the intracellular component of the GHR, 
JAK2 also initiates signaling pathways that involve activation of other tyrosine 
kinases. 
 
Phosphorylated tyrosine residues on JAK2 and/or the intracellular GHR activate 
the MAPK signaling pathway through initial binding and tyrosyl 
  
 
 
115 
phosphorylation of SHC. This then associates with Grb2370. SOS is then 
recruited to the cell membrane and this has guanine nucleotide exchange activity, 
which activates Ras by initiating guanosine triphosphate (GTP) binding. Once 
activated, Ras activates Raf, which has serine and threonine kinase activity. This 
phosphorylates MAPK/ERK Kinase (MEK), which phosphorylates Extracellular 
Signal Regulated Kinases (ERK1 and ERK2)371, also known as the MAPK 
p44/42 pathway. This Raf-MEK-ERK pathway also has negative feedback on 
SOS through phosphorylation. This causes JAK2 to dissociate from SHC-Grb2, 
and terminates the signaling pathway. 
 
ERK1 and 2 phosphorylate CEBPβ, a transcription factor that translocates to the 
nucleus and localises to areas of pericentric heterochromatin and plays a role in 
regulating MAPK dependent transcription372, 373. Although ERKs can enter the 
nucleus via nucleosomes in an energy-independent fashion,  phosphorylated 
ERKs enter the nucleus at an increased rate through energy dependent 
mechanisms374. Here, they play a role in cell adhesion, migration, survival and 
differentiation. They also modulate metabolism, and transcription374. 
 
GH also stimulates the binding of Ras-related protein (Ral)A and RalB to GTP 
both through JAK2 dependent (via activated Ras) and independent pathways375. 
This increases phospholipase D activity and increases phosphatidic acid 
formation, which then activates MAPK. GH binding to the GHR also activates 
the Protein Kinase B (AKT) pathway via the phosphoinositide-3-kinase (PI3K) 
pathway376. This also activates CEBPβ, through release of inhibition from 
glycogen synthase kinase 3 beta377. 
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3.1.2 INSULIN-LIKE GROWTH FACTOR-I PROCESSING AND SIGNALING 
 
IGF-I processing 
Alternative splicing of the six exons of the IGF1 gene on chromosome 12, as 
well as post-transcriptional modification, result in the production of various IGF-
I isoforms. These isoforms differ in the length of their amino terminal 
polypeptides, and the composition of their extension polypeptides on the carboxy 
terminal (E-peptides: IGF-IEa, IGF-IEb, and IGF-IEc). Post-translational 
modification includes cleavage of these E-peptides378. The differential roles of 
each of these IGF-I isoforms are not well understood, but thought to modulate 
the different biologic effects of IGF-I. These include cell proliferation, 
differentiation, migration and survival379. 
 
Glucose-regulated protein 94 (GRP94), a chaperone protein located in the 
endoplasmic reticulum, plays a key role in the post-translational modification of 
IGF-I380. This has been shown to be critical for the local production of muscle 
IGF-I. In the mouse model, there is a significant reduction in muscle mass and 
circulating IGF-I in the presence of depleted muscle GRP-94381. 
 
IGF Receptors 
IGF-I signaling is mediated by binding to the IGF-I receptor. The type 1 IGF 
receptor (IGF-IR) is a heterotetramer comprising two extracellular α and two 
transmembrane β subunits. It has approximately 50% structural similarity to the 
insulin receptor (IR), and this is as high as 84% in the tyrosine kinase domain382. 
Hybrid receptors comprising an IGF-IR αβ heterodimer and an IR αβ 
heterodimer have also been described383. The type 2 IGF receptor (IGF2R) is a 
monomeric glycoprotein receptor. Unlike the IGF1R, this does not have a 
signaling domain but undergoes endocytosis upon binding384. The IGF1R has 
greatest affinity for IGF-I and the IGF2R for IGF-II. However, the IR, IGF1R 
and IGF2R can each bind IGF-I, IGF-II and insulin with variable affinities. As 
this Section of my thesis will include investigations of mechanisms of IGF-I 
resistance, I will focus on signaling via the IGF-IR. 
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IGF Signaling via IGF-IR 
IGF-IR is a tyrosine kinase receptor, and IGF-I binding results in 
autophosphorylation of the receptor, as well as phosphorylation of insulin 
receptor substrate (IRS) proteins and Shc. Phorsphorylated IRS-1 associates with 
PI3K, Grb2, Syp, and Nck. Shc can also associate with Grb2. Activated Grb2 
associates with Sos, an exchange factor that can activate the Ras-MEK-ERK 
pathways. These protein kinases, as well as PI3K, and the mechanistic target of 
rapamycin (mTOR) pathways mediate the downstream effects of IGF-I, 
including phosphorylation of transcription factors and gene expression385, 386 
(Figure 3.1.2). 
 
 
Figure 3.1.2: IGF-I intracellular signaling 
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CHAPTER 3.2: THE ROLE OF GLUCOSE REGULATED PROTEIN 94 IN 
INSULIN-LIKE GROWTH FACTOR-I PROCESSING 
 
 
Publication 
Marzec M, Hawkes CP, Eletto D, Boyle S, Rosenfeld R, Hwa V, et al. A human 
variant of glucose-regulated protein 94 that inefficiently supports IGF 
production. Endocrinology. 2016;157(5):1914-28 (Appendix J). 
 
 
IGF-I is produced as a pro-hormone that is subsequently processed by proteases 
to create the mature, functional hormone. Only processed IGFs are competent to 
bind to the receptor and protect cells from apoptosis387, or instruct tissue 
development in vivo388. Pro-IGF-I and –II both associate with GRP94 and 
require its activity before they are processed387-389. 
 
In this chapter, I describe a multicentre study focused on identifying the in vitro 
and in vivo effects of a hypomorphic mutation in GRP94, namely a proline 
substitution for lysine at amino acid 300 (P300L). My role in this study was in 
the analysis of the clinical phenotype of subjects with this mutation, and will be 
the focus of this chapter. Although I did contribute to the laboratory-based 
experiments, this component of the research was not designed by me and is only 
presented in this thesis as additional background information. 
 
3.2.1 BACKGROUND 
GRP94 is a chaperone protein that resides in the endoplasmic reticulum and is 
selective towards its client proteins. These include immunoglobulins390, β1-
integrins391, glycoprotein Ib-IX-V complex392, Toll-like receptors 2, 4, 5, 7, and 
9393, and IGF-I and –II387, 388. 
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Although many of the specific interactions of GRP94 with its clients are not fully 
understood, its function as a chaperone is likely mediated by its ability to bind 
nucleotides, facilitate ATP hydrolysis, bind calcium and peptides, and undergo 
conformational changes including dimerisation of its N-Terminal domain380. 
GRP94 exists primarily in an extended conformation in solution but the addition 
of these client proteins shifts this towards a more closed conformation394, 395. The 
importance of GRP94 is demonstrated by the fact that homozygous mutations 
have never been described in humans. Homozygous knockout mutations of 
GRP94 are incompatible with embryonic development388, and the grp94 gene is 
also highly conserved in species. 
 
During times of extreme stress, the unfolded protein response (UPR) is a 
complex system that either restores homeostasis or identifies a cell for apoptosis. 
GRP94 expression is increased during endoplasmic reticulum stress396 and plays 
an important role in this UPR. In addition to this, GRP94 also has a role in 
protein “quality control”, where misfolded proteins are marked for cytosolic 
breakdown by the proteasome rather than secretion380, 397. 
 
The hypothesis that hypofunctioning mutations of grp94 can affect IGF-I 
production and body size is supported by two observations. First, a mouse model 
with ablated striated muscle GRP94 has significantly reduced IGF-I 
concentrations and is 30% smaller than controls381. Second, in vitro studies of 
the cellular response to stress in the form of serum withdrawal demonstrate that 
grp94 -/- cells have an impaired response associated with reduced concentrations 
of IGF–II387, 388. 
 
In evaluating the clinical significance of GRP94 in IGF-I production, grp94 gene 
sequencing was performed in 16 children with a combination of normal GH 
secretion, with short stature and low IGF-I concentrations398. One subject had a 
mutation of potential significance, and had a clinical phenotype suggestive of 
primary IGF-I deficiency. This included in utero growth restriction (birthweight 
z-score -2.82), postnatal growth failure, microcephaly and undetectable IGF-I at 
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4 months of age. He had a heterozygous substitution of C to T with a subsequent 
change in amino acid 300 for proline to lysine (P300L). His mother was also a 
carrier of this mutation and her height z-score was -0.9.  
 
Functional studies of the effect of this mutation on GRP94 function are described 
in Appendix J, and demonstrated a reduction of IGF-II secretion to 58% when 
compared with wild type GRP94. The prevalence of this mutation in the normal 
population is up to 4%, which raised the question of whether this mutation 
contributes to variations in human IGF-I concentrations and height. The central 
hypothesis for this population-based study is that hypomorphic GRP94 
heterozygous mutations are a cause of primary IGF-I deficiency and short 
stature. 
 
3.2.2 AIM 
The aim of my analysis was to determine if the P300L mutation is associated 
with short stature and low IGF-I concentrations in various population-based 
cohorts in whom P300L carrier status, height and/or IGF-I concentrations were 
available. 
 
3.2.3 METHODS 
Collaborations were formed between teams with the distinct cohort studies in 
which IGF-I concentrations were measured and height data were available. 
Grp94 gene sequencing was performed where DNA was available, and subjects 
were characterised as carriers of the P300L mutation or wild type GRP94. 
 
Population 1: Health In Men Study (HIMS, Australia) 
The HIMS cohort study was initially designed to determine if screening for 
abdominal aortic aneurysms (AAAs) in at-risk adults reduced mortality and 
improved quality of life. 19,352 males over 65 years of age were identified from 
electoral databases and invited to attend baseline screening. Of these, 12,203 
were recruited399. This study has demonstrated an insignificant reduction in 
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mortality from AAA through screening400, shown an association between 
glucose control and aortic diameter401, and identified predictors of cognitive 
function in men over 80 years of age402. This study provided an opportunity for 
collaboration as IGF-I concentrations were measured to evaluate a potential 
association between the GH/IGF-I axis and cardiovascular outcomes399. In 
addition, peripheral blood was collected for genetic analysis as part of this 
study403. 
 
Population 2: Longevity Genes Project (New York) 
The aim of the longevity genes project is to identify genes that are associated 
with health and independence at 95 years of age, in a cohort of subjects who are 
of Ashkenazi Jewish descent404. This study recruited centenarians and their 
offspring. Blood samples were collected for analysis of cardiovascular risk 
factors405 and other potential biomarkers of longevity406. This study has shown 
that low IGF-I concentrations are associated with longevity in females, and that 
low serum IGF-I is also associated with longer survival in subjects who had a 
prior diagnosis of cancer407. 
 
Population 3: Danish Cohort Study 
This cohort includes 15,663 subjects in 5 separate population-based Danish 
studies408. This is the largest cohort from which data were available on P300L 
phenotype, but IGF-I concentrations were not measured in these subjects. 
However, height measurements were available. 
 
Given the age-related decline in adult height, subjects were grouped according to 
age (20-39 years, 40-59 years, 60-79 years) and sex for the analysis of the effect 
of P300L carrier status on height and IGF-I concentrations. 
 
Statistical Analysis 
For normally distributed continuous variables, mean (SD) were compared 
between P300L carriers and controls using independent samples t-tests. Non-
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normally distributed data were summarised as median (IQR) and compared using 
nonparametric (Mann Whitney U) tests. Extremely high IGF-I values in an 
elderly population may represent pathology (e.g. acromegaly) or laboratory 
errors (e.g. assay artifact from IGFBP interference). For this reason, all IGF-I 
measurements above +3SD from the mean (above 315.5 ng/ml) were excluded as 
biologically implausible from the HIMS Study (26 wild type, 2 P300L carriers). 
Data were analysed using SPSS version 22.0 (IBM, New York, USA). 
 
3.2.4 RESULTS 
Health in Men Study (Australia) 
IGF-I concentrations, height and age were available in 3862 men over 65 years 
of age in the HIMS study. Of these, 112 were heterozygous for P300L mutation 
(carrier rate 2.9%), and one was homozygous for this mutation. IGF-I 
concentrations were lower in P300L carriers (p=0.037). There were no 
significant differences between groups in the available known confounders of 
IGF-I concentration: age (p=0.6); or body mass index (p=0.73) (Table 3.2.1). 
One subject was homozygous for the P300L mutation, and he had an IGF-I 
concentration of 226 ng/ml. 
 
Table 3.2.1: IGF-I and IGFBP-3 concentrations, height, age and BMI according to P300L carrier 
status. *IGF-I concentrations were not normally distributed and are represented as median (IQR). 
Data shown are mean (SD) with Student’s t-test used to compare groups. 
 Wild Type GRP94 
(n=3595) 
P300L 
(n=98) 
p 
IGF-I (ng/ml) 140.3 (53.8) 130 (54.8) 0.037 
IGFBP-3 (mg/L) 3.8 (0.9) 3.7 (1) 0.25 
Height (cm) 171.9 (6.7) 173 (6.4) 0.13 
BMI (kg/m2) 26.6 (3.7) 26.7 (3.8) 0.73 
Age 77.1 (3.6) 76.9 (3.5) 0.57 
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Longevity Genes Project (New York) 
Of the 1369 genotyped subjects (642 male) in this cohort, there were 28 carriers 
(14 male) of P300L. Female carriers were slightly shorter than wild type, 
whereas there was no difference between males (Table 3.2.2). Only ten P300L 
heterozygotes and 22 wild type subjects had IGF-I concentrations measured. 
There was no difference in IGF-I concentrations when corrected for age. 
 
Table 3.2.2: Height and IGF-I in P300L carriers and controls in the Longevity Genes project. 
Mean (SD) shown. ns=not significant 
 P300L Wild Type p 
Males 
Number 14 628  
Age, yrs 78.1 (13) 72.6 (8.5) ns 
Height, cm 170.7 (6.9) 174 (8.6) ns 
Females 
Number 14 713  
Age, yrs 82.3 (13.2) 71.5 (8.7) ns 
Height, cm 154.9 (4.6) 159.5 (7.4) <0.01 
 
Danish Cohort 
P300L genotype was available in 15,633 subjects over 20 years of age (619 
carriers). This represents a population carrier frequency of 4%. No significant 
growth attenuating effect of P300L carrier status was noted in any age- and sex-
stratified subgroup of this population. In fact, female carriers of P300L aged 
between 20 and 59 years of age were taller than wild type counterparts (Table 
3.2.3). 
 
Table 3.2.3: Height of male and female subjects in the Danish cohort, according to P300L carrier 
status. 
 Male Female 
 P300L Wild-type p P300L Wild-type p 
 n Height n Height  n Height n Height  
20-39 years 
(n=1096) 
40 181.4 
(5.8) 
1056 180.9 
(6.4) 
0.6 50 169.5 
(5.4) 
1360 167.4 
(6.3) 
0.01 
40-59 years 
(n=4369) 
157 178.8 
(7.3) 
4212 178.4 
(6.8) 
0.6 181 166.6 
(6.8) 
4100 165.6 
(6.2) 
0.04 
60-79 years 
(n=2469) 
102 174.6 
(6.1) 
2367 174.9 
(6.4) 
0.6 87 162.2 
(5.3) 
1846 162.1 (6) 0.9 
>80 years 
(n=33) 
0  33 174.8 
(8.8) 
n/a 2 162 (8.5) 41 159.3 
(6.2) 
0.7 
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3.2.5 DISCUSSION 
Despite convincing in vitro data to support the deleterious effect of the P300L 
mutation of grp94 on IGF processing, we failed to demonstrate the expected 
clinical phenotype of short stature and reduced IGF-I concentrations in 
heterozygous carriers of this mutation. In the single subject who was 
homozygous for this mutation, IGF-I concentration was within the normal range 
for age. 
 
The absence of a clear clinical phenotype in the larger population studies makes 
it likely that the P300L mutation seen in the original clinical patient was an 
incidental finding in the initial subject with unexplained primary IGF-I 
deficiency, microcephaly and severe short stature. This is supported by the fact 
that his mother was also a carrier of this mutation, and she had a height z-score 
of -0.9. 
 
Numerous potential explanations for this lack of clinical significance are 
proposed. Firstly, the in vitro experiments measured GRP94 activity in the 
absence of a coexisting allele with an unaffected grp94 gene. Although one 
homozygous subject was included, almost all subjects were heterozygous for 
P300L and had a normal gene that may have been compensatory. It is also 
possible that feedback mechanisms such as increased GH production could 
overcome the effect of a hypomorphic variant of GRP94 and result in normal 
IGF-I production and growth. GH measurements were not available to 
investigate this further. 
 
3.2.6 CHAPTER CONCLUSION 
In this chapter, we have taken a candidate gene with biological and in vitro 
plausibility to the population level to determine if the genetic and biochemical 
data correlate with a clinical phenotype. Although the results were disappointing, 
it highlights the challenges in identifying prevalent genes that may have a mild 
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clinical phenotype. These data required significant contributions from numerous 
collaborators and ultimately resulted in negative data. 
 
Through this process, I learned to analyse phenotypes across numerous 
populations and gained insight and hands-on experience in using cell-based 
assays to perform in vitro studies. I also learned to appreciate the complimentary 
roles of clinical phenotyping, querying genetic databases and lab-based research 
in evaluating the significance of novel genetic mutations.  
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CHAPTER 3.3: GENETIC APPROACH TO INSULIN-LIKE GROWTH 
FACTOR-I RESISTANCE 
 
In the previous chapter, we started with a relatively common gene mutation of 
potential significance and studied the clinical phenotype in large populations. 
Here, we describe the reverse process of starting with a rare clinical phenotype 
and taking a genome-wide approach to identifying genetic aetiologies. 
 
In this chapter, I will describe the development of a multi-site genomic approach 
to identifying novel mutations in three of the leading children’s hospitals in the 
United States: Children’s Hospital of Philadelphia (CHOP); Boston Children’s 
Hospital (BCH); and Cincinnati Children’s Hospital Medical Center (CCHMC). 
We used this process to identify children with rare mutations causing IGF-I 
resistance. 
 
3.3.1 IGF-I RESISTANCE 
IGF-I plays a critical role in regulating prenatal and postnatal growth, and infants 
with IGF-I deficiency have significant intrauterine growth restriction and 
postnatal growth failure. In addition, sensorineural hearing loss409, microcephaly 
and developmental delay are part of this clinical phenotype153. 
 
Haploinsufficiency of the IGF-1R can have variable effects on IGF-IR 
expression and reduced IGF-I signaling (3.1.1)410. High IGF-I concentrations and 
short stature are consistent components of the phenotype. At the more severe end 
of the clinical spectrum with large deletions involving the entire IGF1R gene, 
cardiac defects, pulmonary hypoplasia and congenital diaphragmatic hernia may 
be seen411, 412. It is postulated that these additional clinical features may be due to 
the effects of deletions on genes flanking IGF-1R410-412. 
 
Recently, a novel mechanism for IGF-I resistance has been reported as a cause of 
short stature. Mutations in pregnancy-associated plasma protein A2 (PAPP-A2) 
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have been shown to impair proteolytic cleavage of IGF-I from the ternary 
complex and lead to high concentrations of circulating total IGF-I but reduced 
free IGF-I activity413, 414. The clinical phenotype was subtler with height and 
head circumference z-scores just below normal, with high circulating IGF-I and 
–II concentrations. 
 
3.3.2 AIM 
The aim of this study was to utilise electronic health records (EHRs) to identify 
children with a clinical phenotype consistent with IGF-I resistance and to 
identify novel genetic mechanisms for this phenotype. 
 
3.3.3 METHODS 
Genomics Research and Innovation Network (GRIN) 
The GRIN is a collaborative network between CHOP, BCH and CCHMC. This 
was established in 2015 and provides an infrastructure for sharing expertise, 
protocols, ethics committee approval of parallel protocols, EHR search criteria, 
genetic material and research data. The identification of novel genetic 
mechanisms of the rare phenotype of IGF-I resistance was adopted as one of the 
three pilot studies as this infrastructure was being developed. The CHOP 
Institutional Review Board provided ethical approval for this study. A 
collaborative research agreement was also signed to facilitate the sharing of 
research data and protocols between institutions. 
 
Subject identification – Height criteria 
The EHR was searched to identify all children attending CHOP who had an age- 
and sex-specific height z-score of less than -2 using the Center for Disease 
Control growth standards415. 
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Figure 3.3.1: The stepwise approach to using the electronic health record identify children with 
high IGF-I concentrations and short stature 
 
IGF-I concentration: Lab-Specific Factors 
In the United States, the laboratory used for patient tests is often dictated by 
contracts negotiated between health insurance companies and individual 
laboratories. In addition, the IGF-I assay used by each laboratory changes over 
time and this affects the reported reference ranges for each reported 
measurement. We contacted the three most frequently used laboratories and 
requested information on the reference ranges for each of their IGF-I assays used 
between 2000 and 2016. One of the laboratories (QUEST) was unable to provide 
us with this information, and the information provided by another laboratory 
(LabCorp) was inaccurate on manual review. 
 
As an alternative approach, representative samples were identified for each of 
the IGF-I assays in each laboratory using the electronic health record (EHR). The 
reference ranges listed in each assay were recorded manually for the pubertal 
and/or age ranges. Mean and standard deviations were generated from these, and 
an algorithm was created to query the EHR and generate percentiles for each test 
according to pubertal stage and/or age. Some assays reported z-scores directly 
and, where possible, these were extracted and converted to percentiles. 
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In order to validate this approach, we counted the number of samples with IGF-I  
concentrations above the 90th percentile for each assay to ensure that no assay 
was over represented on initial screen.  
IGF-I concentration: Patient-specific factors 
IGF-I concentrations increase during puberty, and precocious puberty in a child 
with short stature would erroneously be identified as IGF-I resistance if age-
specific reference values were used. Pubertal status is not a discrete field in the 
EHR, but is generally included in the text of clinical notes. An example of 
patient data that needed to be reconciled manually is shown in Figure 3.3.2. 
 
 
Figure 3.3.2: Example medical note documentation of pubertal status and laboratory IGF-I 
report of IGF-I concentration requiring reconcilliation 
 
As manually reviewing each chart to extract pubertal status was not feasible, a 
natural language query to extract pubertal status at the time of IGF-I 
measurement was developed. The following text was identified from medical 
records within 3 months of IGF-I measurement and extracted from the EHR for 
manual review: 100 characters before and 100 characters after the word if used): 
“Tanner”, “testes”, “testicular”, “testis”, “Pubic hair”, “breast”, as well as date of 
encounter. If this was in a string of text including a number of these words, all 
intervening text was extracted. Extracted data were then manually reviewed to 
modify IGF-I concentrations for pubertal status where necessary. 
Medical Notes:
Examination: Pubic hair is is Tanner stage 3. Testes are 15 ml bilaterally.
IGF-I Results
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Exclusion Criteria 
GH treatment can artificially increase IGF-I concentrations and was an exclusion 
criterion for this study. In order to exclude all forms of GH used, we excluded 
subjects receiving any of the following medications: Genotropin, Gentropin, 
Humatrope, Norditropin, Nutropin, Omnitrope, Saizen, Somatropin and growth 
hormone. 
 
Further exclusion criteria were applied following manual chart review, to focus 
recruitment on children without co-existing disease or treatment that may 
independently affect IGF-I concentrations and/or growth. These included: 
chronic kidney disease; malignancy receiving treatment at the time of IGF-I 
measurement; high dose steroid treatment; known genetic diagnosis associated 
with short stature. In addition, children receiving GH treatment at the time of 
IGF-I measurement were excluded, unless IGF-I concentrations prior to 
treatment were also elevated. Children who attained height above -2 z-scores 
without treatment, or who had normal IGF-I concentrations at any time on chart 
review were also excluded. 
 
Genetic Testing 
In this collaborative study, Dr Andrew Dauber at CCHMC performed genetic 
testing and analysis. The process is summarised here for additional background, 
but performing this genetic testing was not my personal work. 
 
Candidate gene testing comprised Sanger sequencing of the IGF-I receptor 
(IGF1R), and PAPPA2. If this was negative, whole exome sequencing was 
performed at the CCHMC Sequencing Core. This involved 1 ug of dsDNA 
undergoing 9 cycles of PCR amplification using the Clonetech kit (Clonetech 
Laboratories, CA, USA). This was sequenced using the Illumina HiSeq 2500 
(Illumina Inc., CA, USA), and was analysed using the Broad Institute’s Genome 
Analysis Toolkit (Broad Institute, MA, USA). 
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Variants of minor allele frequency were identified using public databases and 
excluded from analysis. In order to identify novel or de novo variants, dominant 
variants were eliminated if present in the public databases (e.g. Exome 
Aggregation Consortium website) and recessive variants were eliminated if a 
minor allele frequency of greater than 0.001 were noted. This reflects a disorder 
present in less than one in a million people. For potentially significant variants, 
parent samples were sequenced. 
 
Following the identification of a candidate gene, additional searches were 
performed using OMIM, DECIPHER and PubMed to determine if this has been 
previously associated with human disease. In silico prediction tools, known gene 
function, animal model data and gene expression patterns were also reviewed to 
prioritise variants for further mechanistic studies. 
 
3.3.4 RESULTS 
This study was approved by the IRB at CHOP and parallel protocols were 
approved separately by the IRBs at CCHMC and BCH. For the purpose of this 
thesis, I will describe the results from the CHOP protocol. 
 
We identified 68 children with IGF-I concentrations greater than the 90th 
percentile and height z-scores below -2. Of these, 54 children were excluded 
(Table 3.3.1), leaving 14 eligible for recruitment. Of the remaining 14 subjects, 
two no longer lived in the US, eight did not wish to participate, and four were 
recruited. Their clinical details are shown in Table 3.1.2. 
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Table 3.1.1: Excluded children from analysis 
* rhabdomyosarcoma, hemophagocytic lymphohistiocytosis, acute lymphoblastic leukemia. 
** trisomy 21, Turner syndrome, Angelman syndrome, neurofibromatosis type 1, retinitis 
pigmentosa, Aicardi Goutier syndrome, Noonan syndrome 
Number Reason for Exclusion 
4 Chronic kidney disease 
3 Malignant disease receiving treatment* 
8 IGF-I concentration normal when corrected for puberty 
15 Other IGF-I measurements in EHR were within normal range 
10 Normal height without treatment 
5 High dose steroids 
7 Known genetic disorder** 
2 Receiving growth hormone treatment 
 
 
Table 3.1.2: Recruited subjects from CHOP 
Age 
(yrs) 
IGF-I 
z-score 
Height 
z-score 
Birth 
weight  
z-score 
Relevant Clinical Details 
7.5 3 -2.8 -1.8 Attention deficit and hyperactivity disorder, 
constipation, familial short stature. 
8.6 1.9 -3.3 3 Hypotonia, speech and fine motor developmental 
delay, upslanting palpebral fissures. 
7.8 1.6 -2.4 1.1 Sensorineural hearing loss. 
 
3.4 1.7 -4.4 -2.8 Ventricular septal defect, imperforate anus 
 
Exome sequencing was performed on all four subjects. No candidate genes were 
identified in Subjects 2, 3 or 4. Subject 1 had a novel missense variant in the 
IGF1R gene (Val1013Phe). His mother is not a carrier of this mutation, and her 
height is 5 feet 1 inch. His father was not involved in the study and his genetic 
sample was not available for review. This mutation is being regenerated in 
Andrew Dauber’s lab, and functionality is being assessed. 
 
3.3.5 DISCUSSION 
In this study, we have developed an EHR approach to identifying children with a 
clinical phenotype of IGF-I resistance. We have applied this approach to patients 
attending CHOP’s healthcare system and identified 14 subjects who may have 
this rare clinical phenotype. Thus far, we have identified one potentially novel 
mechanism for IGF-I resistance and this is being investigated further. 
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Although we have only identified one potentially pathogenic mutation, this study 
has been successful on a number of fronts. We have formed a collaboration 
amongst the growth centers in three of the largest children’s hospitals in the US, 
and established three parallel research protocols to recruit children with 
abnormal growth. We have also developed a mechanism for data and protocol 
sharing between these institutions. CCHMC and BCH are still recruiting subjects 
and it is possible that these centers will identify additional mutations of interest. 
 
At CHOP, we have overcome a significant barrier to growth research using the 
EHR. We have developed an algorithm to extract IGF-I z-scores and pubertal 
status from the entire population of children attending this center. We now have 
the capacity to generate IGF-I z-scores from the entire population of children 
who attend CHOP, regardless of laboratory or assay used. We have also 
developed a mechanism for reliably extracting pubertal status from the EHR. We 
plan to utilise these algorithms for future genetic and clinical studies involving 
our patient population. 
 
3.3.6 CHAPTER CONCLUSION 
I have participated in large collaborative studies aiming to identify and describe 
novel genetic causes of short stature in childhood. In Chapter 3.2, we started 
with a mutation that was potentially pathogenic and worked through functional 
studies to demonstrate a potential effect on IGF production. In Chapter 3.3, we 
started with a rare clinical phenotype and developed algorithms to identify 
potential subjects using the EHR. 
 
These studies highlight the challenge of finding novel genetic aetiologies of short 
stature. Short stature is a multifactorial trait, of which genetics may be one 
factor. In evaluating the child with short stature, an underlying genetic 
mechanism is possible and many of these have been described358. However, as 
we have shown, finding and proving new genetic aetiologies can be difficult.   
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SECTION 4 
NUTRITION AND THE GROWTH HORMONE / INSULIN-LIKE 
GROWTH FACTOR-I AXIS 
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CHAPTER 4.1: INTRODUCTION 
 
GH is a key regulator of IGF-I production. IGF-I measurement is amongst the 
first screening tests performed in children with suspected GHD, and Section 2 of 
this thesis focused on measuring IGF-I concentrations using a new assay. In 
Section 3, I explored genetic aetiologies of disordered IGF-I production and 
action. 
 
In this Section, I will focus on nutrition, another clinical aspect of childhood 
growth linked to the GH / IGF axis. This appears to be particularly important in 
the fetus and young infant, where nutritional status is most closely associated 
with IGF-I concentrations. 
 
In children identified as having short stature or poor growth of unclear aetiology, 
nutritional evaluation is a key component of the diagnostic evaluation. In early 
infancy, weight is generally considered to be a marker of nutritional status but 
weight measurement does not differentiate fat mass (FM) from fat free mass 
(FFM). In this section, I will explore body composition measures in infancy with 
an emphasis on generating reference data and determining the optimal measures 
of size-adjusted body composition. 
 
Having generated reference data for body composition in infancy, I will then 
consider whether IGF-I and –II measurement at birth is associated with body 
composition and rate of change in body composition in the first two months of 
life. Thus, this section of the thesis will provide a new approach to describing 
nutritional status in infancy and will explore the relationship between these 
measures and the GH/IGF axis.  
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CHAPTER 4.2: NUTRITION, GROWTH AND THE GROWTH HORMONE / 
INSULIN-LIKE GROWTH FACTOR-I AXIS 
 
 
Publication 
Hawkes CP, Grimberg A. Insulin-like growth factor-I is a marker for the 
nutritional state. Pediatr Endocrinol Rev. 2015;13(2):465-77. (Appendix K) 
 
4.2.1 INTRODUCTION 
Faltering linear growth in childhood may be a sensitive but nonspecific sign of 
disease.42 Two of the diagnostic categories that can present with faltering growth 
are insufficient nutrition and disorders of the GH / IGF-I axis. GH stimulates 
IGF-I production, and measurement of IGF-I concentration is commonly used to 
screen for disorders of the axis (1.2.4.1)2, 9. Nutritional status and GH signaling 
can both affect IGF-I concentrations, and an understanding of these overlapping 
effects on IGF-I production is essential in order to interpret IGF-I measurements 
in children.  
 
4.2.2 AIM 
The aim of this review is to provide an overview of the effects of nutrition on the 
GH/IGF-I axis and discuss the clinical implications of these interactions 
throughout childhood, both in undernutrition and overnutrition. 
 
4.2.3 THE GROWTH HORMONE / INSULIN-LIKE GROWTH FACTOR-I AXIS AND 
POTENTIAL INTERACTION WITH NUTRITION 
GH is secreted by the somatotrophic cells of the anterior pituitary gland in a 
pulsatile fashion, with approximately five to eight peaks each day416. This 
pulsatile secretion is stimulated by hypothalamic GHRH, with endocrine 
feedback mechanisms further regulating this system. These include somatostatin, 
IGF-I, and ghrelin (Figure 4.2.1). Nutritional status can interact with the 
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GH/IGF-I axis at numerous points in the pathway, at both the hormone secretion 
and post-receptor signaling levels. 
 
Figure 4.2.1: The effect of undernutrition on GH secretion. Leptin modifies hypothalamic 
regulation of GH secretion through hypothalamic receptors, and in severe undernutrition 
insufficient leptin reduces GH production both directly and through the consequent increase in 
Neuropeptide Y. Anterior pituitary GH secretion is controlled by hypothalamic GHRH and 
somatostatin, as well as feedback mechanisms through IGF-I, ghrelin and GH concentrations. 
GH= Growth Hormone, IGF-I = Insulin-like Growth Factor-I, IGFBP = Insulin-like Binding 
Protein, ALS = Acid Labile Subunit, GHRH = Growth Hormone Releasing Hormone 
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4.2.3.1 The impact of undernutrition on the regulation of growth hormone 
secretion 
In chronic undernutrition, alterations in leptin and neuropeptide Y (NPY) 
concentrations can reduce GH secretion. Leptin is produced by adipose tissue417, 
and normal concentrations of circulating leptin are required for GH secretion. In 
animal studies where leptin anti-serum was used to reduce serum leptin 
concentrations, there was an associated reduction in GH secretion418. The 
mechanism for this interaction may be through a direct effect on hypothalamic 
leptin receptors, or indirectly through NPY. Leptin suppresses hypothalamic 
NPY production, and NPY suppresses GH release419, 420. Thus, in starvation there 
are reduced leptin concentrations and increased hypothalamic production of 
NPY, which may reduce pituitary GH secretion. 
 
The oxyntic glands of the gastric fundus secrete Ghrelin and this binds to the GH 
secretagogue receptor 1a, stimulating GH secretion by the anterior pituitary. 
Three days of caloric restriction prior to GH stimulation testing may increase the 
peak stimulated GH concentration achieved during testing of GH-sufficient 
children203. Ghrelin concentrations are increased during fasting and suppressed 
with feeding421, and may mediate this effect. However, ghrelin administration in 
chronic malnutrition is not associated with a rise in GH concentration422. 
 
4.2.3.2 The impact of undernutrition on growth hormone signaling 
The GH receptor is a type 1 cytokine receptor that is expressed predominantly by 
hepatocytes. GH binding results in rotation of one of the monomers of this 
dimeric receptor, and the intracellular domain binds JAK2359. This activates 
numerous signaling pathways, specifically the STAT -1, -3, -5a, -5b, MAPK and 
PI3K pathways376 (Figure 4.2.2). Activation of these intracellular signaling 
pathways, primarily STAT5b, stimulates transcription of IGF-I (This pathway is 
described in more detail in 3.1.1). 
 
Undernutrition may affect GH signaling at multiple points on the pathway and 
cause a state of GH resistance. In animal and cell-based models, caloric 
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restriction is associated with a reduction in GH receptor mRNA transcription423, 
424. Insulin increases hepatic GH receptor availability425, and reduced insulin 
concentration during fasting may play a role in the reduction of GH receptor 
transcription. Calorie and protein malnutrition can also cause GH resistance 
through effects on post-receptor signaling.  
 
Figure 4.2.2: Nutrition and Intracellular Growth Hormone Signaling. 
Growth hormone binds to the extracellular domain of the dimeric GH receptor, and results in 
activation of multiple intracellular signaling pathways. GH receptor expression is reduced in 
caloric restriction. FGF21 and Sirtuin-1 concentrations are increased in fasting, and both of these 
reduce tyrosine kinase phosphorylation of STAT5b. 
JAK2 = Janus kinase 2, MAPK = Mitogen-activated protein kinase, ERK = Extracellular-signal 
regulated kinase, PI3K = Phosphoinositide 3 kinase, PKB = Protein kinase B (also known as 
AKT), Stat = Signal transducer and activator of transcription, FGF21 = Fibroblast growth factor 
21, GH = growth hormone, IGF-I = insulin-like growth factor-I 
 
 
Fibroblast growth factor 21 (FGF21) is produced by adipocytes and hepatocytes, 
and concentrations are increased in fasting426. FGF21 reduces STAT5b 
phosphorylation and increases Suppressor of Cytokine Signaling 2 (SOCS2) 
expression, both of which decrease IGF-I production427. FGF21 also increases 
IGFBP-1 expression, which further reduces IGF-I bioavailability for signaling428. 
Another potential mechanism involves Sirtuin-1, a deacetylase that mediates the 
metabolic response to fasting through its effects on glucose and lipid 
metabolism429. Sirtuin-1 also inhibits the tyrosine phosphorylation of STAT5430, 
and represents an additional cellular mechanism of GH resistance in 
malnutrition. Zinc431, magnesium432 and vitamin B6433 deficiencies may also be 
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associated with GH resistance and reduced IGF-I, although the mechanisms of 
each of these are unknown. 
 
4.2.4 NUTRITION AND INSULIN-LIKE GROWTH FACTOR-I FROM THE FETUS 
THROUGH ADOLESCENCE 
Prenatal GHD has minimal effect on birth size219, whereas children with IGF-I 
receptor mutations or primary IGF-I deficiency are born with severe intrauterine 
growth restriction153. The GH-independent regulation of fetal IGF-I is poorly 
understood, but the pattern of changes in fetal IGF-I concentration mirrors 
weight gain. Fetal serum IGF-I concentrations increase steadily throughout the 
third trimester350, which coincides with the period of most rapid increase in fetal 
weight. In addition, umbilical cord IGF-I concentrations at birth correlate with 
birth weight275 (Chapter 2.4). 
 
Following birth, IGF-I levels are closely associated with weight and nutritional 
intake222, 434. While adequate caloric intake is necessary for symmetrical infant 
growth, caloric excess will increase infant weight more than length and head 
circumference435. Changes in circulating IGF-I concentrations can reflect 
increases in protein and caloric intake, and IGF-I measurement has been 
suggested as a method of monitoring feeding, particularly in preterm infants436. 
In early infancy, formula fed infants have increased adiposity and higher IGF-I 
concentrations than breastfed infants313, 437, 438. The effect of milk in increasing 
IGF-I concentrations has been studied further in 2 to 3 year-olds. In this 
population, circulating IGF-I is increased by 30% when milk intake increases 
from 200 to 600 ml/day, an effect predominantly due to the casein component of 
milk439-441. 
 
In prepubertal children, lower BMI is associated with lower serum IGF-I 
concentrations442. Although reduced caloric intake is associated with low 
circulating IGF-I, nutritional factors beyond calories and protein should also be 
considered in children with unexpectedly low IGF-I levels. Zinc deficiency, for 
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example, in peripubertal children is associated with lower IGF-I and IGFBP-3 
concentrations. IGF-I concentrations improve with zinc replacement in these 
children431, 443. Iodine deficiency is also associated with low circulating IGF-I, 
but replacement of iodine deficiency can have the effect of reducing IGF-I 
concentrations further444. This finding is most likely related to the effect of 
iodine replacement on thyroid function. Excess iodine can suppress thyroid 
function through the Wolff-Chaikoff effect. IGF-I concentrations are also 
reduced in hypothyroidism445, 446. 
 
IGF-I concentrations increase during puberty, and energy requirements are also 
increased during this time447. The sex steroids of puberty increase pituitary GH 
secretion, which in turn increases IGF-I production. The combination of 
increased sex steroids, GH and IGF-I cause the pubertal growth spurt. 
Insufficient nutrition can delay the onset of puberty448, and leptin concentrations 
above a certain threshold appear to be required for puberty to proceed449, 450. Low 
IGF-I concentrations in adolescents suffering from malnutrition can appear even 
lower relative to reference ranges if age-based rather than pubertal stage-specific 
reference ranges for IGF-I are reported. 
 
4.2.5 UNDERNUTRITION AND INSULIN-LIKE GROWTH FACTOR-I 
4.2.5.1 Populations at risk for GH/IGF axis effects from insufficient intake  
Sufficient nutrition is a balance between caloric intake and energy expenditure. 
Caloric intake may be affected by food availability and appetite, and increased 
energy expenditure may put active or pubescent children at risk for 
undernutrition. In this section, we will review populations who are at particular 
risk. 
 
Food availability can be a significant issue for many families, and may not be 
immediately apparent during a clinical visit. The worldwide prevalence of 
undernourishment is estimated at 11.3%451, and an estimated 50 million people 
in the United States are uncertain of having enough food452. This may affect the 
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type and quantity of food available453, 454. As will be discussed later in this 
section, even a transient interruption to calorie or protein availability can result 
in a reduction in IGF-I concentrations (Figure 4.2.3)455. This may be relevant in 
families where the next paycheck is required before food can be purchased. 
 
Dietary intake may be decreased despite adequate food availability due to certain 
feeding behaviors and/or diminished appetite. Sometimes the dietary intake is 
inadvertently over-restricted by the parent(s) and/or child due to fear of 
obesity456-458 or hypercholesterolemia458, to the extent that nutritional growth 
stunting ensues. Unstructured mealtimes, particularly those with distractions, as 
well as food aversions and dysfunctional parent-child interactions related to 
eating can all lead to failure to thrive, a topic extensively reviewed elsewhere459. 
Undernutrition can also result from decreased appetite, which may be 
endogenous (such as from delayed gastric emptying) or secondary to 
medications. Attention deficit and hyperactivity disorder (ADHD) affects 
approximately 7% of children460, and methylphenidate or dexamphetamine are 
commonly used to treat this disorder. These medications are associated with 
appetite suppression and subsequent weight loss461. In a small study that 
included healthy children treated with methylphenidate, reduced weight and BMI 
were seen within 4 months of treatment and an associated reduction in IGF-I 
concentration was observed462. 
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Figure 4.2.3: Seven days of 50% caloric restriction (35 Cal/kg) resulted in a reduction in mean 
IGF-I amongst eight prepubertal children. Mean IGF-I also decreased during 33% protein 
restriction (0.66 g/kg) in 6 other prepubertal children. Figure modified from Smith et al455 
 
4.2.5.2 Populations at risk for GH / IGF axis effects from increased 
demands 
The recommended caloric intake in children and adolescents is dependent upon 
energy expenditure. The estimated energy requirements in childhood varies 
according to age and sex, and ranges from 520 kcal/day in the infant female to 
3,152 kcal/day in the adolescent male. This is increased further in the setting of 
regular rigorous exercise447. Nutritional intake should be considered in the 
context of an individual’s activity level, as similar dietary intakes may be 
sufficient for a sedentary child but insufficient for an extremely active child. This 
chronic nutritional insufficiency may affect IGF-I concentrations.  
 
Failure to meet the nutritional demands of competitive sport is prevalent amongst 
adolescents463-465. For example, a study of adolescent soccer players showed that 
the mean caloric intake was almost 500 kcal/day less than estimated 
requirements466. At the extreme end of the spectrum of undernutrition in sport, a 
triad that includes low energy availability, menstrual dysfunction and reduced 
bone mineral density has been well described in females467. Up to 8% of athletic 
Calorie Restriction
Protein Restriction
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females have two or more features of this triad468, and low estrogen and IGF-I 
levels are thought to play a role in the pathogenesis of the low bone mineral 
density469. However, the adverse effects of undernutrition in males should not be 
underestimated, and the International Olympic Committee’s recent guidelines 
has replaced the term “Female Athlete Triad” to “Relative Energy Deficiency in 
Sport”470. This expands the definition to include both male athletes and other 
health repercussions beyond the original three, and acknowledges the variable 
degrees of severity of this condition470. IGF-I concentrations in gymnasts are 
lower than in controls471, and this may be a associated with the high prevalence 
of insufficient nutritional intake in this sport463. 
 
Reduced IGF-I concentrations are also seen in systemic diseases associated with 
increased energy requirements and/or malabsorption. These conditions include 
inflammatory bowel disease, cystic fibrosis, cardiac disease (particularly 
cyanotic conditions and congestive failure) and acquired immune deficiency 
syndrome (AIDS). Ensuring adequate nutrition in each of these conditions is one 
of the key components of management. Poor linear growth is seen in children 
with severe disease, and low IGF-I concentrations may reflect insufficient 
nutritional intake in these children. 
 
4.2.5.3 Populations at risk for GH / IGF axis effects from malabsorption 
Low IGF-I concentrations may be an early sign of malabsorptive disorders, even 
in the absence of gastrointestinal symptoms. Celiac disease may present with a 
broad spectrum of symptoms and signs ranging from asymptomatic mild 
malabsorption (called monosymptomatic celiac disease, where the only symptom 
is growth failure472) to severe malnutrition and secondary failure to thrive. Even 
in minimally symptomatic children, IGF-I concentration is lower than controls at 
diagnosis and normalises with a gluten-free diet in parallel to increasing BMI473. 
In children with established celiac disease, gluten exposure leads to a reduction 
in circulating IGF-I concentration proportional to the degree of small bowel 
mucosal inflammation474. The correlation of IGF-I levels with celiac disease 
activity has been demonstrated in many pediatric474-476 and adult477 studies, and 
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IGF-I has even been suggested as an additional marker for monitoring celiac 
disease activity for this reason475. 
 
Complicating the observation of low IGF-I concentrations in children with 
undiagnosed celiac disease is the putative link between celiac disease and GH 
deficiency. Ferrante et al performed GH stimulation testing in adults with new 
onset celiac disease, and found that a quarter of patients were characterised as 
having impaired GH secretion on these tests478. It should be noted, however, that 
the stimulation tests were performed at baseline and not repeated following 
initiation of a gluten-free diet. As mentioned previously, blunted response to GH 
stimulation testing was found in children with protein malnutrition479. This 
responded to dietary replacement, and should caution physicians against 
performing stimulation testing prior to dietary management. However, a 
potential diagnosis of comorbid GHD should be considered in children with 
celiac disease who don’t have improved linear growth despite adherence with a 
gluten-free diet480, 481. 
 
Poor growth and low IGF-I concentrations may also be a presentation of 
pediatric Crohn’s disease. One tenth of affected children are more than two 
standard deviations below the mean for height at diagnosis482, and they have 
numerous reasons for having reduced IGF-I concentrations. These include 
malnutrition complicated by increased metabolic rate during illness, increased 
inflammatory cytokines, and delayed puberty473. IGF-I concentrations increase 
during disease remission483. 
 
4.2.5.4 The effect of mild protein or caloric restriction on the GH/IGF-I axis 
The GH/IGF axis is sensitive to less severe and transient nutritional restrictions. 
Smith et al455 measured serum IGF-I levels in prepubertal children prior to and 
after six days of 50% calorie or 33% protein restriction. IGF-I levels were 
reduced during the periods of decreased intake of either calories or protein 
(Figure 4.2.3). This reduced IGF-I concentration during restriction is due to GH 
resistance rather than decreased GH secretion, as has been shown in similar 
  
 
 
146 
experiments in children with confirmed GHD receiving unchanged GH doses 
during dietary adjustments. In these children, IGF-I production in response to 
GH treatment was reduced during fasting484. In normal, fasted children, IGF-I 
levels returned to baseline concentrations following resumption of a normal 
diet455. Similar effects on IGF-I concentrations have also been shown in adults 
undergoing a short period of fasting485. In addition to reduced IGF-I 
concentrations, caloric restriction also renders the growth plate less responsive to 
IGF-I and GH through reduced expression of growth plate GH and IGF-I 
receptors486. 
 
4.2.5.5 The effect of severe protein or caloric restriction on the GH/IGF-I 
axis 
The GH/IGF-I axis has been studied in children with extreme deficiency of 
protein (kwashiorkor), calories (marasmus) or both protein and calories 
(marasmic kwashiorkor)487. In all three of these types of undernutrition, low 
IGF-I and increased GH concentrations are seen. When GH stimulation testing 
was performed in children with protein malnutrition prior to nutrition therapy, 
the baseline GH concentration was higher and the increase in GH secretion upon 
stimulation testing was lower than in controls or following refeeding479. 
 
Hintz et al488 studied 27 Thai children under 5 years of age, and Soliman et al479 
studied 51 Egyptian children under 3 years of age with kwashiorkor, marasmus 
or marasmic kwashiorkor and both showed similar results. Prior to nutritional 
repletion, GH concentrations were increased and IGF-I concentrations were 
decreased relative to controls. There were no significant differences in the 
magnitude of these changes between the three groups of severe undernutrition. 
Serum IGF-I and albumin levels did not correlate at baseline488, suggesting that 
reduced IGF-I concentration is not merely a result of decreased amino acid 
availability or reduced hepatic protein synthesis. 
 
Nutritional replacement in children with severe protein and/or calorie 
malnutrition can normalise the GH/IGF-I axis. Within two weeks of re-feeding, 
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IGF-I concentrations can double in severely malnourished children, to a level 
within 2 standard deviations of the mean for the population489. After 50 days of 
intensive inpatient nutritional therapy488, basal GH and IGF-I levels are 
indistinguishable from those of controls (Figure 4.2.4). Interestingly, IGF-I z-
scores are not associated with weight-for-height z-scores in severe malnutrition, 
but they have a linear relationship after two weeks of refeeding489. Similarly, 
nutritional interventions are associated with early increases in IGF-I levels, even 
before changes in anthropometric measures are observed.490 
 
 
 
Figure 4.2.4: The effect of nutritional treatment on serum IGF-I and GH in a group of children 
with severe protein-energy malnutrition. 
Mean ± SEM IGF-I concentrations in healthy control subjects are shown in grey. Figure 
modified from Hintz et al.488 
 
4.2.6 EXCESS NUTRITION AND INSULIN-LIKE GROWTH FACTOR-I 
Approximately one fifth of children in developed countries are overweight and, 
even in developing countries with a high prevalence of undernutrition, the 
percentage of children who are overweight is increasing491, 492. Obese children 
are taller than non-obese in childhood, but enter puberty earlier493 and have 
comparable adult heights494-496. Children who develop obesity earlier in 
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childhood are more likely to have taller stature in childhood than their peers497. 
As will be outlined in this section, obesity affects the GH/IGF-I axis, and this 
may play a role in this accelerated statural growth. 
 
4.2.6.1 Obesity and the GH/IGF-I Axis 
Obesity is associated with reduced spontaneous total GH secretion through a 
reduction in both pulse frequency and amplitude498, 499. Furthermore, the 
circulating half-life of GH in obese subjects is reduced to 11 minutes in 
comparison to 15 minutes in non-obese controls498. Decreased amplitude of GH 
secretion is seen also during provocative testing, where peak stimulated GH 
concentrations in obese children500-502 and adults503 are lower than in non-obese 
controls. This can lead to children with increased BMI being misclassified as 
having GHD, even when BMI is within the normal range502. 
 
Despite reduced circulating GH levels, IGF-I concentrations in obese individuals 
are similar to, or higher than, non-obese controls (discussed later in this 
section)500, 504-506. Growth hormone binding protein (GHBP) is the extracellular 
component of the GH receptor, and serum concentrations of GHBP are increased 
in obesity. This may reflect increased GH sensitivity at the receptor level in 
obese children.507 Increased GH sensitivity in children with higher BMI is 
supported by a study of IGF-I concentrations in children following 
administration of a fixed dose of GH. Children with high normal BMI had a 
greater rise in serum IGF-I concentrations when compared with those with low 
normal BMI508. 
 
Numerous studies have shown an association between IGF-I and leptin 
concentrations509-511. Animal studies show that administration of low doses of 
exogenous leptin result in a transient change in GH secretion but sustained 
reduction in circulating IGF-I concentrations. At higher doses, there is 
suppressed appetite and increased IGF-I levels512. This effect of leptin on IGF-I 
production appears to be independent of GH. However, GH can play a role in 
regulating leptin, as high doses of GH can increase leptin mRNA expression513. 
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Leptin may also play an independent role in linear growth, through its direct 
action on the growth plate. At the growth plate514, leptin synergises with thyroid 
hormone in regulating chondrocyte differentiation.515 A phenomenon of “growth 
without GH” has been described in children where obesity and leptin may play a 
role in transiently maintaining normal growth velocity in children with GHD. 
This can be seen in children with coexisting hypothalamic obesity and GHD 
associated with craniopharyngioma516, or in other children with severe obesity 
and GHD517. GHD may be masked by normal growth rate in these children, and 
they should be followed closely as this normal rate of growth may not be 
maintained and intervention with GH therapy may be indicated.  
 
4.2.7 INSULIN-LIKE GROWTH FACTOR-I CONCENTRATIONS AND 
BIOAVAILABILITY IN OBESITY 
Undernutrition consistently results in a reduction of IGF-I concentrations, but the 
opposite effect is not seen in obesity. Reinehr et al measured serum IGF-I 
concentrations in 319 obese children prior to, and after, a weight loss 
intervention program. They found no difference between baseline IGF-I 
concentrations in obese subjects or controls, and no association between weight 
loss and reduction in IGF-I levels518. This lack of association between obesity 
and increased IGF-I concentrations has been replicated elsewhere504, 519. In a 
population-based study of over six thousand adults, an inverse U-shaped 
association between IGF-I concentration and BMI was shown, with peak IGF-I 
concentrations at a BMI range of 22.5 to 25 kg/m2 in males and 27.5 to 30 kg/m2 
in females506. 
 
Although total IGF-I concentrations may not be significantly increased in 
obesity, the amount of free IGF-I relative to total IGF-I is increased504. This 
increase in IGF-I bioavailability is largely due to the effect of nutrition on the 
IGF binding proteins (IGFBPs). Increased BMI and high insulin levels are 
associated with a reduction in levels of IGFBP-1520, 521 and IGFBP-2504, which 
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can increase free IGF-I concentrations. IGFBP-3 concentrations are similar in 
obese and normal weight children504. 
 
4.2.7.1 Potential implications of GH/IGF-I changes from overnutrition  
The association between obesity and risk for several diseases of adulthood is 
mediated, at least in part, by the increase in GH sensitivity and IGF-I 
bioavailability from overnutrition. Obesity is a risk factor for cancer522, and 
increasing BMI by 5 kg/m2 will increase the relative risk of developing many 
different types of malignancies523. Overweight patients who develop cancer have 
a worse prognosis than those with normal weight522, 524. The mechanism for this 
association is not fully understood, but thought to be multifactorial and include 
the IGF-I signaling pathway525. There is evidence at the extreme ends of the 
spectrum of IGF-I to support this link: the incidence of colon cancer is increased 
in acromegaly526; and congenital IGF-I deficiency appears to confer protection 
against the development of malignancies524, 527, 528. The link between the 
overexpression of growth factors, or their receptors, and cancer is established 
(reviewed in 529), and the increased concentrations of free IGF-I in obesity may 
play a role in this association. 
 
4.2.8 CLINICAL IMPLICATIONS 
The GH/IGF-I axis is sensitive to nutritional status, and under- or overnutrition 
can affect this axis at each level from regulation of secretion to intracellular 
signaling. Evaluating the child’s nutritional status is essential in the proper 
interpretation of IGF-I concentrations, and failure to do this can result in 
misdiagnosis of a disorder of the GH/IGF-I axis. 
 
4.2.8.1 The clinical implications of undernutrition and IGF-I measurements 
IGF-I measurement has a central role in the screening evaluation of potential 
disorders of the GH/IGF-I axis2. GH stimulation testing is often used to confirm 
GHD in the child whose screening IGF-I concentration is low. However, these 
tests have poor reproducibility and specificity for this condition130, 131. 
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Consequently many normal children will be misclassified as having GHD using 
these tests47, 48, and this is a risk when children with low IGF-I concentrations 
from undernutrition undergo GH stimulation testing. These children have GH 
resistance and are unlikely to respond to GH therapy in the absence of nutritional 
replacement484. Ineffective GH treatment will also have significant healthcare 
resource implications530, and may expose patients to risk64, 66. 
 
The sensitivity of the GH/IGF-I axis to transient or minor changes in nutritional 
substrate availability is clinically relevant in children undergoing evaluation for 
short stature. Brief periods of reduced caloric intake can result in reduced IGF-I 
concentrations, even before any effect on body composition, weight or BMI is 
appreciated. Thus, nutritional history should include recent, as well as chronic, 
dietary intake. Similarly, energy expenditure through exercise, pubertal 
requirements447 or chronic disease should be considered when assessing the 
sufficiency of nutritional intake.  
 
It should be remembered that the effect of nutrition on IGF-I concentration is not 
solely dependent on caloric intake. Inadequate protein consumption can also 
lower IGF-I levels. Deficiency of micro-nutrients including zinc, magnesium and 
iodine, as well as hormones including thyroxine (reduced in sick euthyroid 
syndrome during nutritional stress and/or disease) may also result in low IGF-I 
concentrations and should be considered as possible aetiologies. 
 
Thus, careful evaluation of the patient’s weight and BMI charts is as important 
as inspection of the height and height velocity charts. Three-day diet recording 
and analysis for macro- and micronutrient sufficiency is a worthwhile diagnostic 
test, as is repeating the IGF-I measurement following a period of nutritional 
intervention, in children suspected of undernutrition prior to performing any GH 
stimulation testing.  
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4.2.8.2 The clinical implications of overnutrition and IGF-I measurements 
Unlike undernutrition, IGF-I concentrations in patients with overnutrition are 
less likely to result in diagnostic confusion. Total IGF-I levels are generally 
normal or elevated in obesity, although free IGF-I concentrations tend to be 
increased. Recent dietary history may be of relevance in these children, however, 
short-term caloric restriction in obese children may also reduce IGF-I 
concentrations. The effect of obesity on the GH/IGF-I axis should be considered 
when interpreting the results of provocative GH stimulation testing, as a blunted 
response to pharmacological stimuli has been reported in these children. 
 
The long-term implications of obesity for adverse health outcomes are of 
significant concern in the current obesity epidemic. Nutrition-mediated 
alterations in the GH/IGF-I axis in obesity may play a causative role in the 
pathogenesis of many of these comorbidities, and is an active area of current 
research. 
 
4.2.8.3 Potential new roles for IGF-I measurement 
The consistent effect of undernutrition in reducing IGF-I concentrations may 
provide an additional clinical role to IGF-I measurement. Monitoring IGF-I 
concentrations has been suggested as a measure of nutritional sufficiency436, 490, 
531. Weight gain in preterm and low birth weight infants is mirrored by increases 
in IGF-I levels, and this may be an additional marker of nutritional sufficiency in 
this population436. Another potential clinical role for IGF-I measurement may be 
the monitoring of activity of diseases associated with malabsorption, such as 
celiac disease475. IGF-I concentrations are sensitive to short-term nutritional 
insufficiencies, and may be affected before symptoms such as weight loss are 
noticeable. 
 
4.2.9 CHAPTER CONCLUSION 
IGF-I concentration is sensitive to acute and chronic changes in nutritional 
status. Thus, interpretation of IGF-I measurements should take into account the 
nutritional status of the patient. Given the poor specificity of GH stimulation 
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testing for GHD, caution is advised against progressing to these tests prior to 
addressing nutritional issues in patients where nutrition may be affecting IGF-I 
measurements. Likewise, the diagnosis of primary IGF deficiency cannot be 
made until undernutrition is excluded as a cause of the low IGF-I levels. GH and 
recombinant IGF-I treatment are neither appropriate nor effective interventions 
for increasing growth of children and adolescents with nutritional stunting. 
Nutritional repletion is the therapy of choice in that setting. 
 
While weight and BMI are the most commonly used methods for describing 
nutritional status, noninvasive methods for studying body composition are 
available. In the following chapters, I will describe reference data for body 
composition parameters in infancy. Having described normative data for IGF-I 
measurement in infancy (Chapter 2.4), I will then explore the relationship 
between these parameters and IGF-I and –II concentrations. 
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CHAPTER 4.3: BODY COMPOSITION IN THE FIRST FEW DAYS OF 
LIFE 
 
Publication 
Hawkes CP, O’B Hourihane J, Kenny LC, Irvine AD, Kiely M, Murray DM. 
Gender- and gestational age-specific body fat percentage at birth. Pediatrics. 
2011;128(3):E645-E51. (Appendix L) 
 
Presentation 
Hawkes CP, O’B Hourihane, J, Kenny LC, Irvine AD, Kiely M, Murray DM. 
Body Composition at birth; normative values.  
American Pediatric Society / Society for Pediatric Research. Denver, May 2011. 
European Sociery for Paediatric Research, Newcastle, Sept 2011. (Appendix M) 
 
4.3.1 BACKGROUND 
Nutrition is a key regulator of childhood growth. This is most obvious at the 
extreme end of caloric undernutrition, where adolescents with anorexia nervosa 
are have poor linear growth that improves with weight gain532. Similar growth 
patterns are also seen in children with celiac disease before and after 
treatment533-535, and in other causes of severe malnutrition536 (See Chapter 4.2). 
 
Assessing nutritional status in infancy can be challenging. Weight, weight-for-
length, Ponderal index (mass/length3) and body mass index (BMI, (mass/length2) 
are the proxy measures of adiposity most commonly used in infants. Weight 
alone is an imprecise measure of adiposity, as it is comprised of all tissue 
compartments and is dependent on length537. The relationship between length 
and weight is age-dependent during childhood, and children with similar BMI 
can have different amounts of FM. Ponderal index538 and skinfold thickness539 
are also poor predictors of body fat in early life. 
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The accurate measurement of FM is possible using noninvasive techniques 
including dual-energy x-ray absorptiometry (DXA), Air Displacement 
Plethysmography (ADP) and bioelectric impedance analysis (BIA)540. Magnetic 
resonance imaging (MRI)541 and DXA can provide localised information on fat 
distribution. For very young infants, ADP is a preferred technique because it 
does not involve radiation or require sedation. This technique can also tolerate 
infant movement, and has been validated in infants against deuterium dilution 
body composition analysis542 and DXA543. 
 
In this, and subsequent chapters, I will describe reference data for body 
composition in infancy and determine if these measures correlate with serum 
IGF-I and –II concentrations at birth. I will first describe the measurement of 
percentage body fat (%BF) at birth, before exploring and describing new indices 
for FM and FFM in the first three months of life. 
 
4.3.2 AIM 
The aim of this study is to describe reference data for %BF in infants born after 
36 weeks’ gestation within the first 4 days of life, and to determine the effect of 
infant sex and gestation on this. 
 
4.3.3 METHODS 
4.3.3.1 Study Population and Measurements 
Infants born during the study peroid of March 2008 to October 2010 at a 
gestational age between 36 and 41+6 weeks’ gestation, enrolled in the Cork 
BASELINE Birth Cohort Study, were eligible for inclusion. Eligibility and 
exclusion criteria for this cohort study are outlined in 2.4.3. 
 
Gestational age, sex, birth weight and length were recorded at birth for each 
infant. Gestational age was determined from a first trimester scan or the last 
menstrual period (LMP). Gestational age based on LMP was confirmed against 
dates calculated from a first trimester dating scan. If there was disparity of more 
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than 7 days between LMP and scan dates, then the scan-based gestational age 
was used. Body composition was calculated using the ADP within the first four 
days of life. 
 
Maternal BMI was measured on initial visit at 16 weeks gestation. Maternal 
cigarette use was self reported. Infant anthropometric measurements were 
recorded on the same day as PEAPOD™ measurement, using standardised 
operating procedures. Length was measured using a neonatometer to the nearest 
milimeter. Mid arm circumference was measured once on the left arm at the 
midpoint between the olecranon and acromion processes. Abdominal 
circumference was measured once at the level just above the umbilicus, in 
centimeters to one decimal place. 
 
4.3.3.3 Air Displacement Plethysmography 
The PEAPOD™ Infant Body Composition System (Life Measurement Inc, 
Concord, CA) is an air-displacement plethysmograph that allows for the 
measurement of body composition in infants between 1 and 8 kg body weight. 
The naked infant is placed in a closed chamber. Air displacement is measured 
using pressure and volume changes. Calculated body volume and body mass are 
used to determine body density. Age and gender-specific fat-free mass density 
values are used to calculate the percentage body fat544, 545. Interobserver 
variability was reduced by one trained midwife performing almost all 
measurements as per standard operating procedure. 
 
4.3.3.4 Statistical analysis:  
Data were entered prospectively into a secure internet database, and SPSS 
(version 16, SPSS Inc Chicago, Illinois USA) was used for analysis. Infants were 
grouped by gestational age (weeks + days) into 3 groups; 36-37+6, 38-39+6 and 
40-41+6. Weighted average (Haverage) percentile values were calculated at 2.5, 
5, 10, 25, 50, 75, 90, 95 and 97.5. 
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One way ANOVA analysis was used to compare categorical clinical and 
demographic variables between groups and independent samples t-tests were 
used to compare continuous variables. As %BF was normally distributed (Fig 1), 
independent samples t-tests were used to compare between groups. One way 
ANOVA testing was used to compare %BF between the three gestational age 
groups. This was also used to determine if there was a significant difference in 
%BF between days of PEAPOD measurement. Stepwise linear regression was 
used to determine the independent effect of gestation on %BF. 
 
4.3.4 RESULTS 
Of the 1203 recruited infants delivered during the study period, 743 were born 
between 36 to 41+6 weeks and had had ADP performed within the first four days 
of life. The excluded infants included: 417 born prior to PEAPOD availability; 
31 had ADP performed after four days of life; and 12 were born outside the 
gestational range of 36 to 41+6 weeks.  
 
Most (553/743, 74.4%) PEAPOD measurements were taken on the second or 
third day of life; mean (SD) = 1.9(0.9) days. Within the limit of day 0-4, day of 
measurement did not influence %BF (p=0.08). The demographics of our 
population are shown in Table 4.3.1. There was no significant difference in 
ethnicity, mean maternal age, mean maternal BMI and socioeconomic status 
between gestational age categories. 
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Table 4.3.1 Demographic data of study population, categorised by gestational age. 
Data presented as mean (SD) 
aNew Zealand Socioeconomic Index (NZSEI-96)546, 547  
bOne-way ANOVA 
 36-37+6wk 38-39+6wk 40-41+6wk Total p-valueb 
Number 45 243 455 743  
Male, n (%) 23 (51.1) 139 (57.2) 228 (50.1) 390 (52.5) 0.2 
Gestational Age, weeks 37.2 (0.6) 39.1 (0.5) 40.8 (0.5) 40.1 (1.2) <0.001 
Birth weight, g 2955 (313) 3326 (422) 3643 (437) 3498 (470) <0.001 
Age at Peapod, days 2.1 (1) 1.9 (0.9) 1.8 (0.9) 1.9 (0.9) 0.06 
Caucasian Ethnicity, n (%) 44 (97.8) 240 (98.8) 447 (98.2) 731 (98.4) 0.8 
Maternal age, years 29.8 (4.9) 29.7 (4.6) 29.7 (4.3) 29.7 (4.5) 0.9 
Maternal University Degree 
or Higher, n (%) 
15 (33.3) 102 (42) 222 (48.8) 339 (45.6) 0.05 
Smoked in Pregnancy, n (%) 14 (31.1) 65 (26.7) 125 (27.5) 204 (27.5) 0.8 
Maternal BMI at 16 weeks’  23.6 (4.2) 24.6 (4.1) 24.9 (4.1) 24.7 (4.2) 0.1 
Socioeconomic Statusa  (%) 
1 
2 
3 
4 
5 
6 
 
2 (4.4) 
7 (15.6) 
18 (40) 
3 (6.7) 
4 (8.9) 
11 (24.4) 
 
10 (4.1) 
41 (16.9) 
91 (37.4) 
17 (7) 
42 (17.3) 
42 (17.3) 
 
34 (7.5) 
60 (13.2) 
176 (38.7) 
37 (8.1) 
69 (15.2) 
79 (17.4) 
 
46 (6.2) 
108 (14.5) 
285 (38.4) 
57 (7.7) 
115 (15.5) 
132 (17.8) 
 
0.9 
 
 
 
 
 
4.3.4.1 Gestational Age Categories 
Mean body fat percentage increased with gestational age. At 36 to 37+6 weeks’ 
gestation, mean (SD) %BF was 8.9% (3.5), which increased to 10.3% (4) at 38 to 
39+6 weeks and 11.2% (4.3) at 40 to 41+6 weeks (p<0.001) (Table 4.3.2). On 
stepwise linear regressional analysis, gestational age remained a significant 
association (R = 0.193, p<0.001) when corrected for maternal BMI at 16 weeks’ 
gestation, socio-economic group, maternal age and cigarette consumption. The 
other significant and consistent association with %BF on multi-variate analysis 
was maternal BMI at 16 weeks’ gestation (Table 4.3.3). %BF increased linearly 
with increasing gestation and increasing maternal BMI. 
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Table 4.3.2: Male and Female measurements at different gestational ages  
aIndependent Sample t-test, bANOVA, *Denotes variables measured by PeaPod 
 Male Female TOTAL P-value* 
36-37+6 weeks gestation 23 22 45  
Birth weight g (SD) 3009 (340) 2898 (277) 2955 (313) 0.24 
Fat mass g (SD)* 253 (99) 245 (112) 249 (105) 0.801 
Body Fat % (SD)* 8.8 (3.2) 8.9 (3.8) 8.9 (3.5) 0.968 
Fat Free Mass g (SD)* 2588 (285) 2485 (227) 2548 (261) 0.188 
Fat Free Mass % (SD)* 91.2 (3.2) 91.1 (3.8) 91.1 (3.5) 0.968 
Head Circumference cm (SD) 33.5 (1.3) 33.3 (1.1) 33.4 (1.2) 0.453 
Ponderel Index (kg/m3) 27 (3.1) 26 (2.5) 26.5 (2.9) 0.241 
Length (cm) 48.2 (2.5) 48.2 (1.7) 48.2 (2.1) 0.973 
Abdominal Circumference (cm) 32.2 (1.9) 31.3 (1.4) 31.7 (1.7) 0.085 
Midarm Circumference (cm) 9.8 (0.7) 9.7 (0.8) 9.7 (0.8) 0.681 
38-39+6 weeks gestation 139 104 243  
Birth weight 3362 (436) 3279 (399) 3326 (422) 0.13 
Fat mass g (SD)* 322 (159) 351 (148) 334 (155) 0.159 
Body Fat % (SD)* 9.8 (3.9) 11.1 (3.9) 10.3 (4) 0.012 
Fat Free Mass g (SD)* 2879 (331) 2757 (311) 2827 (328) 0.004 
Fat Free Mass % (SD)* 90.2 (3.9) 88.9 (3.9) 89.7 (4) 0.012 
Head Circumference cm (SD) 34.8 (1.4) 34.1 (1.3) 34.5 (1.4) <0.001 
Ponderel Index (kg/m3) 27.2 (2.5) 27.7 (2.3) 27.4 (2.5) 0.132 
Length (cm) 49.8 (1.9) 49.1 (1.8) 49.5 (1.9) 0.004 
Abdominal Circumference (cm) 33 (2) 32.9 (2) 33 (2) 0.806 
Midarm Circumference (cm) 10.4 (1) 10.2 (0.9) 10.3 (1) 0.12 
40-41+6 weeks gestation 228 227 455  
Birth weight 3687 (431) 3598 (440) 3643 (437) 0.029 
Fat mass g (SD)* 358 (171) 437 (188) 397 (184) <0.001 
Body Fat % (SD)* 10 (3.9) 12.5 (4.4) 11.2 (4.3) <0.001 
Fat Free Mass g (SD)* 3122 (348) 2962 (345) 3042 (355) <0.001 
Fat Free Mass % (SD)* 90 (3.9) 87.5 (4.4) 88.8 (4.3) <0.001 
Head Circumference cm (SD) 35.4 (1.3) 34.9 (1.2) 35.1 (1.3) <0.001 
Ponderel Index (kg/m3) 27.4 (2.5) 27.9 (2.3) 27.6 (2.4) 0.026 
Length (cm) 51.2 (1.8) 50.5 (1.7) 50.9 (1.8) <0.001 
Abdominal Circumference (cm) 33.9 (1.9) 33.7 (2) 33.8 (2) 0.526 
Midarm Circumference (cm) 10.8 (1) 10.8 (1) 10.8 (1) 0.397 
Total cohort 390 351 743  
Birth weight 3531 (472) 3460 (466) 3498 (470) 0.04 
Fat mass g (SD)* 339 (165) 400 (182) 368 (176) <0.001 
Body Fat % (SD)* 9.8 (3.9) 11.9 (4.3) 10.8 (4.2) <0.001 
Fat Free Mass g (SD)* 3003 (372) 2872 (355) 2941 (370) <0.001 
Fat Free Mass % (SD)* 90.2 (3.9) 88.1 (4.3) 89.2 (4.2) <0.001 
Head Circumference cm (SD) 35.1 (1.4) 34.6 (1.3) 34.8 (1.4) <0.001 
Ponderel Index (kg/m3) 27.3 (2.5) 27.7 (2.4) 27.5 (2.5) 0.023 
Length (cm) 50.5 (2) 50 (1.9) 50.3 (2) <0.001 
Abdominal Circumference (cm) 33.4 (2) 33.3 (2.1) 33.4 (2) 0.503 
Midarm Circumference (cm) 10.6 (1) 10.6 (1) 10.6 (1) 0.911 
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Table 4.3.3: Stepwise linear regression of factors affecting body fat percentage. 
*Maternal BMI at 16 weeks gestation,  
** Number of cigarettes smoked per day during pregnancy as measured by maternal report. 
Independent 
variables 
Correlation 
coefficent 
p-value Standardised 
Beta coefficient 
t-value 
Gestational age 0.200 <0.001 0.192 5.32 
Maternal BMI* 0.114 0.006 0.099 2.71 
Cigarette 
consumption**  
-0.011 0.387 -0.011 -0.302 
Socio-economic 
group 
0.029 0.450 0.013 0.329 
Maternal age -0.24 0.263 -0.026 -0.672 
Dependent variable = %Body fat day 1-4. F =7.815, p<0.001 
 
4.3.4.2 Effect of gender 
The %BF in males and females was normally distributed within each gestational 
age category (Fig 4.3.1). Males had lower mean %BF than females in each 
category. The difference became more pronounced with advancing gestational 
age, and was statistical significance in the 38 to 39+6 (p=0.012) and 40 to 41+6 
(p<0.001) weeks’ gestation categories. 
 
While females had a greater %BF than males at each gestational age, males had a 
greater birth weight. This was not significant at 36-37+6 weeks (p=0.24) or 38-
39+6  weeks (p=0.13), but was significance at 40-41+6 weeks; with males 
weighing 3683g (SD=435g) and females weighing 3593g (SD=447g) (p=0.029). 
It should be noted that there were increased numbers of subjects at later 
gestational ages, which may have increased power to detect differences. 
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Figure 4.3.1 Body fat percentages for males and females at 36-37+6, 38-39+6 and 40-41+6 weeks 
gestation. Normal curves displayed.  
 
4.3.4.3 Centile Chart 
A centile chart was compiled for males, females and all infants at each 
gestational age category, and is shown in Table 4.3.4.  
 
Table 4.3.4: Centiles for body fat percentage according to gestational age and sex 
Centile 36-37+6 weeks 38-39+6 weeks 40-41+6 weeks 
 Male Female All Male Female All Male Female All 
97.5th 14.9 17.5 17.1 19 18.2 18.4 18.2 22.1 19.8 
95th 14.5 16.9 14.4 17.1 17.7 17.5 16.2 19.2 18.3 
90th 13 13.1 12.9 14.5 16.3 15.5 15 17.9 16.7 
75th 11.9 12 11.9 12.2 14.1 13 12.7 15.4 14.2 
50th 9.2 8.9 9.2 9.6 11 10.3 9.9 12.5 10.9 
25th 6 5.7 5.9 7.2 7.9 7.5 6.9 9.4 8.1 
10th 4.6 4 4.4 4.7 6.2 5.1 4.9 7.2 5.8 
5th 3.4 1.8 3.3 3.2 4.7 3.4 3.4 5.6 4.4 
2.5th 3.1 1.4 1.7 2.4 2.9 2.6 2.8 4.7 3.2 
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4.3.5 DISCUSSION 
This large observational birth cohort study shows the distribution of %BF in the 
first 4 days of life amongst first born infants greater than 36 weeks’ gestation in a 
largely Caucasian Irish population. We have shown an upward trend in %BF at 
increasing gestational age, and demonstrated a significantly higher %BF at birth 
in females than in males. We have created a centile chart for %BF in male and 
female infants that will assist physicians and researchers in the interpretation of 
measured neonatal body fat percentage. 
 
Previous studies of %BF at birth in term infants have shown varying mean 
values. This has varied from 8.6±3.7% (n=87) in Italian infants548, to 10.6 ± 
4.6% (n=87) in cohort of 87 American infants549 and 12.9 ± 4% in 108 full term 
Swedish infants in the first 10 days of life550.  No previously studied cohorts 
have been large enough to delineate normative data for gestational age categories 
in term infants. Our mean values varied considerably depending on the 
gestational age and sex of our studied infants and this may explain the variance 
seen between previous reports. 
 
In this cohort, we have found that females have a greater %BF than males at 
birth at each of the studied gestational age categories; a difference that increased 
with advancing gestational age. While it is known that female children551 and 
adults552 have higher fat mass and lower lean body mass than males, there is 
disagreement in the published literature regarding the degree of difference, and 
whether or not this is present from birth. In 1967, Foman et al first observed this 
difference using a multicomponent model to determine body fat, based on 
measurements of total body water, total body potassium and bone mineral 
content. This finding has been replicated using dual energy x-ray 
absorptiometry553, 554, and ADP555. However, Butte used the multicompartment 
model in 76 infants and did not find a difference between sexes at 2 weeks of 
age556. Eriksson and Gilchrist in two seperate studies using ADP found that %BF 
did not differ significantly between sexes at one and two weeks of age550. Once 
again these cohort sizes were much smaller (108 and 80 infants respectively). 
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As expected we found that male infants were heavier than their female 
counterparts at each gestational age. Despite this, their %BF was lower, meaning 
that this increase in weight was due to increased fat free mass. There is evidence 
that boys grow faster than girls in utero, and are more reliant on placental 
function and maternal nutrition during pregnancy557, 558. Male infants seem more 
vulnerable to undernutrition, as evidenced by the greater effect of the Dutch 
famine on the male risk of later cardiovascular disease559,  and the greater effect 
of malnutrition on male infants in animal experiments560, 561. 
 
As our study recruited primiparous volunteers with singleton pregnancies, and 
took place in a single Irish centre, there is a potential bias that may affect the 
generalisability of the results. However, our study population closely reflects that 
of the Irish population as a whole. In the Irish census of 2006, the demographics 
of women aged 15-44 compared with our study population were as follows: 
Caucasion 94% vs 98.4%; Completed 3rd level education 33.7% vs 45.6%562. A 
recent study of 1000 pregnant Irish women recorded a mean(SD) first trimester 
BMI equal to 25.7563. This compares closely with 24.7(4.2) found in our study 
population. Thus, the babies included in our study are close to a representative 
sample of Irish first born infants. 
 
4.3.6 CHAPTER CONCLUSION 
Neonatal adiposity cannot be evaluated without accurate reference data, and this 
study was an important first step in characterising this. The observation that 
males weigh more but have less body fat than females demonstrates that body 
composition measurement may provide additional nutritional information 
beyond weight in early life. While %BF is commonly used as a measure of 
adiposity, it does not correct sufficiently for body size. In the next study, we 
build on the data generated from this study by developing a measure of fetal 
adiposity that is independent of infant size and can be used in describing body 
composition in the first three months of life.   
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CHAPTER 4.4: DEFINING BODY COMPOSITION IN THE FIRST TWO 
MONTHS OF LIFE AND CORRELATING WITH GROWTH AT TWO 
YEARS 
 
Publication 
Hawkes CP, Zemel BS, Kiely M, Irvine AD, Kenny LC, O’B Hourihane J, 
Murray DM. Body composition within the first 3 months: optimized correction 
for length and correlation with BMI at 2 years. Horm Res Paediatr. 
2016;86(3):178-187 (Appendix N). 
 
Presentation 
Hawkes CP, Zemel BS, Kiely M, Irvine A, Kenny LC, O’B Hourihane J, Murray 
DM. Body composition in the first 2 months of life – optimized correction for 
length, reference data and correlation with obesity at 2 years. American 
Pediatric Society / Society for Pediatric Research. Baltimore, May 2016 (Poster 
Presentation) (Appendix O). 
 
4.4.1 INTRODUCTION 
In the previous study, I described reference data for %BF at birth. However, a 
confounding effect of body size on total FM and FFM has been described in 
adults564 and children565. %BF is also susceptible to this effect, as two 
individuals with the same %BF could have very different amounts of absolute 
FM566. Thus, the determination of an index of FM and FFM that is independent 
of size was required in order to investigate the interaction of body composition 
with IGF-I and –II concentrations (Chapter 4.5). 
 
FM relative to length (L) is often used to correct FM for body size; fat mass 
index (FM/L2) and fat free mass index (FFM/L2) are commonly used in older 
children and adults. Whether these represent the optimal indices to correct FM 
and FFM for length in infancy has not been examined previously. 
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Rapid weight gain in early infancy increases future cardiometabolic risk567-570 
and predicts obesity in later childhood571, 572, adolescence and adulthood573, 574. In 
addition to being a marker of nutritional status, I hypothesised that changes in 
body composition in infancy may also identify children who are at risk of future 
obesity. 
 
4.4.2 AIM 
The aims of this study were 1) to determine the optimal index of FM and FFM 
that is independent of length in the first three months of life, 2) to describe 
reference data for FM, FFM, %BF, as well as for parameters corrected for length 
in early infancy and 3) to determine if these measurements in early infancy can 
be used to identify children who will have an increased BMI at two years of age. 
 
4.4.3 METHODS 
Mothers and their children were recruited at 20 weeks’ gestation through the 
SCOPE pregnancy study575 and followed up from birth through the Cork 
BASELINE birth cohort study (ClinicalTrials.gov NCT: 01498965) (additional 
details in 2.4.3)344. Infants were recruited over the study period from August 
2008 to August 2011. Ethical approval was granted by the Clinical Research 
Ethics Committee of the Cork Teaching Hospitals. 
 
For this study, we included all children born between 37 weeks and 41 weeks, 6 
days’ gestation. Birth assessments of body composition were defined as 
measurements obtained up to and including day four of life. Ninety percent of 
two month visits in this cohort took place between 49 and 86 days of life, and 
these were included as the “two month” body composition evaluations. 
 
4.4.3.1 Demographics 
Details regarding feeding type were recorded at each visit from parental report. 
Gestational age was determined using the first day of the last menstrual period 
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(LMP). Ultrasound gestational age was used if it was performed before 16 
weeks’ gestation and a discrepancy of greater than six days between this and 
LMP was noted, or if the ultrasound scan at 20 weeks’ reported a discrepancy of 
10 or more days with LMP.575 
 
4.4.3.2 Anthropometry 
At birth and two months, weight, length, and occipito-frontal circumference 
(OFC) were measured using standardised protocols and recorded on a secure 
online database. Supine length was measured to the nearest millimeter at birth 
using a Harpenden neonatometer (Harlow Healthcare, London, UK), and at two 
months using a Seca 210 mat (Harlow Healthcare, London, UK). Standing height 
was measured at 24 months of age using a Seca 206 tape (Harlow Healthcare, 
London, UK). Infants were weighed unclothed.  
 
4.4.3.3 Body composition assessment 
Body composition was measured at birth and two months of age using ADP 
(PEAPODTM Infant Body Composition System, Life Measurement Inc, Concord, 
CA)576, as described in 4.3.4.2. 
 
4.4.3.4 Statistical Analysis 
All data were analyzed using SPSS version 21.0 (IBM, New York, USA). Mean 
(SD) were reported for normally distributed data, and comparison between 
independent groups were made using Student’s t-test for independent variables. 
Categorical variables (exclusive breastfeeding status and Caucasian ethnicity) 
were compared using Chi Squared tests. 
 
Determination of the optimal length-corrected index of fat mass and fat free 
mass in infancy 
In order to determine the optimal index of FM and FFM corrected for length, we 
used a method previously described by Wells et al565, and Cole et al577. 
Logarithmic conversion of FM (LogFM), FFM (LogFFM) and Length 
  
 
 
167 
(LogLength) at birth and two months were calculated. Linear regressions of 
LogFM or LogFFM were performed separately with LogLength as the 
independent variable, similar to the Benn Index used to define the optimal power 
for weight-for-height indices578. This analysis used measurements at birth and 
aged two months. The slope of the regression line for each analysis delineates 
the optimal power of length in the FM/Lx or FFM/Ly that is least dependent on 
length. 
 
We confirmed these results using the closest integer of x or y determined by the 
previous calculation. Linear regression for length (independent variable) and 
FM/Lx (dependent variable) were performed. A regression coefficient close to 0 
between length and FM/Lx was considered to represent an index of fatness that is 
independent of length. Pearson’s correlation coefficient was also used to 
determine the contribution of length to the measure of FM/Lx. This analysis was 
performed separately at birth and at two months. The same approach was used 
for FFM. 
 
Reference values of body fat percentage, fat mass/length3 and fat free 
mass/length2 at birth and two months 
Gender-specific reference curves for %BF, FM/L3 and FFM/L2 were generated 
using LMS Chartmaker Pro (Harlow Printing Ltd., Tyne and Wear, UK). The 
LMS method used by this software has been described previously347, 348. A Box-
Cox transformation is used to obtain normality, and separate smooth curves are 
generated for skewness, median and variability. These are constrained to smooth 
changes over time, and combined in one graph. 
 
Evaluation of body composition at birth and two months, and BMI at two years 
Children with ADP performed at birth and two months, and who had BMI 
available at two years were included in this analysis. Age- and sex-specific z-
scores for FM, FFM, FM/L3, FFM/L2, and %BF were generated from this 
population using the reference values described above. Sex-specific BMI z-
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scores at two years of age based on the World Health Organization reference27 
were calculated using Stata 12.0 (StataCorp, College Station, TX, USA),346. 
Multiple linear regression analysis was performed using BMI z-score at two 
years as the dependent variable and age- and sex-specific z-scores for FM/L3, 
FFM/L2 at birth and at two months as the independent variables. Logistic 
regression was used to determine the odds of having a BMI z-score ≥ 2 at two 
years is based upon FM, FFM, FM/L3, FFM/L2 and %BF z-scores at birth and 
two months. 
 
4.4.4 RESULTS 
Of the 2137 infants included in this birth cohort, 2032 were born between 37 
weeks and 41 weeks, 6 days’ gestation. Body composition was measured using 
ADP before five days of age in 1063 (526 females) and from 49 to 86 days of 
life in 922 (445 females). ADP was performed in 725 term children (348 female) 
both at birth and two months of age. BMI at two years was available in 562 (267 
female) of these infants (Figure 4.4.1). Characteristics of the infants who had 
ADP body composition assessment performed at birth and two months of age are 
shown in Table 4.4.1. 
 
Figure 4.4.1: The number of subjects recruited and undergoing body composition measurement 
at birth (<5 days) and two months (49-86 days), and body mass index measurement at two years.  
 
 
Table 4.4.1: Body Composition Measurements within the first four days of life in term infants. 
Mean (SD). 
P values represent the significance of the difference between males and females in each 
parameter at each time point measured using t-test (or *Fisher’s exact test, 2-sided). 
 BIRTH (0-4 days) TWO MONTHS (49-86 days) 
 Male 
(n=537) 
Female 
(n=526) 
p Male 
(n=477) 
Female 
(n=445) 
p 
Gestation, weeks 40.2 (1.1) 40.2 (1.1) 0.5 40.2 (1.1) 40.2 (1.1) 0.83 
Term Infants
Body Composition Measurements
< 5 Days 49 - 86 Days
Both Measurements
2032
1063 922
725
BMI Measured at 2 Years
562
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Exclusively 
Breastfed at time of 
measurement, n (%) 
158 
(29.4%) 
187 
(35.6%) 
0.3* 131 
(27.5%) 
132 
(31.9%) 
0.47* 
Caucasian, n (%) 531 
(98.9%) 
517 
(98.5%) 
0.81 531 
(98.9%) 
517 
(98.3%) 
0.17 
Weight, kg 3.57 (0.45) 3.47 (0.45) 0.001 5.65 (0.69) 5.25 (0.57) <0.001 
Length, cm 50.7 (2) 50.1 (1.9) <0.001 59 (2.1) 57.9 (2.2) <0.001 
Head 
Circumference, cm 
35.1 (1.4) 34.5 (1.3) <0.001 40.2 (1.3) 39.3 (1.4) <0.001 
Age at PeaPod, days 1.9 (1) 1.78 (1) 0.045 65.5 (8) 65.7 (8.2) 0.7 
Total body mass, kg 3.38  
(0.44) 
3.29 (0.42) 0.001 5.65 (0.68) 5.25 (0.57) <0.001 
Fat Mass, kg 0.36 (0.17) 0.41 (0.17) <0.001 1.21 (0.34) 1.19 (0.31) 0.18 
Fat free mass, kg 3.02 (0.35) 2.88 (0.33) <0.001 4.44 (0.45) 4.06 (0.38) <0.001 
Body fat, % 10.2 (4) 12.04 (4) <0.001 21.2 (4.3) 22.3 (4.2) <0.001 
Fat Free Mass Index, 
kg/m2 
11.74 
(1.01) 
11.46 
(0.98) 
<0.001 12.73 
(0.84) 
12.1 (0.8) <0.001 
Fat Mass/length3, 
kg/m3 
2.67 (1.18) 3.18 (1.17) <0.001 5.88 (1.52) 6.07 (1.4) 0.046 
 
Determination of the optimal length-corrected measure of fat mass in infancy 
We first determined the optimal index of FM, and FFM least influenced by 
length. The overall slope of the regression line relating LogFM to LogLength at 
birth was 5.3 (5.9 males, 5.6 females), and at two months was 3.3 (3.5 males, 3.4 
females). This indicates that FM/L5 at birth and FM/L3 at two months are 
optimal indices of fatness corrected for length. The overall slope of the 
regression line for LogFFM with LogLength was 2 at birth (1.9 males, 2.1 
females) and 2.2 at two months (2.2 males, 1.9 females). 
 
Separate regression analyses were performed to confirm that these indices 
minimised the association of FM and FFM with length. The regression 
coefficient for FM/L3 with length was 0.12 (SEM 0.02) (R2 0.04) at birth, and -
0.005 (SEM 0.03) (R2<0.001) at two months (Table 2). The regression 
coefficient for FFM/L2 was 0.03 (SEM 0.02) (R2 0.003) at birth, and 0.04 (SEM 
0.01) (R2 0.01) at two months. These results indicate that FM/L3 minimises the 
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association of FM and length at birth and two months. While FM/L5 may be 
more independent of length at birth, the contribution of length to the FM/L3 at 
birth is low (R2 = 0.04), and using the same index as two months allows for 
comparison between age groups. Using a similar analysis (Table 4.4.2), FFM/L2 
should be used as an index of FFM at birth and two months.  
 
Table 4.4.2: Regression analysis of length on FM and FM/Lx at birth and two months of age. 
 0-4 days of life (n=1063) 49 – 86 days of life (n=922) 
 R2 Regression 
Coefficient 
(SEM) for 
Length 
p R2 Regression 
Coefficient 
(SEM) for 
Length 
p 
Dependent 
Variable 
      
FM 0.194 0.039 
(0.002) 
<0.001 0.18 0.062 
(0.004) 
<0.001 
FM/L  0.136 0.061 
(0.005) 
<0.001 0.076 0.066 
(0.008) 
<0.001 
FM/L2 0.083 0.091 
(0.009) 
<0.001 0.019 0.055 
(0.014) 
<0.001 
FM/L3 0.039 0.121 
(0.018) 
<0.001 <0.001 -0.005 
(0.025) 
0.84 
FM/L4 0.011 0.123 
(0.036) 
0.001 0.024 -0.18 
(0.042) 
<0.001 
FM/L5 <0.001 0.01 
(0.072) 
0.9 <0.001 0.004 
(0.015) 
0.8 
       
FFM 0.531 0.124 
(0.004) 
<0.001 0.572 0.156 
(0.004) 
<0.001 
FFM/L  0.214 0.129 
(0.007) 
<0.001 0.3 0.149 
(0.007) 
<0.001 
FFM/L2 0.003 0.029 
(0.015) 
0.05 0.012 0.043 
(0.012) 
<0.001 
FFM/L3 0.144 -0.401 
(0.029) 
<0.001 0.161 -0.293 
(0.021) 
<0.001 
FFM/L4 0.437 -1.719 
(0.058) 
<0.001 0.494 -1.141 
(0.036) 
<0.001 
FFM/L5 0.644 -5.285 
(0.117) 
<0.001 0.698 -3.072 
(0.063) 
<0.001 
 
Reference values for adjusted fat mass in infancy at birth and two months of 
age 
Reference centile charts for FM/L3, FM and %BF are shown in Figure 4.4.2, and 
FFM/L2 and FFM are shown in Figure 4.4.3. During the first two months of life, 
mean (SD) FM/L3 increased approximately two-fold (males 2.7 (1.2) to 5.9 (1.5) 
kg/m3, females 3.2 (1.2) to 6.1 (1.4) kg/m3). A similar increase is noted in %BF 
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from (males 10.2 (4) to 21.2 (4.3)%, females 12 (4) to 22.3 (4.2)%). FFM/L2 
remained relatively constant during these two months (males 11.7 (1) to 12.7 
(0.8) kg/m2, females 11.5 to 12.1 (0.8) kg/m2). Females had increased FM/L3 and 
%BF at birth (p<0.001, p<0.001) and two months (p=0.046, p<0.001), and lower 
FFM/L2 at birth (p<0.001) and two months (p<0.001) compared to males (Table 
4.4.1). 
 
Figure 4.4.2: Sex-specific centile charts for fat mass/length3 (A and B), fat mass (C and D) and 
body fat percentage (E and F) in term infants. Note that these charts show normative data from 
days 0 to 4, and 49 to 86 days in this population. 
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Figure 4.4.3: Sex-specific centile charts for fat free mass (A and B), and fat free mass/length2 in 
term infants (C and D). Note that these charts show normative data from days 0 to 4, and 49 to 86 
days in this population. 
 
Body composition and anthropometric determinants of increased BMI at two 
years of age 
Complete data on body composition measurements at birth and two months and 
BMI at two years were available in 562 (267 female) participants. The mean 
(SD) BMI at two years was 16.6 (1.5) in males, and 16.4 (1.3) in females. Mean 
(SD) BMI z-score at two years for males and females was 0.64 (0.9) and 0.67 
(0.9) respectively.  
 
FM and FFM at birth explained 0.06 of the variance in BMI z-score at age two 
years. By two months of age, these measures explained up to 0.18 of this 
variance (Table 4.4.3). Correcting FM and FFM for length did not improve the 
overall explained variance in the linear regression model. Changes in body 
composition z-scores were also not strong predictors of BMI z-score at age two 
years. Weight and length z-scores at two months were marginally better at 
predicting BMI z-score at two years than body composition at two months 
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(R2=0.21). Weight z-score at two months was the strongest independent 
predictor of BMI at two years (R2=0.17), and compares favourably with FM/L3 
(R2=0.02 at birth, 0.14 at two months) or FFM/L2 (R2=0.06 at birth, 0.11 at two 
months). 
 
Table 4.4.3: Linear regression models for BMI z-score at two years. 
Models were generated using FM and FFM corrected for length, or not corrected for length. The 
predictive value of standard weight and length measurements were also used in a separate model. 
Explained variance (R2) of models using single variables at one timepoint  a, at two variables at 
one timepoint b or two variables at two timepoints c are presented separately. z-scores are sex- 
and age-specific. 
BMI z-score at 
2 years 
Estimate SEM 95% CI P value R2 
Corrected for Length:  
FM/L3 and FFM/L2 at birth and 2 months, for BMI at 2 years 
FFM/L2 z-score 
at birth 
0.107 0.037 0.035, 
0.18 
<0.001 0.06 a 
0.07 b 
0.19 c 
FM/L3 z-score at 
birth 
0.027 0.034 -0.041, 
0.094 
0.4 0.02 a 
FFM/L2 z-score 
at 2 months 
0.179 0.038 0.104, 
0.253 
<0.001 0.1 a 
0.17 b FM/L3 z-score at 
2 months 
0.241 0.035 0.172, 
0.31 
<0.001 0.11 a 
Not Corrected for Length: 
FM and FFM at birth and 2 months, for BMI at 2 years 
Fat Free Mass z-
score at birth 
-0.110 0.056 -0.12, 
0.099 
0.845 0.06 a 
0.06 b 
0.18 c 
Fat Mass z-score 
at birth 
0.001 0.038 -0.074, 
0.076 
0.981 0.03 a 
Fat Free Mass z-
score at 2 
months 
0.201 0.053 0.096, 
0.306 
<0.001 0.11 a 
0.18 b 
Fat Mass z-score 
at 2 months 
0.258 0.039 0.182, 
0.333 
<0.001 0.14 a 
Weight and Length at birth and two months, for BMI at 2 years 
Weight z-score 
at Birth 
0.128 0.059 0.013, 
0.244 
0.03 0.06 a 
0.08 b 
0.22 c 
Length z-score 
at Birth 
-0.130 0.052 -0.233, -
0.028 
0.013 0.01 a 
Weight z-score 
at 2 Months 
0.547 0.056 0.436, 
0.657 
<0.001 0.17 a 
0.21 b Length z-score 
at 2 Months 
-0.169 0.053 -0.273, -
0.065 
0.002 0.03 a 
 
 
At two years of age, 39 of these children (23 males, 16 females) had BMI z-
scores ≥ 2. Increasing z-scores for FM and FFM at birth and two months 
increased the odds of having a BMI ≥ 2 at two years of age. Increases in FM, 
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FM/L3 and weight z-scores at two months of age were associated with the largest 
increase in the odds of having an increased BMI at two years (Table 4.4.4). 
 
Table 4.4.4: The odds ratio (95% CI) of having BMI z-score ≥ 2 at two years for every unit 
increase in z-score of body composition measurements at birth and two months of age. 
FFM=Fat Free Mass, FM=Fat Mass, L=Length 
BMI z-score ≥ 2, at 2 years Odds Ratio 95% CI P 
FFM/L2 z-score at birth 1.36 1.02, 1.82 0.036 
FM/L3 z-score at birth 1.46 1.09, 1.96 0.012 
FFM/L2 z-score at 2 months 1.62 1.21, 2.16 0.001 
FM/L3 z-score at 2 months 2.5 1.83, 3.42 <0.001 
Body Fat % z-score at birth 1.38 1.03, 1.85 0.032 
Body Fat % z-score at 2 months 2.24 1.64, 3.04 <0.001 
    
Δ FFM/L2 z-score (birth to 2 months) 1.01 0.74, 1.38 0.95 
Δ FM/L3 z-score (birth to 2 months) 1.3 0.99, 1.7 0.06 
Δ Fat Mass z-score (birth to 2 months) 1.36 1.03, 1.8 0.032 
Δ Fat Free Mass z-score (birth to 2 
months) 
1.07 0.66, 1.71 0.79 
Δ  Body Fat % z-score (birth to 2 
months) 
1.28 0.98, 1.69 0.075 
Δ  Body Weight z-score (birth to 2 
months) 
0.88 0.54, 1.44 0.6 
    
Fat Free Mass z-score at birth 1.58 1.16, 2.15 0.004 
Fat Mass z-score at birth 1.52 1.13, 2.04 0.005 
Fat Free Mass z-score at 2 months 1.79 1.33, 2.41 <0.001 
Fat Mass z-score at 2 months 2.71 1.97, 3.72 <0.001 
    
Weight z-score at Birth 1.9 1.38, 2.63 <0.001 
Length z-score at Birth 1.34 1, 1.78 0.048 
Weight z-score at 2 Months 2.27 1.64, 3.13 <0.001 
Length z-score at 2 Months 1.31 0.98, 1.75 0.072 
 
4.4.5 DISCUSSION 
Here I describe reference data for body composition measured by ADP at birth 
and two months of age in a large cohort of infants. FM and FFM are influenced 
by length at birth and two months, and these analyses provide optimal indices for 
length that minimise this interaction. This study also describes reference charts 
for these new measures, which allow for the description of FM and FFM 
independent of length. 
 
Infants undergo a significant change in body composition over the first two 
months. There is a two-fold increase in mean FM/L3 and %BF, while FFM/L2 
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remains relatively constant. This demonstrates that, while the absolute FFM 
increases, it remains fairly constant relative to linear growth. In contrast, there is 
a disproportionate increase in FM. This increase in FM in the first two months of 
life has also been shown in other smaller studies579, 580 and the rate of increase in 
FM slows after this first two months579. A doubling of adiposity in healthy 
subjects, as demonstrated by FM/L3 or %BF in this study, has not been reported 
at any other period in postnatal life581. 
 
Rapid weight gain in early life may have significant implications for future 
health, particularly cardiometabolic risk568, 582-584, but it is not known if these 
associations are related to specific changes in body composition. It is possible 
that the reference charts provided in this manuscript may be used to determine if 
an infant’s FM/L3 or FFM/L2 is within the normal ranges. However, the clinical 
implications of FM/L3 or FFM/L2 outside of the normal range in the first two 
months of life are currently unknown and subject to further study. These 
parameters may be of particular relevance for monitoring children born small for 
gestational age (SGA)585, where rapid weight gain in the first two years is 
associated with increased abdominal fat and adiposity as well as reduced lean 
mass at four years of age586. Infants born SGA have decreased insulin sensitivity 
within the first two years of life, 586, 587 and this decreases over the following 
years in association with the rate of early weight gain587. It is possible that 
tracking changes in FM/L3 or FFM/L2 in these infants may represent an area for 
future research and intervention to decrease future cardiometabolic risk. 
 
In this study, we have investigated the utility of body composition measurements 
in the first two months in predicting obesity at two years. There is no accepted 
definition of obesity at two years of age, and it is possible that BMI at this age is 
not an ideal indicator of future cardiometabolic risk. We have shown that weight 
and length measurements at two months confer greater prediction of elevated 
BMI at two years than body composition measurements at two months, which 
may reflect a relatively constant pattern in weight and linear growth between two 
months and two years. The limited utility of BMI in early life is also shown by 
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studies that demonstrate BMI at one and two years of age being weaker 
predictors of obesity in adulthood, than BMI in later childhood and 
adolescence573, 588.  
  
Limitations in the utility of the reference data described in this study are related 
to the unknown effects of ethnic and societal influences on body composition 
during the first two months of life. This Irish birth cohort study includes a 
relatively homogeneous, stable population of infants of European ancestry born 
in a single hospital in one mixed urban/rural area in Ireland. In this population, 
the rate of exclusive breastfeeding at two months was low in comparison to 
many other populations, at approximately 30%. Feeding modality may affect 
body composition at this early age, and exclusively formula fed infants have 
been described to have increased FFM, but not necessarily FM, when compared 
with exclusively breastfed infants at four months580. These factors may limit the 
generalisability of these reference data. 
 
In conclusion, there are significant changes in adiposity in the first two months 
of life whereas FFM remains relatively constant when corrected for length. 
Although the clinical implication of this change in body composition is 
unknown, significant weight gain at this age confers increased future 
cardiometabolic risk and requires further investigation. The length correction 
indices, and reference data provided in this study contribute to our understanding 
of the changes in body composition occurring during this time, but do not 
increase our prediction of BMI at two years above standard weight and length 
measurements.  
 
4.4.6 CHAPTER CONCLUSION 
In Chapters 4.3 and 4.4, I have explored the use of ADP in describing body 
composition in infancy. I initially described and published reference data for 
%BF at birth, but subsequently developed new measures of reporting FM and 
FFM corrected for infant size. Given the relationship between nutritional status 
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and the GH / IGF axis (Chapter 4.2), I will investigate the relationship between 
these body composition indices and IGF-I and IGF-II production in the next 
chapter.  
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CHAPTER 4.5: CORRELATION OF INSULIN-LIKE GROWTH FACTOR-I 
AND –II WITH BODY COMPOSITION 
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4.5.1 INTRODUCTION 
In this chapter, I will bring together data and concepts from a number of previous 
chapters. Having reviewed the interaction between the GH / IGF-I axis and 
nutritional status (Chapter 4.2), described body composition in the first few days 
of life (Chapter 4.3), and developed a new size-independent index of FM and 
FFM in the first two months of life (Chapter 4.4), I will now determine if there is 
a relationship between body composition over the first two months and IGF-I 
and –II concentrations at birth. I will use the new IGF-I and –II measurements by 
LCMS described in Chapter 2.4 to explore this relationship. 
 
4.5.2 BACKGROUND 
IGF-I and –II play an important role in regulating fetal growth, as demonstrated 
by infants with IGF-I and –II signaling defects having significant prenatal 
growth failure152, 329. Regulation of IGF-I and -II in utero appears to be more 
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dependent on nutrition196 than GH. Infants with GHD have normal size at 
birth332, 589 whereas IGF-I and –II concentrations are reduced in intrauterine 
growth restriction590, and animal models show that IGF-I and –II expression are 
reduced in response to intrauterine nutritional deprivation591, 592. In early infancy, 
nutrition continues to play a major role in IGF-I production where formula 
feeding and high protein intake are associated with increased IGF-I 
concentrations299, 313, 437. 
 
Birth weight is often used as a proxy for adiposity, but these do not always 
correlate269, 270 and it is possible that IGF-I and –II concentrations are associated 
more closely with body composition than birth weight. Infants born SGA have a 
greater deficit in body fat than lean mass and have lower IGF-I concentrations267, 
suggesting that IGF-I levels may be more closely associated with body fat than 
lean mass at birth. Similarly, IGF-I levels at birth are associated with Ponderal 
index, a marker of adiposity221. At five years, IGF-I concentrations correlate 
more closely with FFM whereas IGF-II concentrations are associated with 
FM593. At eight years of age, IGF-I concentrations continue to correlate more 
closely with FFM594, 595, but may also be associated with adiposity594. These 
associations of IGF-I and –II with body composition parameters diminish during 
puberty595. 
 
IGF-I measurement may also be useful in assessing growth trajectories, but 
whether this can be used to predict changes in body composition is not known. In 
children born appropriate for gestational age, higher IGF-I concentrations at 
three months of age are associated with increased weight gain over the preceding 
three months299. Higher IGF-I concentrations at three months of age are also 
associated with increased linear growth over the following nine months, without 
an associated increase in adiposity301. This dynamic relationship between IGF-I 
concentrations and rate of growth is also seen at five years of age, where higher 
IGF-I concentrations are seen in children who had more weight gain over the 
first two years of life regardless of weight at the time of IGF-I measurement596.  
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There are limited data describing the association of IGF-I and -II concentrations 
with detailed body composition measurements at birth, or studying the predictive 
value of IGF-I and –II concentrations on subsequent dynamic changes on body 
composition. The aim of this study is to determine if IGF-I and -II measurements 
at birth are associated with body composition at birth, and the trajectory of body 
composition changes in the first two months of postnatal life. 
 
4.5.3 METHODS 
Children were enrolled in the Cork BASELINE birth cohort study at birth 
(ClinicalTrials.gov NCT: 01498965) between August 2008 and August 2011344 
(additional details in 2.4.3). Ethical approval was granted by the Clinical 
Research Ethics Committee of the Cork Teaching Hospitals. 
 
4.5.3.1 Body Composition assessment 
ADP (PEAPODTM Infant Body Composition System, Life Measurement Inc, 
Concord, CA)576 was used to measure body composition at birth and two 
months, as described in 4.3.4.2. 
 
Birth measurements were included if they occurred within the first four days of 
life and  two month measurements if they were taken between 49 and 86 days of 
life. In order to adjust FM and FFM for body size, FM/length3 (FM/L3) and 
FFM/L2 were calculated and converted to age- and sex-specific z-scores 
(Chapter 4.4)270. 
 
4.5.3.2 Sample collection and storage 
Umbilical cord samples were collected at birth. They were processed to serum 
within three hours of collection, and stored at -80oC until analysed. Samples 
were analysed at Quest Laboratories (NJ, USA) by LCMS, as outlined in 2.4.3.5. 
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4.5.3.3 Statistical Analysis 
The LCMS assay cannot detect IGF-I concentrations below 16 ng/ml or IGF-II 
concentrations below 32 ng/ml. Where samples had concentrations below these 
values, a concentration of 15 ng/ml for IGF-I or 31 ng/ml for IGF-II was 
assigned. Z-scores for FM/L3 and FFM/L2 were age- and sex-specific at birth and 
two months. The change in z-score between birth and two months was calculated 
by subtracting the age- and sex-specific z-score at birth from the two-month z-
score. 
 
Data analyses were performed using SPSS 21.0 (IBM, New York, USA). Mean 
(SD) were reported for normally distributed data and compared using Student’s 
independent sample T-tests. Linear regression analysis was used to evaluate the 
relationship between continuous variables. 
 
4.5.4 RESULTS 
There were 2137 infants enrolled in the Cork BASELINE birth cohort. Of these, 
105 were excluded from this study for prematurity, 932 did not have sufficient 
cord blood available for IGF measurement, and a further 499 did not have body 
composition measurement performed both at birth and two months. Complete 
measurements of IGF-I and –II at birth and ADP measurements at birth and two 
months of age were available in 601 term infants (317 male). Characteristics of 
these subjects are shown in Table 4.5.1. 
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Table 4.5.1: Characteristics of population. Unless otherwise stated, mean(sd) are presented. 
 Males Females All 
Number, n 317 284 601 
Gestational Age, weeks 40.2 (1.1) 40.2 (1) 40.2 (1.1) 
Birth weight, kg 3.57 (0.45) 3.49 (0.45) 3.53 (0.45) 
Weight at 2 months, kg 5.66 (0.68) 5.3 (0.57) 5.49 (0.66) 
Length at birth, m 0.51 (0.02) 0.5 (0.02) 0.5 (0.02) 
Length at 2 months, m 0.59 (0.02) 0.58 (0.02) 0.59 (0.02) 
     
IGF-I, ng/ml 49.6 (23.9) 56.6 (24.3) 52.9 (24.3) 
IGF-II, ng/ml 421.4 (98.1) 428.5 (103.7) 424.8 (100.8) 
    
FM/L3 at Birth, kg/m3 2.7 (1.2) 3.2 (1.2) 2.9 (1.2) 
FM/L3 at 2m, kg/m3 5.9 (1.5) 6.2 (1.4) 6 (1.5) 
FFM/L2 at Birth, kg/m2 11.8 (0.9) 11.5 (0.9) 11.7 (0.9) 
FFM/L2 at 2m, kg/m2 12.8 (0.8) 12.1 (0.8) 12.5 (0.9) 
    
Change in FM/L3 z-score from 
birth to 2-months 
0 (1.2) 0.1 (1.2) 0.05 (1.2) 
Change in FFM/L2 z-score 
from birth to 2-months 
0.04 (1) -0.02 (1.1) 0.01 (1) 
 
4.5.4.1. Association of IGF-I and –II levels at birth with body composition at 
birth 
Increased IGF-I concentrations were associated with higher FM/L3 and FFM/L2 
z-scores at birth (R2=-0.05, P<0.001 and R2=0.02, P=0.016 respectively) (Figure 
4.5.1). These associations were also seen separately in both sexes. IGF-II 
concentrations at birth were associated with FFM/L2 z-score at birth (R2=0.01, 
P=0.014) but not with FM/L3 z-score at birth (R2=0.002, P=0.3). When males 
and females were analysed separately, IGF-II concentration was only associated 
with FFM/L2 z-scores at birth in females (R2=0.02, P=0.034) and not males 
(R2=0.005, P=0.2). 
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Figure 4.5.1: Scatter-plot and linear regression comparing IGF-I (A and B) and –II (C and D) 
concentrations with age- and sex-corrected FM/L3 and FFM/L2 z-scores at birth. The associations 
between IGF-I concentration and FM/L3 and FFM/L2 z-scores and the association between IGF-
II concentration and FFM/L2 z-score at birth were significant. 
 
4.5.4.2. Association of IGF-I and –II at birth with body composition 
trajectory over the first 2 months 
FM/L3 and FFM/L2 z-scores at two months were not associated with IGF-I 
(R2=0.001, P=0.4 and R2<0.01, P=0.8 respectively) or IGF-II (R2=0.002, P=0.3 
and R2<0.002, P=0.3 respectively) concentrations at birth (Figure 4.5.2). This 
indicates that body composition at two months was not predicted by IGF-I or –II 
concentrations at birth. Separate analysis in males and females showed that there 
was also no sex-specific association. 
 
However, the change in FM/L3 and FFM/L2 z-score was associated with IGF-I 
concentrations at birth and the change in FM/L3 was associated with IGF-II 
concentration at birth. Higher IGF-I and/or IGF-II concentrations were 
associated with a reduction in FM/L3 z-score between birth and two months, 
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although the association was stronger for IGF-I than for IGF-II concentrations 
(R2= 0.04, P<0.001, and R2=0.007, P=0.04 respectively). When males and 
females were analysed separately, IGF-II concentrations at birth were predictive 
of changes in FM/L3 in females (R2=0.03, P=0.006) but not males (R2<0.001, 
P=0.8) (Table 4.5.2). 
 
IGF-I concentrations at birth were associated with changes in FFM/L2 in males 
(R2<0.036, P=0.001) but not females (R2<0.007, P=0.17). 
 
 
Figure 4.5.2: Scatter-plot and linear regression comparing IGF-I and –II concentrations at birth 
with age- and sex-corrected FM/L3 and FFM/L2 z-scores at 2 months. 
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Table 4.5.2: The relationship between sex- and gestational age-corrected FM/L3 and FFM/L2 z-
scores at birth and years, with IGF-I and IGF-II concentrations at birth. For this analysis, IGF-I 
and –II are the dependent variables and FM/L3 or FFM/L2 measures are independent variables. 
 IGF-I IGF-II 
 R2 Regression 
coefficient 
(SEM) 
p R2 Regression 
coefficient 
(SEM) 
p 
Males 
FM/L3 z-score at 
birth 
0.048 5.04 (1.26) <0.001 0 0.37 (5.3) 0.95 
FM/L3 z-score at two 
months 
0.001 -0.56 (1.32) 0.67 0 -1.06 (5.42) 0.85 
FFM/L2 z-score at 
birth 
0.025 3.85 (1.35) 0.005 0.005 7.24 (5.58)  0.2 
FFM/L2 z-score at 
two months 
0.001 -0.8 (1.36) 0.56 0 0.07 (5.56) 0.99 
Change in FM/L3 z-
score from birth to 
two months 
0.04 -4.12 (1.09) <0.001 0 -1.02 (4.56) 0.82 
Change in FFM/L2 z-
score from birth to 
two months 
0.036 -4.52 (1.32) 0.001 0.005 -6.96 (5.5) 0.21 
       
Females 
FM/L3 z-score at 
birth 
0.047 5.26 (1.42) <0.001 0.008 9.04 (6.19) 0.14 
FM/L3 z-score at two 
months 
0.004 -1.52 (1.4) 0.28 0.012 -11.1 (6) 0.07 
FFM/L2 z-score at 
birth 
0.02 3.35 (1.4) 0.016 0.016 12.67 (5.95) 0.034 
FFM/L2 z-score at 
two months 
0.004 1.53 (1.45) 0.29 0.009 9.71 (6.19) 0.12 
Change in FM/L3 z-
score from birth to 
two months 
0.05 -4.48 (1.1) <0.001 0.03 -13.49 
(4.92) 
0.006 
Change in FFM/L2 z-
score from birth to 
two months 
0.007 -1.8 (1.3) 0.17 0.001 -3.46 (5.62) 0.54 
       
ALL 
FM/L3 z-score at 
birth 
0.05 5.1 (0.95) <0.001 0.002 4.23 (4.03) 0.29 
FM/L3 z-score at two 
months 
0.001 -0.87 (0.97) 0.37 0.003 -5.64 (4.02) 0.16 
FFM/L2 z-score at 
birth 
0.024 3.7 (0.97) <0.001 0.01 10 (4.1) 0.014 
FFM/L2 z-score at 
two months 
0 0.3 (1) 0.76 0.002 4.62 (4.1) 0.27 
Change in FM/L3 z-
score from birth to 
two months 
0.04 -4.17 (0.79) <0.001 0.007 -6.9 (3.35) 0.04 
Change in FFM/L2 z-
score from birth to 
two months 
0.019 -3.21 (0.94) 0.001 0.003 -5.25 (3.9) 0.18 
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4.5.5 DISCUSSION 
This study has demonstrated the relationships between IGF-I and -II 
concentrations at birth and neonatal body composition in a large well-defined 
cohort. Higher IGF-I concentrations at birth are associated with increased 
adiposity and lean mass, while increased IGF-II concentrations are associated 
with increased lean mass in females only. IGF-I and –II concentrations at birth 
are not predictive of body composition parameters at two months, however they 
are predictive of rates of change in body composition during the first two months 
of life. Lower IGF-I concentrations at birth are strongly associated with an 
increase in adiposity in both sexes, but only an increase in lean mass in males. 
Low IGF-II concentrations at birth are associated with increased adiposity in 
females only. 
 
The relationship between IGF-I concentration at birth and adiposity is not 
surprising. There is a strong association between IGF-I concentrations and birth 
weight282, 349, as well as with nutritional status196. IGF-II is an important prenatal 
growth factor. Chorionic villi expression of IGF2 mRNA is associated with birth 
weight597 and paternally inherited IGF2 mutations are associated with growth 
restriction329. Animal models also support this important role of IGF-II in 
regulating prenatal growth598. It is possible that IGF-II is more critical to growth 
prior to the third trimester352, 353, and this may explain the absence of association 
between body composition and IGF-II concentrations at birth. 
 
Although IGF-I and –II concentrations at birth are not directly associated with 
body composition parameters at two months, there is an association with 
trajectory of accumulation of adiposity and lean mass. Significant changes occur 
in body composition during the first three months of life, with a two-fold 
increase in FM corrected for length. Lean mass remains relatively stable during 
this time270. The inverse relationship between IGF-I concentration at birth and 
the change in adiposity may simply reflect the early “catch up” accumulation of 
body fat in infants with relative intrauterine growth restriction at birth. The same 
inverse association was seen between lean mass and IGF-I concentration at birth, 
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indicating that this “catch-up” is not limited to adiposity but also occurs in lean 
mass.  
 
The consequences of this relationship may extend to the interplay between 
intrauterine nutritional status, the GH / IGF axis and the postnatal fetal 
programming of adult disease. Pregnancies complicated by limited access to 
nutrition are associated with increased IGF-I concentrations in adulthood, and it 
is hypothesised that chronic IGF suppression in utero results in an irreversible 
“overshoot” of this axis in later life599. Although we do not have IGF-I or –II 
concentrations measured in these infants at two months, it is possible that the 
rebound effect of chronic intrauterine suppression of these growth factors is 
demonstrated this early with rapid accumulation of adiposity, and possibly lean 
mass. Children who have rapid early weight gain have increased BMI and insulin 
resistance as early as eight years of age600, and SGA children with rapid early 
weight gain have persistent increases in adiposity when compared with similar 
weight control children who were not born SGA601. Although the mechanisms 
for these persistent metabolic complications are unknown, it is possible that low 
IGF-I concentration at birth is a biomarker for future risk. 
 
We have shown sex-specific associations between IGFs and early trajectories in 
body composition. Over the first two months of life, increases in adiposity are 
inversely associated with IGF-II concentrations at birth in females but not males 
whereas, conversely, increases in lean mass over the first two months were 
inversely associated with IGF-I concentrations at birth in males and not females. 
At birth, females have more body fat than males despite lower birth weight269 
and there are gender specific differences in visfatin and high molecular weight 
adiponectin concentrations at birth in SGA infants, reflecting gender differences 
in body fat distribution267. There are also differences in the GH / IGF axis at 
birth with females having higher IGF-I concentrations, and GH secretion may 
also be more sensitive to negative feedback from IGF-I concentrations in 
females254. Further complicating interpreting our data is the onset of mini-
puberty within the observed two-month window in many infants602, 603, and this 
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increased exposure to androgens may confound the changes in lean mass that we 
have described. 
 
Strengths of this study include the large, well-defined, relatively homogenous 
study population. All children were term, healthy and Irish, making confounding 
factors unlikely to contribute to these findings. The large number of children 
with available body composition measurement is also unique for investigating 
these relationships. IGF-I and –II measurement by standard RIAs can be subject 
to assay interference by IGF binding proteins. However, LCMS was used in this 
study and this technique is not subject to this interference from binding 
proteins238, 241. A weakness of the study is the lack of available IGF-I and –II 
measurements at two months, to further investigate the hypothesis that IGF-I and 
-II may be useful biomarkers of metabolic risk during catch-up growth. Also, 
this study only included term infants and it is not known if the association is 
similar for preterm infants. Data were not available for the entire birth cohort, 
and it is not known if this introduced bias to our analysis.  
 
4.5.6 CHAPTER CONCLUSION 
IGF-I concentrations at birth are associated with adiposity and lean mass at birth 
and the trajectory of FM and FFM accumulation over the first two months. IGF 
measurement may have a role in evaluating body composition at birth and 
determining risk of rapid early changes in body composition and future 
metabolic risk. Sex differences in the association of IGF-I and -II concentrations 
at birth with body composition trajectories over the first two months of life exist 
and require further investigation.  
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5.1: OVERVIEW 
 
5.1.1 MAIN FINDINGS OF THIS RESEARCH 
In this thesis, I have explored a number of new approaches to improving the 
diagnostic evaluation of children with short stature, and investigating disorders 
of the GH/IGF-I axis. I have also described reference data for body composition 
in infancy and explored how this relates to IGF-I and –II concentrations at birth. 
Figures 5.1 and 5.2 provide a pictorial overview of the components of the 
clinical evaluation that I have studied, and demonstrates how my work 
contributes to the current clinical approach to the child with short stature or poor 
growth. The main findings of each section of my thesis follow. 
 
Figure 5.1: The current clinical approach to disorders of the GH/IGF-I axis 
 
 
Figure 5.2: The contributions of this thesis to the established literature supporting the current 
clinical approach to disorders of the GH/IGF-I axis 
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5.1.1.1 Section 1: The Diagnosis of GHD in Childhood 
Here, I explored modifications to the GHST in an effort to improve the 
specificity of the evaluation of children with suspected GHD. In children 
undergoing GHST, serial GH measurement after IVP and prior to administering 
a GH secretagogue in the context of a GHST is worthwhile. This will more than 
double the number of children who are considered GH sufficient based on this 
test206. Where infants are being evaluated for unexplained hypoglycemia with a 
diagnostic fasting study, modifying the study to include serial GH measurements 
after glucagon administration will increase the specificity of the test for GHD 
from 10% to 65%604, 605. 
 
5.1.1.2 Section 2: Mass Spectrometry and IGF-I Measurement 
In Section 2, I have described that the reported normal concentrations of IGF-I in 
the first 18 months of life vary considerably in all reported studies that describe 
this measurement in healthy infants124. I considered assay interference as a 
possible explanation for this discrepancy, and then described reference data for 
IGF-I and -II concentrations at birth using a new LCMS assay. Using this assay, 
IGF-I and –II concentrations at birth were associated with weight, length, and 
OFC at birth. Low IGF-I concentrations at birth were associated with accelerated 
increases in weight and OFC z-scores over the first two months. 
 
5.1.1.3 Section 3: Genetic Approaches to Disorders of the GH/IGF-I Axis 
In Section 3, I have shown that despite GRP94’s putative mechanism for 
affecting IGF-I production and supporting lab-based data, heterozygous 
mutations that affect protein function do not correlate with reduced IGF-I 
concentrations or short stature in the normal population606. I have also 
demonstrated that it is possible to use the EHR to identify children with a clinical 
phenotype consistent with IGF-I resistance, and used this approach to identify 
one child with a possibly pathogenic mutation of the IGF-IR. 
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5.1.1.4 Section 4: Nutrition and the GH/IGF-I Axis 
In Section 4, I have described normal body composition at birth269 and within the 
first two months of life270. Despite increased weight at birth, males have less fat 
than females269. When corrected for length, adiposity doubles while lean mass 
remains stable during the first two months of life270. Higher IGF-I concentrations 
at birth are associated with increased adiposity and lean mass. IGF-I and –II 
concentrations at birth are associated with rates of change in body composition 
in the first two months of life. 
 
5.1.2 SUMMARY OF IMPACT ON MY CLINICAL CARE 
This research has already influenced my clinical practice, and my studies have 
changed the way in which I interpret the results of many of the diagnostic tests 
used in children with unexplained short stature. 
 
Clinically, I now frequently request random GH concentrations when measuring 
IGF-I levels in children with short stature for whom I am considering GHD as a 
possible diagnosis. While low or undetectable GH concentrations do not 
necessarily warrant further investigation, phlebotomy can be a stimulus for GH 
secretion206 and, occasionally, reassuringly high GH concentrations can be seen 
after phlebotomy in GH sufficient children. Similarly, poor nutrition can cause 
GH resistance196 and may be associated with a random GH level being high in a 
child with a low IGF-I concentrations. Of course, other causes of GH resistance 
in addition to undernutrition should also be considered in this setting. This 
approach may help to redirect the diagnostic evaluation away from GHD and 
prevent unnecessary GHST and/or GH treatment. 
 
In addition to changes to my approach to testing for GH reserve, I also have also 
generated data to support interpreting IGF-I concentrations in infancy. This 
research has prompted me to receive a number of “second opinion” clinical 
referrals. One of these cases, in particular, highlights how this research has 
influenced my decision-making. I recently received a second-opinion referral of 
an 11-month old patient. He was born at normal birth weight following an 
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uncomplicated pregnancy and delivery, and had been well until five months of 
age. Over the following three months, for unexplained reasons, he did not gain 
weight and started to show some motor developmental delay with central 
hypotonia. Following dietetic and physiotherapy support, his nutritional status 
improved and his weight and development now resembled that of a normal 11-
month old. 
 
His pediatric endocrinologist measured IGF-I concentrations as part of his 
otherwise normal diagnostic laboratory evaluation. His IGF-I concentration was 
measured by Quest’s LCMS assay and was reported as undetectable. His IGFBP-
3 concentration was within the normal range. His endocrinologist wanted to 
perform an MRI of his pituitary to rule out pituitary malformations, and also 
requested adrenal stimulation testing prior to proceeding to pituitary imaging 
under general anesthesia. 
 
The work undertaken in this thesis led me to recommend an alternative approach 
on this occasion. Firstly, the reference data currently used by Quest in reporting 
IGF-I concentrations is based on samples from 43 children under one year of age 
and using a chemoluminescent immunoassay rather than LCMS318. I have shown 
wide variability in the reported IGF-I levels in children under one year of age124. 
I also know that many normal infants at birth have undetectable IGF-I by the 
LCMS assay (Chapter 2.4). Poor nutrition will also increase the likelihood of 
undetectable IGF-I concentrations even further196. This child’s linear growth was 
now reassuring, developmental delay had resolved, and nutritional status was 
improving. Thus, the only indication for imaging was now an undetectable IGF-I 
concentration. He did not have hypoglycemia605 or micropenis. I repeated the 
IGF-I measurement following a further two months of improved nutrition. He 
remained well during this time, continued to have normal growth, and his IGF-I 
measurement was improved at 29 ng/ml (Z-Score -1). He did not undergo 
general anaesthesia and MRI pituitary. 
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5.1.3 SUMMARY OF CONTRIBUTION TO THE MEDICAL LITERATURE AND 
POSSIBLE FUTURE DIRECTIONS 
The studies included in this thesis have already led to ten peer-reviewed 
publications (Appendices A, B, D, F, G, H, J, K, L, N)62, 124, 196, 206, 211, 269, 270, 604, 
606, one book chapter (Appendix C)607 and five presentations at international 
meetings (Appendices E, I, M, O, and P). An additional two manuscripts were 
submitted for publication at the time of thesis completion (Chapters 2.4 and 4.5). 
 
5.1.3.1 Section 1 
The limitations of GHST in diagnosing GHD are well established, and the recent 
guidelines for GH treatment in GHD strongly recommend against using the 
GHST as the sole diagnostic criterion of GHD72. These guidelines also refer to 
the difficulty in differentiating children with partial GHD from children with 
normal GH secretion, and recommend sex-steroid priming in select patients to 
improve the diagnostic yield. In Section 1 of this thesis, I have described two 
studies that may further improve the diagnostic yield of the GHST. IVP may be 
utilised as an additional stimulus to further improve the diagnostic utility of this 
test. 
 
Prior to my study of serial GH measurement after glucagon administration in the 
context of a fasting study, the two most helpful studies in this area confirmed 
that GH concentrations during spontaneous hypoglycaemia is poorly specific for 
GHD12 and spontaneous hypoglycaemia is associated with a blunted GH 
response when compared to insulin induced hypoglycaemia185. I have developed 
and studied a way to integrate a GH test into the diagnostic evaluation of 
children with unexplained hypoglycaemia. This can improve the specificity of 
the fasting study test for GHD. This approach has been adopted as routine care at 
CHOP, the largest referral centre for children with hypoglycaemia in North 
America. Potential future modifications for this approach might include using 
intramuscular, rather than intravenous, glucagon. 
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5.1.3.2 Sections 2 and 4 
In Section 2, I have described assay variability in IGF measurement and explored 
the utility of a new LCMS assay for IGF-I and –II. Variation between commonly 
used immunoassays is a significant issue260. Although this LCMS assay has 
already been shown to be unaffected by IGFBP interference238, 241, we have not 
demonstrated that LCMS provides a clinically relevant improvement in the 
diagnostic utility of the test. Future studies in this area will need to directly 
compare IGF measurement between this assay and commonly available 
immunoassays. 
 
The observation that low IGF-I concentrations at birth are associated with weight 
gain (Chapter 2.4) and increases in length adjusted-FM and –FFM over the 
subsequent two months is potentially significant. Rapid weight gain in early 
infancy can be associated with cardiovascular morbidity586, 608-610, premature 
adrenarche611, 612, polycystic ovarian syndrome613, visceral fat excess609 and 
obesity601. This appears to be particularly concerning in children with prenatal 
growth restriction. Although the mechanisms for these associations are not clear, 
it is possible that the future management of children at risk of developing these 
complications may include monitoring the rates of change in body composition. 
 
My reference data may provide a guide in determining whether an infant’s 
FM/L3 or FFM/L2 is within the normal range and this may be a parameter to 
follow. Similarly, low IGF-I concentration at birth may identify children at risk 
of excessive ‘catch-up’ growth and identify infants for closer observation. IGF-I 
levels have been suggested as a marker of the nutritional state, so it is also 
possible that serial IGF-I measurement in infancy may have a role in monitoring 
weight gain and evolving metabolic risk in infancy. In order to investigate this 
further, there may be utility in studying serial IGF-I and –II concentrations 
during the first year of life, and determining if these are useful markers for 
changes in body composition during infancy. 
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The gender-specific relationships between IGF-I and –II and body composition 
trajectories add to the data on differences between metabolic parameters in males 
and females at birth267, and may be a source of further study. We did not find a 
strong association for IGF-II concentrations at birth with body composition or 
growth, and the role of IGF-II in infancy warrants further study. 
 
5.1.3.3 Section 3 
As the cost of genetic testing reduces and this diagnostic modality becomes more 
accessible, genetic studies may be performed earlier in the evaluation of children 
with short stature in the future. There are known monogenic causes of short 
stature358, but previously undescribed variants  provide a diagnostic dilemma 
when found. A mutation in GRP94, for example, had a possible mechanism for 
causing short stature, and supporting laboratory data, but did not impact upon 
adult height when studied on a population level. Future studies into the P300L 
variant may explore effects on glucose homeostasis or immune function. Our 
research in novel mechanisms for IGF-I resistance will continue through in vitro 
studies of the mutation that we have identified. We have also developed a 
mechanism for collaboration in genetic studies of growth between three of the 
largest children’s hospitals in the US, and may explore other rare growth 
phenotypes in the future. 
 
5.1.4 MY FUTURE DIRECTIONS 
This thesis has laid the groundwork for current research studies of mine that are 
in various stages of development. I currently have a “Junior Investigator Pilot 
Grant” award to study the potential role of body composition, muscle strength, 
bone density and cardiovascular parameters in predicting the clinical response to 
GH treatment in paediatric patients (5.1.4.1). Furthermore, I am a member of 
active research collaboration between CHOP and CCHMC looking to identify 
novel genetic aetiologies of short stature in children (5.1.4.2). 
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The hypercalcaemia and vitamin D intoxication study mentioned in Chapter 2.3 
also opened up another avenue of research for me (5.1.4.3). Specifically, I am 
now investigating a potential role for rifampicin in the management of 
hypercalcaemia in children and adults with biallelic inactivating CYP24A1 
mutations614. I have also described a novel clinical phenotype of hypercalcaemia 
in children on a ketogenic diet615.  
 
5.1.4.1 Growth hormone sensitive short stature in childhood; A novel 
multisystem approach to diagnosis and characterising the effects of 
treatment 
GH mediates many non-growth related effects that guide treatment in adult 
GHD, but these are largely ignored in the diagnosis of pediatric GHD and in the 
monitoring of treatment efficacy616. The multisystem phenotype of adult GHD is 
well described. This includes reductions in lean body mass, exercise tolerance, 
fractional shortening of cardiac myocytes and high-density lipoprotein (HDL) as 
well as increases in fat mass, central adiposity, intima media wall thickness, 
triglycerides and low-density lipoprotein617. The effects of GH treatment on each 
of these systems may be dose-dependent618, but whether or not adverse effects of 
partial deficiency on each of these systems correlates with severity of deficiency 
in children is not known. Given the poor sensitivity and specificity of the GHST 
for GHD (Section 1), these may represent additional tools for the diagnosis of 
GHD. 
 
The primary objective of this funded study is to utilise many of the known 
physiological effects of GH to determine if these could be used in combination to 
improve the identification of children who would respond to GH treatment with 
a significant increase in linear growth. Secondary objectives are to determine if 
1) early changes in these parameters will predict growth response in the first year 
of treatment and 2) GH treatment results in favorable effects on cardiometabolic 
risk, bone density, body composition, cardiac function and vascular endothelial 
function in pediatric patients. This successful grant application is shown in 
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Appendix Q. At the time of thesis submission, three subjects have been recruited 
to this study. 
 
5.1.4.2 Identifying and studying the novel variants in the GH/IGF-I axis 
We plan to build on our established genetics of growth collaboration between 
CHOP, BCH and CCHMC. We have developed processes for identifying 
children with rare growth phenotypes at CHOP through automated searches of 
the EHR. Similar processes are now in place at CCHMC and BCH, and a 
mechanism for sharing data has been established through a research 
collaborative agreement and parallel IRB approved research protocols. The 
development of this infrastructure has overcome a significant barrier to prior 
collaborative growth research. 
 
We have now applied to the National Institute for Health for funding to continue 
this work. This R01 grant application was under review at the time of submission 
of this thesis (Primary Investigator: Dr Andrew Dauber). 
 
5.1.4.3 Rifampicin in patients with homozygous CYP24A1 mutations 
My study of unexplained elevated 1,25(OH)2D concentrations in vitamin D 
intoxication (Chapter 2.3)211 was the start of my research path in calcium 
metabolism under the mentorship of Professor Michael Levine. 
 
We have published a case series describing a novel hypercalcemia phenotype in 
patients on the ketogenic diet615, which was the first study to describe this 
association. We have also published a novel approach to a rare but untreatable 
form of hypercalcaemia, namely homogenous inactivating mutations of 
CYP24A1. Incidentally, our collaborator, Dr Andrew Dauber was one of the first 
to describe this rare condition619. 
 
Dr Levine and I have described the potential of rifampicin to treat 
hypercalcaemia in these patients614. The National Institute for Health has funded 
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an R01 grant to prospectively study this therapeutic approach (Principal 
Investigator: Michael Levine) and this began in July 2017. 
 
5.1.5 PERSONAL REFLECTION 
This has been a journey of personal growth, failures and successes. All of the 
preceding chapters and studies describe completed projects, most of which have 
made it all of the way to peer-reviewed publication. However, each success has 
been built on a foundation of numerous failures. I will summarise the most 
significant of these disappointments before reflecting on my personal growth. 
 
5.1.5.1 Genetic markers of Growth Response to GH treatment 
In the early stages of this thesis, an opportunity arose to collaborate with Dr 
Andrew Dauber, the Director of the Growth Center at CCHMC. He had 
performed whole exome sequencing on a large number of patients who had GHD 
and were treated with GH. The Center for Applied Genomics at CHOP has 
processed over 100,000 genomes in pediatric patients with detailed clinical 
phenotypes. My aim was to identify children from this database who had been 
treated with GH, and to combine our data with Dr Dauber’s cohort. This may 
have been an important step towards identifying genetic markers of GH 
responsiveness. 
 
However, after months of searching this database, it became apparent that there 
were not enough subjects recruited to the CHOP genetics study who had been 
treated with GH. Furthermore the clinical data available on the small number of 
patients were not sufficiently detailed to contribute to Dr Dauber’s well-
characterised cohort. This collaboration was abandoned, but this led to further 
work with Dr Dauber (Chapter 3.3 and 5.1.4.2). 
 
5.1.5.2 Growth response to GH treatment in type 1 diabetes 
Poor glycemic control in children with type 1 diabetes mellitus (T1D) attenuates 
peak height velocity and may delay the onset of puberty620. Height at onset of 
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diabetes, glycemic control and duration of diabetes influence final adult 
height621, 622. Thus, children with T1D are at an increased risk of impaired 
growth and this may lead to an evaluation for possible GHD. When compared 
with controls, children with T1D have lower IGF-I concentrations623, 624. This is 
most prominent in children without residual beta cell function and with poor 
glycaemic control624. In this context, it is possible that loss of negative feedback 
of IGF-I on the anterior pituitary results in increased GH production, which may 
contribute to increased insulin resistance and the cycle may continue with 
increased hyperglycemia.625 
 
In children with T1D, there is the additional complication of the effect of GH 
treatment on glycaemic control. In a German study including 2-year follow up of 
21 children with T1D treated with GH, there was an increase in median 
haemoglobin A1c (7.3 to 8.1%) and total daily insulin dose (0.7 to 1.1 u/kg/day). 
Height SDS did not change significantly during those two years of treatment (-
2.3 to -2). 
 
With this in mind, I hypothesised that a large number of children with T1D were 
being misdiagnosed as having GHD and receiving GH treatment. I also thought 
that a) it is likely that the growth response to treatment was poor as most of these 
children don’t have GHD but do have GH resistance and b) GH treatment has 
additional complications in these patients due to the negative effect on glycaemic 
control. In order to test this hypothesis, I received funding from the Diabetes 
Center at CHOP to perform a retrospective review of the EHR to identify 
children with T1D treated with GH. The aim of the study was to determine if 
children with T1D who meet clinical criteria of GHD have a growth response to 
GH treatment that is similar to children without GHD. 
 
Preliminary search of the EHR indicated that there were more than 100 children 
with diabetes who were treated with GH and this fuelled my enthusiasm for this 
project. However, once all of the data were extracted from the EHR, it became 
apparent that the EHR had miscoded many children with diabetes insipidus as 
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having T1D. Only nine children with T1D were treated with GH and, of those, 
only four had complete data available for review. I decided that this was not 
sufficient to test the hypothesis, and the study was abandoned. 
 
5.1.5.3 GRP94 
The original title for this thesis was “Altered function in Glucose Regulated 
Protein 94: A novel mechanism of intra-uterine growth restriction and primary 
IGF-I deficiency”. However, when I started to learn the laboratory skills to 
investigate this further, Dr Marzec had already completed many studies 
describing the pathogenicity of the most common polymorphism (P300L, 
Chapter 3.2). I had begun to work on describing the clinical phenotype, and 
noted that the laboratory findings did not result in a significant effect on growth 
or IGF-I production. There were a number of rarer genetic mutations identified 
in the grp94 gene in these populations that could have been investigated further 
with in vitro and population studies. However, I considered it likely that further 
research on this particular gene would not result in significant clinically relevant 
data. I turned my attention to clinical research, which is my main research 
interest and redirected my PhD under the supervision of my mentorship team. 
 
5.1.6 PERSONAL GROWTH 
Over the past three years, I have developed a number of important research skills 
and attained many of the necessary tools for a career in clinical research. For 
this, I am grateful to my mentorship team for their guidance, support and advice. 
 
In order to gain the necessary research skills, I have attended courses at the 
University of Pennsylvania in biostatistics, data management and in reviewing 
medical literature. I have also attended courses at CHOP in good clinical practice 
for research trials and responsible conduct of research, as well as seminars 
hosted by the IRB to gain insight into the process of ethical review at CHOP. 
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Through direct mentorship, I have been guided in hypothesis development, data 
management, data analysis and manuscript preparation. My biggest challenge 
has been performing studies with clear aims and ensuring that the data were 
directly focused on the central aim of my study. I am especially grateful to Prof 
Grimberg and Dr Murray for helping me to improve in this area. The guidance 
that I have received in attaining the necessary research skills for success has been 
invaluable to me. I have already started to use these skills in mentoring more 
junior trainees as the senior author on their research626, 627. In addition to the 
generic research skills that I have learned from my mentors, I hope to have 
absorbed some of their patience, willingness to teach and accessibility. 
 
I have also learned the importance of carving out my own research path and to 
follow directions that I believe to be both interesting and important. The most 
difficult part of this PhD was the decision to redirect my studies away from the 
research laboratory and towards clinical studies. Professor Argon had provided 
me with a lot of support in developing laboratory skills and writing grant 
applications. I am extremely grateful to him, both for providing me with this 
opportunity and, more importantly, for supporting my decision to redirect my 
research away from the laboratory. I believe that this decision has been 
responsible for the success that my research has brought and ensured that I 
continued to enjoy this experience. 
 
The most important lesson learned in the past few years, however, is the value of 
strong and diverse mentorship and collaboration. Without the selfless support of 
all of the mentors listed in the acknowledgements section of this thesis, I would 
not have had the opportunity to undergo this personal development or to 
contribute to the field of growth research. The friendships that I have built in the 
course of completing this thesis will be invaluable as I progress through my 
career. 
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I also recognise that the sacrifices required for me to complete this thesis were 
not just made by me. My wife and children have also been important members of 
my team, and this work would not have been possible without their support. 
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Hawkes CP, Grimberg A. Measuring growth hormone and insulin-like growth 
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Appendix G:  
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Appendix I:  
Hawkes CP, Murray DM, Kenny LC, Kiely M, Sikora K, Caulfield MP, Argon Y, 
Reitz RE, McPhaul MJ, Grimberg A. Measurement of IGF-I and –II 
concentrations at birth by mass spectrometry in a large birth cohort: correlation 
with anthropometry. Pediatric Endocrine Society, Washington DC. September 
2017 (Poster Presentation) 
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Gender- and Gestational Age-Specific Body Fat Percentage at Birth. Pediatrics. 
2011;128(3):E645-E51. 
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Appendix M:  
Hawkes CP, O’B Hourihane, J, Kenny LC, Irvine AD, Kiely M, Murray DM. 
Body Composition at birth; normative values. American Pediatric Society / 
Society for Pediatric Research. Denver, May 2011. European Society for 
Paediatric Research, Newcastle, Sept 2011. 
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1.  To describe %BF within the first 4 days of life, in infants 
born after 36 weeks’ gestation 
2.  To detail the effect of infant sex and gestation on %BF 
Data collected as part of an ongoing  pregnancy/birth cohort 
study; the SCOPE/BASELINE study.  
1.  SCOPE pregnancy study: Recruits primiparous, low risk 
women at 15±1 weeks’ gestation.  
2.  BASELINE birth cohort: The maternal-fetal dyads of the 
SCOPE study are recruited to the BASELINE birth cohort 
study 
Infants have %BF measured within 4 days of life using the 
PEAPOD™. 
 
Included in this study are infants between 36 and 41+6 weeks’ 
gestation, born between March 2009 and October 2010. 
793 recruited infants were delivered during study period.  Of these 12 were outside of our gestational range, and 31 
did not have body composition measured within 4 days. Demographic data is displayed on Table 1.  
 
Mean(SD) body fat at birth was 10.8(4.2)%, but this varied significantly with sex and gestational age (Table 2). In 
each gestational age category males had lower mean %BF than females, with the difference increasing with gestational 
age (Table 3). This decreased %BF occurred despite increased birth weight and fat free mass 
 
On stepwise linear regressional analysis, gestational age remained a significant association (R=0.193, p<0.001) when 
corrected for maternal BMI at 16 weeks’ gestation, socio-economic group, maternal age, and cigarette consumption. 
Maternal BMI at 16 weeks’ gestation also was significantly and consistently associated with %BF at birth. 
 
1.  %BF increases with gestational age from 36 to 41+6 weeks’ gestation. 
2.  Females have a greater %BF at birth than males, despite lower 
birthweight. 
In utero growth has an immediate and far-reaching influence on 
health 
 
Assessment of neonatal adiposity is difficult, as birth weight 
centiles and skin fold thickness do not correlate well with body 
composition. 
 
The PEAPOD™ (Life Measurement Inc, Concord, CA) uses air 
displacement plethysmography to measure body fat percentage 
(%BF) in infants (Fig 1). It has been shown to provide reliable 
and accurate measurements of %BF. 
Table 1: Demographic Data of the Study Population, 
categorised by Gestational Age 
aNew Zealand Socioeconomic Index          bOne –way ANOVA 
Table 2:Male and Female Measurements at Different Gestational Ages  
aIndependent Sample t-test     bANOVA 
*Denotes variables measured by PEAPOD 
Table 3: Centiles for %BF grouped by Gestational Age and Sex 
Fig 1: Body Composition measurement using the PEAPOD™ 
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Appendix N:  
Hawkes CP, Zemel BS, Kiely M, Irvine AD, Kenny LC, O’B Hourihane J, 
Murray DM. Body Composition within the First 3 Months: Optimized Correction 
for Length and Correlation with BMI at 2 Years. Horm Res Paediatr. 
2016;86(3):178-187. 
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Appendix O:  
Hawkes CP, Zemel BS, Kiely M, Irvine A, Kenny LC, O’B Hourihane J, Murray 
DM. Body composition in the first 2 months of life – optimized correction for 
length, reference data and correlation with obesity at 2 years. American 
Pediatric Society / Society for Pediatric Research. Baltimore, May 2016 
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Appendix P:  
Hawkes CP, Zemel BS, Kenny LC, Kiely M, Sikora K, Caulfield MP, Argon Y, 
Reitz RE, McPhaul MJ, Grimberg A, Murray DM. The relationship between 
IGF-I and –II and body composition at birth and over the first 2 months of life. 
Pediatric Endocrine Society, September 2017 (Poster Presentation) 
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PROJECT DESCRIPTION 
 
ABSTRACT: 
Current guidelines for evaluating children with possible growth hormone deficiency (GHD) 
include monitoring growth, measuring growth factors and performing growth hormone (GH) 
stimulation testing. This approach has poor specificity for disease and only half of children 
subsequently treated with GH respond to treatment. GH treatment costs approximately $30,000 
to 50,000 per patient per year. GH affects many physiological parameters other than growth, 
and these effects are the indications for treatment of adult GHD. Muscle mass, strength, body 
fat, echocardiographic features, vascular endothelial function and lipid profiles are affected by 
GHD and improved with GH treatment. The aim of this pilot study is to generate preliminary data 
for a larger study to determine if children who will respond to GH treatment have 1) baseline 
characteristics that predict response, 2) changes in these characteristics within 3 months of 
treatment that also predict response, and 3) characteristics after one year of treatment that 
more closely resemble untreated non-GHD controls. This pilot study will include 30 patients 
followed prospectively for one year. 
 
 
!
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Background 
Most patients referred for evaluation of short stature have either constitutional delay of growth 
and puberty (CD) or idiopathic short stature (ISS).1 Distinguishing these two diagnoses from 
isolated growth hormone deficiency (GHD) is difficult, as tests have poor sensitivity and 
specificity. Current recommendations include consideration of growth, bone age, and levels of 
insulin-like growth factor I (IGF-I), and IGF protein-3 (IGFBP-3) to screen for GHD, followed by a 
confirmatory growth hormone stimulation test (GHST).2, 3 
Growth response to growth hormone (GH) treatment is extremely variable,4 and 30-50% of 
currently treated patients do not respond.4 GH generates almost $2 billion in annual sales 
revenue,5 and costs up to $50,000 per patient per year.6 The GHST has a central role in the 
decision to prescribe GH. However, up to 50% of normally growing children will be misclassified 
by these tests as having GHD, depending on the threshold and stimulus used.7 Furthermore, 
peak stimulated GH concentration on these tests does not correlate with growth response to GH 
treatment,8-10 and most children will pass a GHST if repeated when they reach adult height.11 
GH mediates many non-growth related effects that guide treatment in adult GHD, but are largely 
ignored in the evaluation of pediatric GHD or monitoring of treatment.12 The multisystem 
phenotype of adult GHD is well described. This includes reductions in lean body mass, exercise 
tolerance, fractional shortening of cardiac myocytes and high-density lipoprotein (HDL) as well 
as increases in fat mass, central adiposity, intima media wall thickness, triglycerides and low-
density lipoprotein (LDL).13 The effects of GH treatment on each of these systems may be dose-
dependent,14 but whether or not adverse effects of partial deficiency on each of these systems 
correlates with severity of deficiency in children is not known. 
The interaction between GH and body composition, cardiac function and bone mineral density in 
pediatrics warrants further investigation. These may have significant implications for children 
with undiagnosed GHD, both for diagnosis and for monitoring response to therapy. Fluid 
retention, a known complication of GH treatment even in normal children,15 complicates 
measurement of muscle mass using indirect measures such as dual-energy x-ray 
absorptiometry (DXA), or air displacement plethysmograpy. Pairing these methods with a 
reliable measure of total body water, such as deuterium oxide, would allow more detailed 
characterization of changes in muscle mass with GH therapy. 
Specific Aims 
This pilot study will generate the preliminary data 
necessary to conduct a more definitive study aimed 
at improving the identification of children who will 
have a positive growth response to GH treatment, 
and will provide information on the detailed 
physiological responses to GH treatment both in 
children who have a growth response to treatment, 
and those who do not. We will conduct a 1-year 
prospective, longitudinal study of children with short 
stature treated with GH, and untreated controls with 
similar stature. Four groups will be identified based 
on treatment and growth in the first year: 
Responders, Non-responders, Constitutional Delay 
(CD) and Idiopathic Short Stature (ISS) (Figure 1). 
Physiological characteristics measured in this study 
are listed in Table 1, and these will be measured at baseline, 3 months and 1 year. 
Hypothesis 1: Responders, compared with non-responders, ISS and CD, will have 
physiological characteristics (e.g. increased body fat, altered lipid profile, reduced brachial 
artery reactivity) at baseline that are predictive of a significant response to GH therapy. 
 
Figure 1: Diagram showing the categorization of 
patients based on GH treatment status and growth 
during one year of observation. After 1 year of 
treatment, responders grow >0.7 SD, non-
responders do not. After 1 year of observation, 
children with constitutional delay (CD) grow >0.7 SD, 
but idiopathic short stature (ISS) do not.  
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Hypothesis 2: Responders, compared with non-responders, ISS and CD, have changes in 
physiological characteristics within 3 months of treatment that predict their response to therapy. 
Hypothesis 3: Following one year of GH treatment, responders, compared to non-responders, 
ISS and CD, have physiological characteristics that resemble untreated GH sufficient controls. 
Preliminary Data 
Over the past six years, there have been 1301 GHSTs performed at CHOP, and 600 (46%) of 
these patients were subsequently treated with GH. Many physiological parameters have been 
shown to respond to GH treatment, but most studies do not include a positive growth response 
to treatment and utilize poorly specific stimulation testing to categorize patients as having GHD. 
!Body composition: Children with GHD have reduced lean body mass and increased fat mass 
at diagnosis, with a change in body water within 6 weeks of treatment possibly correlating with 
growth response to treatment.16-21 No study has used multiple modalities of assessing body 
composition22 to differentiate changes in body water from muscle mass or concurrently 
evaluated muscle function (i.e. strength). Adults with untreated childhood-onset GHD have 
reduced knee extensor muscle strength, and this improves with treatment.23 
!Bone Mineral Density: Height Z-adjusted areal bone mineral density and volumetric lumbar 
spine bone density is lower in children with ISS and GHD than age and sex-matched reference 
ranges,18 but the response of these parameters within one year of treatment is variable.18, 24  
!Cardiac and Vascular Endothelial Function: Children with GHD have lower left ventricular (LV) 
mass, and functional changes in myocardial contractility.25 LV mass changes are seen within 3 
months of GH treatment.25-27 Carotid intima media thickness may also be increased in children 
with GHD.28 Endothelial function is impaired in adult GHD and responds to treatment.29 
!Other Markers: Lipid profile,30, 31 leptin,32 fasting insulin,16, 33 IGF-I,34, 35 IGFBP-3,36 IGFBP-2,37 
Homocysteine, Tumor Necrosis Factor Alpha,38 and fibrinogen38 may be altered in children with 
GHD. 
!Genetic Markers: Next generation sequencing has been used to identify variants associated 
with short stature. The correlation of these loci with GH responsiveness is not known.39-41 
!Dermal Thickness: Skin thickness and elasticity are 
reduced in children with GHD, and these may improve 
with treatment.42 This effect is also seen in adults.43 
Subjects and Recruitment 
Eligibility criteria: Height-for-age <2 SDS, IGF-I <-1SD, 
Tanner stage 1 or 2, GHST performed. Exclusion 
criteria: Comorbidities or medications that may affect 
growth. Families will be invited to participate in the 
study on the day of GHST. Children subsequently not 
treated with GH will also be eligible as controls.  
Methods 
Children meeting inclusion criteria will be followed for 
one year. They will be evaluated at the CTRC Nutrition 
Core Lab at baseline, three months and at one year. 
The components of each visit are listed on Table 1. 
Additional samples will be collected at each visit for 
additional analysis supported by future grant 
applications. 
Analysis 
Patients will be divided into four groups, based on their 
GH treatment status and their growth response to the 
first year of GH treatment (Figure 1). The goal of this 
Table 1: Study Protocol. All measured at baseline, 
3 months and 1 year (except *baseline only or 
**baseline and 1 year only) 
Laboratory Studies 
Lipid profile, Bone markers (calcium, phosphorus, 
parathyroid hormone, urinary calcium:creatinine), 
Growth Factors (IGF-I and IGF-II). 
*DNA Banking (Center for Applied Genomics), Zinc 
**Ultrasensitive LH 
Detailed Anthropometry 
Muscle Strength: Hand grip dynamometry, knee 
kick, jump (force plate). 
Body Composition 
Dual-energy x-ray absorptiometry 
Air displacement plethysmography 
Bioimpedence absorptiometry  
Peripheral quantitative CT 
Deuterium dilution (GH untreated at baseline only, 
GH treated at baseline, 3 months and 1 year) 
Cardiac Echo 
Endothelial Function: Carotid intima media 
thickness, Brachial Artery Reactivity Testing, Pulse 
Wave Velocity. 
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pilot study is to estimate effect sizes that will be used to power a larger prospective study. This 
will involve estimating group means and standard deviations, mean analyses to assess group 
differences and identify potential interactions that might be assessed in our future prospective 
study. 
For the analyses listed below, each characteristic will be included as the dependent variable in a 
logistic regression model that includes an indicator for variable of treatment and response. We 
do not anticipate achieving statistical significance in this pilot study, so our primary assessment 
will be of the fitted group means and estimated standard deviation. 
Comparisons performed in multisystem parameters will be as follows: 
H1: Baseline parameters between responders and a) non-responders, b) CD and c) ISS. 
H2: Change from baseline to 3 months in multisystem parameters between responders and a) 
non-responders, b) CD and c) ISS. 
H3: Multisystem parameters of responders at 1 year will be compared with a) non-responders, 
b) CD and c) ISS at one year. 
Study Feasibility and CTRC Resources Requested 
Approximately 18 children undergo GH stimulation testing each month, over half of whom are 
expected to meet eligibility criteria. The evaluations included in the study protocol are estimated 
to require 2.5 hours in total, and the majority of patients will be aged 7-12 years. CTRC 
resources requested are: Nursing (phlebotomy), Nutrition (anthropometry, body composition), 
Cardiology (echocardiography, brachial artery reactivity testing), Biostatistics, Laboratory, 
Informatics (database and CRF development). 
Significance and the need for Junior Investigator Pilot Grant Program funds 
This project will be the most comprehensive longitudinal evaluation of children with presumed 
GHD performed, and has potential to improve clinical care of children with short stature. The 
integration of multiple methods of body composition analysis, bone health, echocardiography, 
and metabolic outcomes will generate pilot data for accurate calculation of sample sizes and 
power analyses in support of a larger study to test the hypotheses listed above. Improving our 
understanding of the non-growth related effects of GH in pediatric patients could have 
significant implications for patients, society and future research. We anticipate that this work will 
improve identification of GH responders, and reduce exposure of non-responders to 
unnecessary risk, and society to the cost.44-48 
Additional avenues of future study have been planned. DNA will be bio banked for future 
analysis in collaboration with the CHOP Center for Applied Genomics, using genomic data 
collected by this center on >45,000 children as controls. We anticipate that this collaboration will 
potentially identify genetic markers of GH responsiveness, either in this pilot cohort or in the 
larger subsequent study. Serum samples will be stored on each patient for future analysis of 
markers of GH responsiveness and the effect of treatment. These are exciting and novel future 
areas of research that will be supported by data and specimens collected, as well as experience 
gained, in completing this pilot study. 
Timetable 
Figure 2: Proposed study timetable. 
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